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11: Chapter I: The physiological regulation of parturition.
A review of the physiology of the cervix, myometrium and fetal membranes and
the changes that occur in these structures at the time of parturition. Proposed
mechanisms of regulation are discussed, including the effects of prostaglandins
and chemokines, particularly lnterleukin-8 on the uterine tissues and their
leucocyte populations. The potential role of progesterone in the modulation of
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and their implications discussed.
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Placental explants were obtained at term from caesarean and spontaneous
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immunostaining for IL-8 and of CD-45, CD-68 and neutrophil elastase in the third
trimester placenta is reported.
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regulation by steroids and mifepristone.
Decidual explants were obtained at caesarean section and were cultured with
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the localisation of IL-8 and the leucocyte populations present in this tissue.
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is reported.
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The onset of parturition involves both cervical ripening and co-ordinated myometrial
activity. There is increasing evidence that inflammatory mediators such as cytokines and
prostaglandins are involved in this process. Cervical ripening is associated with
degradation of the collagen by neutrophil derived matrix metalloproteinases. The cytokine
interleukin-8 (IL-8) is a potent neutrophil chemoattractant and thus could be pivotal to the
events leading to the onset of cervical ripening.
It is clear that progesterone is central to the maintenance of pregnancy and therefore
antigestagens, such as mifepristone, have been utilised for termination of pregnancy in the
first and second trimesters of pregnancy. There is also some evidence to suggest that the
withdrawal of progesterone results in the onset of labour. The antigestagens provide a
means to study the effects of progesterone withdrawal on the production of cytokines and
prostaglandins by uterine tissues and thus to further elucidate the nature of the interaction
between these mediators and progesterone at the time of parturition.
This thesis contains a randomised placebo-controlled clinical trial to assess the
effectiveness of mifepristone in causing cervical ripening in women at term. This showed
that the administration of 200mg mifepristone to primigravid pregnant women with
unfavourable cervices at term significantly improved cervical ripening as compared with
placebo (p=0.01), whereas the improvement following the administration of 50mg
mifepristone to comparable women was just below the level of significance.
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The role of antigestagens in the regulation of inflammatory mediators in uterine tissues is
as yet unclear. Laboratory studies were performed to investigate the effects of
antigestagens on the production of IL-8 and other mediators by placenta, decidua and
cervix. These studies showed that third trimester placental and decidua obtained in the
third trimester and cervical tissue from the first trimester all produced IL-8. In the third
trimester. IL-8 was demonstrated in placenta and decidua by immunohistochemistry and
shown to be localised to perivascular regions, which is in keeping with its putative role in
neutrophil migration into uterine tissues. The production of IL-8 by placental explants
was significantly increased (p<0.05) in samples collected after spontaneous vaginal
delivery as compared with those from pre-labour caesareans. Culture of placental explants
with antigestagens produced a variable, but generally increased effect on IL-8 production.
For example, onapristone caused a significant increase in IL-8 production by explants
from spontaneously delivered placentae. The effects of progesterone, dexamethasone and
mifepristone on production of IL-8 by decidual explants was examined. Progesterone and
dexamethasone caused a suppression of IL-8 production which was partially reversed by
culture with mifepristone. These results did not however reach a statistically significant
level, possibly due to the large variation in production between the samples. Cervical
biopsies were obtained in the first trimester of pregnancy following pre-treatment with
mifepristone at varying time-points and production of IL-8, monocyte chemoattractant
peptide-1 (MCP-1, a cytokine), prostaglandin E2 and PGF2« was determined. The first
trimester cervix produces all the mediators studied, regardless of whether mifepristone had
been administered to the women prior to sample collection or not. There was an increase
noted in the production of these mediators, particularly MCP-I, but again this did not
reach statistical significance.
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This thesis thus demonstrates that the inflammatory mediators studied, in particular IL-8,
are produced in the placenta, decidua and cervix The alterations in this production shown
after labour or antigestagen administration provide further evidence that these cytokines
are integral to the mechanism by which parturition is initiated. The significant effect of
mifepristone in promoting cervical ripening in women at term supports the hypothesis that
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The hypothesis for these studies is that use of antigestagens, in particular mifepristone,
will increase the production of IL-8 and other inflammatory mediators in uterine tissues
increasing the influx of neutrophils into the uterine cervix allowing release of their lytic
enzymes and leading to cervical ripening. The studies described examine the production
of IL-8 by placenta, decidua and first trimester cervix and the effects of antigestagens on
this phenomenon. The in vivo effects of the antigestagen mifepristone in ripening the
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INTRODUCTION.
The progression of pregnancy demands that the function of each component of the uterus
alters as gestation progresses. With the continuation of pregnancy from implantation to
parturition, the roles of the various parts of the uterus are required to reverse completely.
The uterine cervix, for example, must remain closed and non-compliant throughout
gestation to prevent premature delivery. During parturition, by contrast, it must efface and
dilate to allow delivery of the fetus. Similarly, myometrial contractions prior to full term
would threaten the continuation and viability of the pregnancy but become essential at term
to effect delivery. The fetal membranes provide protection for the fetus, both as a physical
barrier and by cushioning it in amniotic fluid, their preterm rupture can have severe effects
on fetal growth and development or may indeed lead to delivery of the fetus. Around the
time of parturition, however, they will usually rupture spontaneously.
The regulation of these functions during pregnancy and parturition remains to be fully
elucidated. There appears to be a cascade of events culminating in the onset of labour in
which prostaglandins, particularly prostaglandins E2 (PGEo), F2a (PGF2a) and
cytokines, such as interleukin-8 (IL-8), interleukin-1(3 (IL-1(3) and tumour necrosis
factor-a, (TNF-a) have been implicated. The effect of these and the many other factors
involved in maintaining pregnancy and causing its termination at parturition are
hypothesised to be under steroid and in particular progesterone, control. The physiology
of the events leading to fetal delivery and the evidence for their control by endocrine and
paracrine factors is reviewed in the following discussion.
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1.1: THE CERVIX.
l.li: Structure of the cervix.
The composition of the cervix is markedly different from the corpus of the uterus, in that it
is composed mainly of a connective tissue of collagen and elastin embedded in a
proteoglycan matrix1 with only a small amount of smooth muscle present (<15%) as a thin
layer at the periphery of the non-pregnant cervix-'3. By contrast, the corpus consists
mainly of smooth muscle. The junction between the two uterine components is at the
fibromuscular junction, which lies close to but is not synonymous with the internal os.
The majority of the connective tissue in the cervix is formed by collagen as was first
described by Danforth in 19471 and confirmed by a further report in 19544. There are
five types of collagen which each contain three polypeptides coiled into a triple stranded
helix. These molecules are extracellularly ordered into fibrils. About one third of the
amino acid residues in collagen are glycine with proline and the 3- and 4-hydroxyprolines
providing another 21 to 23%. The polypeptide helices are composed such that every third
residue is glycine, the intervening residues vary between the types of collagen. Glycine
does not contain a bulky terminal group and thus a tightly coiled helix can form. In the
human cervix the collagen present is of types I (70%) and III (30%) T5,6 {n these types
of collagen the collagen molecules are organised into a staggered longitudinal pattern.
Collagen types II, IV and V are predominantly found in cartilage and basement
membranes respectively, but small amounts of type IV collagen have been found in the
human cervix 7. Collagen is produced by fibroblasts, although smooth muscle may also
be capable of its synthesis. It is synthesised on membrane bound ribosomes as pre-
procollagen. This contains a signal peptide that ensures the passage of the peptide through
the endoplasmic reticulum and which is then cleaved off to produce procollagen 8
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(molecular weight around 150,000), containing an N-terminal peptide extension and a
COOH-terminal domain. Post-translational modification occurs intracellularly with
hydroxylation of proline and lysine residues and glycosylation of hydroxylysine prior to
the complete molecule being secreted from the cell via Golgi-derived vesicles. Once in the
extracellular space, the procollagen extensions are enzymatically cleaved by Nhb-terminal
and COOH-terminal procollagen peptidases and the collagen molecules thus produced
aggregate into fibrils by intermolecular cross linking of lysine and hydroxylysine residues
which are converted to active groups by the enzyme peptidyl lysine oxidase T9-11.
Another small component of the cervical connective tissue is elastin. Like collagen this
consists of one third glycine residues but it has a lower content of proline and
hydroxyproline and a higher proportion of valine and alanine residues. Unlike collagen,
elastin is not formed into a triple helix. The elastin chains are cross linked by desmosines
which form between lysine and allysine (formed by the action of lysyl oxidase on lysine).
It is proposed that the elastin fibril contains regions known as 'oiled coils' which are
spring-like and can stretch to 2 to 2.5 times the length of the molecule 10. It is believed
that it is the elastin in the cervix which is responsible for its elastic recoil during uterine
contractions Elastin is degraded by elastases.
The proteoglycan matrix of the cervix, in which the collagen bundles and elastin are
embedded, consists of heteropolysaccharide side-chains (glycosaminoglycans or GAGs)
covalently linked to a central polypeptide core. The glycosaminoglycans all consist of
repeating disaccharide groups, typically containing a large number of sulphate groups
which endow the molecule with highly hydrophilic characteristics. The exception is
hyaluronic acid which is not sulphated and not attached to a core protein. The
predominant GAGs in the cervix are chondroitin-4 and chondroitin-6 sulphate and
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dermatan sulphate (its epimer) 13,14, the attachment of either one of these to a small
protein core forms decorin 7'15, the most abundant proteoglycan in the cervix. Other
GAGs present in the cervix include keratan sulphate, heparan sulphate and hyaluronic
acid. Hyaluronic acid is a much larger molecule than the other GAGs present with a
molecular weight of up to 80x 106- It forms a backbone for the proteoglycan complex with
core proteins and their attached glycosaminoglycan side chains attached to it 16. The
arrangement of the proteoglycans with their peripheral GAGs is thought to be essential to
maintain the collagen alignment within, and thus the rigidity of, the cervix. The binding
of GAGs to collagen is dependent on their length and their charged density. Those which
contain iduronic acid i.e. dermatan sulphate and heparan sulphate bind more strongly than
those lacking this residue. Dermatan sulphate has the capability to bind orthogonally to
collagen fibrils and thus is important for the stabilisation of collagen whereas both
hyaluronic acid and chondroitin sulphate bind weakly to collagen. Hyaluronic acid has
also been noted to have a particularly high affinity to water H,17#
l.lii: Cervical modification associated with parturition.
The collagen of the cervix changes both qualitatively and quantitatively as labour
approaches. The fibrils become dissociated from their tightly organised bundles to appear
more widely scattered in an increased amount of ground substance 3,5,18 The quantitative
changes in the amount of collagen present has been reported to be of varying extents.
The hydroxyproline content of the cervix has been measured as an equivalent for collagen
concentration and a moderate reduction in the concentration following cervical dilatation
has been reported in several studies U5,14,19 q^is biochemical method of detection
would also be expected to detect the depolymerised fibrils of collagen which are still
biochemically intact although they have lost their structural rigidity and so it may not be
the most accurate method by which to assess the functional effect of alterations in collagen
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structure. In the sheep cervix during parturition, scanning electron microscopy showed a
loosening of the collagen bundles in the cervical stroma 20. In a refinement of this
technique, Junqueira et al -1 described a histochemical method using a Picrosirius red
stain which when viewed through a polarising microscope shows only oriented
polymerised collagen as bright red or yellow bifringence but does not highlight dissociated
collagen. Using this method they compared the histology of non-pregnant and
intrapartum human cervices -- and found that during labour the appearance of the collagen
fibres showed irregularities, such as lack of continuity and variations in thickness that
suggested the collagen was being corroded by a process of local degradation. Areas of
amorphous material which were seen around these degraded fibrils were thought to be
conglomerations of partially depolymerised collagen. Further evidence for the occurrence
of collagenolysis in the cervix at term has been provided by the use of antibodies specific
to the degraded a2 chain of type I collagen. Using this antibody an increase in this
product was demonstrated by immunoassay and immunoblotting in the guinea pig cervix
during labour -3. These findings provide support for the hypothesis that cervical
dilatation is associated with significant collagenolysis. The absolute concentration of
collagen (as measured by extractable hydroxyproline) in the cervix has been shown to be
inversely proportional to the degree of 'ripeness' of the cervix-4, In contrast the
proportion of elastin in the uterus increases dramatically during pregnancy to about eight
times the non-pregnant state, this increase rapidly reverses following delivery of the
fetus-5. These changes in structure of the connective tissue of the cervix seem likely to be
causative of at least some of the functional changes in the cervix at term and during
parturition.
There are also alterations in the GAGs of the cervical matrix at the time of parturition. The
overall concentration of these substances has been described as rising 2.5-fold before the
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onset of labour with an associated relative increase in the amount of hyaluronic acid
(which is relatively more hydrophilic than other GAGs). This increase was noted in
human cervical biopsies taken when the cervix was two to three centimetres dilated
following which there was a decrease in the GAG content of cervices taken at six to eight
centimetre dilatation with an associated decrease in the hyaluronic acid concentration-6.
Early work by Danforth et al18 initially suggested an increase in GAG levels during labour
but other groups suggest a precipitous fall in GAG levels after the onset of parturition, the
first to decrease being dermatan sulphate, followed by decreasing amounts of hyaluronic
acid and chondroitin sulphate13 -6 with a rise in heparan sulphate during the active phase
of labour17-18. As heparan sulphate is localised mainly in vessel walls its increase during
pregnancy and during parturition may be a result of the increasing vascularity of the cervix
at this time-6. In the guinea pig, circulating levels of hyaluronic acid significantly increase
at parturition to around five times the antenatal levels, decreasing to the pre-pregnancy
levels within two days post-partum37. These findings of marked alterations in the GAG
content of the cervix in the course of labour have however, been disputed by a study
which examined biopsies from non-pregnant and intrapartum cervices-3. The relative
quantities of glycosaminoglycans were determined after proteolytic digestion and
microelectrophoresis. Although there was a relative increase in chondroitin sulphate and
decrease in dermatan sulphate in the intrapartum samples it was commented that these
were minor changes relative to the dramatic changes in histology and biochemistry of the
cervix at this time and so of "relatively little importance in this process"33. Further
studies, however,17-38 have confirmed marked decreases in GAG levels in cervical tissue
and in the lower uterine segment around the time of parturition. In a study of human uteri
the concentrations of hyaluronic acid in the cervix, fundus and isthmus of the uterus were
found to be decreased in term pregnant women as compared with the non-pregnant
state19. Some of the discrepancies between these studies may have arisen due to the
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precise timing at which the samples were taken. As described above in several studies
there is an increase in the GAG content of the cervix prior to the onset of labour and
during its initial active phase followed by a decrease in the concentration during the later
phases of labour-6. It follows that conflicting results could arise if the precise point
during labour at which samples were taken is not clearly defined.
It is therefore apparent that there are changes occurring in the glycosaminoglycan content
of the cervix associated with the development of a looser stroma with more hydrophilic
properties. It is evident that rapid changes in the concentrations of GAGs can occur and
that marked differences have been observed in the concentrations of these substances in
late pregnancy and during parturition-6. The precise nature and alterations in the relative
concentrations of the individual GAGs and in particular the extent of any decrease in
hyaluronic acid levels remains controversial. The cervix at term and during labour
contains a higher proportion of water than in the non-pregnant state, reported in one study
to be 78.4% compared with 74.4% 18 and in other work to increase to as much as 86% of
the cervical content14.
These biochemical changes in the cervix are accompanied by changes in its physical
properties as parturition approaches and throughout labour. The cervix softens, shortens
(effaces ) and then dilates to allow passage of the fetus. In the sheep cervix the stretch
modulus of the cervix (that is the ratio of stress to strain) decreases gradually during
pregnancy and then exhibits a marked decrease immediately prior to the onset of labour-9.
The changes in structure of the cervix at the time of parturition, with a decrease in the
concentration of collagen and its dissociation, a looser matrix and an increase in the water
content means that the cervical tissue offers low resistance to force applied and the fibres
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will move under tension. During myometrial contractions cervical tissue is thus drawn up
into the lower segment of the uterus, in the processes of effacement and dilatation11.
l.liii: Role of collagenases and leucocytes.
Studies such as that of Junqueira -- described above confirm that collagenolysis occurs in
the term cervix which in all probability facilitates cervical ripening and dilatation.
Collagen extractabilty is the solubility of collagen following standard pepsin digestion and
there is a four-fold increase in this parameter during cervical ripening suggesting that there
is active lysis of collagen occurring at this juncture. The main lytic enzymes with effect in
the cervix are collagenase and elastase.
Collagenases are members of the family of matrix metalloproteinases (MMPs). The MMP
family are responsible for the degradation of components of the extracellular matrix. All
members of the MMP family contain three domains, the 'pre' domain signalling for
cellular export, the 'pro' domain, the removal of which activates the enzyme, allowing
zinc binding to the 'catalytic' domain30. Some of the MMP members involved in the
degradation of collagen also contain a haemopexin domain which allows them to cleave
fibrillar collagen. MMP-1 (interstitial collagenase) has specificity for collagens type I, II,
III and X, MMP-8 (neutrophil collagenase) is specific for collagens I, II and III and
MMP-13 for collagen I. The specificity of MMPs is diverse and other MMPs are also
involved in collagen and elastin degradation such as MMPs 2, 3, 9, 10, 11 and 1230. The
activity of the MMPs is inhibited by tissue and plasma inhibitors, the former being known
as TIMPs (tissue inhibitors of metalloproteinases).
The MMPs catalyse the initial hydrolysis of collagen by cleaving each of its three chains
between residues 771 and 772 into two fragments. The cleavage products thus produced
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are more susceptible to thermal denaturation than intact collagen and it is proposed that
they denature at body temperature to gelatin which is further degraded by MMPs acting as
gelatinases. The small peptides thus produced are then be further cleaved.
MMPs have been demonstrated in human fetal membranes and it has been shown, in
particular, that MMP-3 and 9 increase as labour begins and then decrease following
delivery31-3-. Levels of collagenase, both active and latent forms, extracted from the
uterine lower segment (which was assumed to correlate with levels in the cervix in the
study) increased thirteen to fourteen fold during cervical dilatation at term as compared
with prior to labour- During labour there is a significant increase in the levels of
circulating collagenase33. In samples of pregnant guinea pig cervices, levels of
procollagenase increase 6-fold and levels of its net activity double at parturition34. The
role of collagenase has been studied further using a technique by which active collagenase
was extracted from cervical biopsies and its activity in degrading radiolabeled collagen
assayed. Biopsies were collected from the posterior cervical lip of non-pregnant and
pregnant women at differing stages of gestation and labour35. There were no significant
difference in the levels of active collagenase in non-pregnant women, those in the first
trimester of pregnancy and those in the early stages of labour. However in the final stages
of cervical dilatation (from 6 to 8cm) collagenase activity rose significantly as compared
with the first trimester of pregnancy and as compared to the third trimester levels pre-
labour. This increase in cervical levels of collagenase during labour has been confirmed in
a more recent study-8 using biopsies from the posterior cervical lip during pregnancy and
from the lower uterine segment at elective caesarean.
In addition to the increase in collagenase noted during active labour there has also been
shown to be an increase in the degradation product DNP-peptidase which has been
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reported as between 3 to 4 times the levels found pre labour19'36 and in PZ-peptidase, also
a product of collagen catabolism, which doubles its levels in the cervix at term.37.
Fibroblasts, which are present in the cervix are capable of synthesising collagenase, but
there is accumulating evidence that other cells, in particular neutrophils are implicated in
the increased collagenase release into the cervix around the time of parturition. Neutrophil
collagenase, also known as MMP-838 was sequenced in 199039 and found to have 72%
chemical similarity with fibroblast collagenase with four additional glycosylation
regions.39. In contrast to fibroblasts which constitutively synthesise and release
collagenase, neutrophils synthesise and store collagenase in intracellular granules during
their development in the bone marrow. MMP-8 has been sequenced and found to contain
467 amino acids with areas of homology to both fibroblast collagenase and other
metalloproteinases39. MMP-8 has a different rate of hydrolysis of collagen substrates to
tissue collagenase (MMP-1). MMP-1 cleaves collagen type III about 15 times more
rapidly than it cleaves collagen type I whereas MMP-8 cleaves collagen type I about 20
times faster than it cleaves collagen type III40. This specificity of MMP-8 correlates with
the proportions of collagen types I and III present in the cervix. In biopsies of non¬
pregnant cervices, the most common cell population is fibroblasts whereas in the
intrapartum period there is a heavy infiltration of neutrophils into the cervical stroma, in
addition to which there are increased numbers of mast cells and macrophages in the
intrapartum cervical stroma33. In this study the neutrophils were particularly seen in
association with venules and appeared to be migrating from them. These histological
findings support the proposal by Liggins that cervical ripening resembles an inflammatory
reaction and that an explanation of the process of cervical ripening must account for this
similarity41. The increase in collagenase described during labour has been examined36'35
using in-situ hybridisation to fibroblast collagenase specific mRNA. Using messenger for
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fibroblast collagenase this was not demonstrated in cervical biopsies obtained from
women in labour. Examination of the polymorphonuclear leucocyte population in the
cervix, however, showed a marked accumulation of these cells in the capillaries of the
cervix at term, with massive stromal infiltration occurring at the onset of cervical dilatation
and subsequent immunofluorescent evidence of degranulation of these leucocytes to
release human leucocyte collagenase detectable with specific antibody-6'35- An increase in
leucocyte elastase activity in the cervix as pregnancy progresses has also been
described42. It thus seems that the collagenase demonstrated in the cervix at term is
derived from neutrophils. Cultures of rabbit cervical explants have been described as
releasing a neutrophil chemoattractant agent which is thought to be interleukin-8 (IL-8), a
potent attractor and activator of neutrophils. IL-8 is also present in and released by many
uterine tissues, including human cervix43. The potential role for this cytokine in
neutrophil recruitment and activation at the onset of parturition is explored further below.
During cervical ripening and dilatation at term in human pregnancy therefore, there is
degradation of collagen which is evident both histochemically and biochemically, the
former method of investigation providing a truer representation of the dramatic alterations
in collagen structure during this period. These catalytic changes in collagen are mediated
by collagenase, the levels of which have been demonstrated to increase both peripherally
and in the cervix during labour. Further examination of the source of this collagenase is
supportive of its being released from the specific granules of neutrophils as opposed to
being synthesised by the cervical stromal fibroblasts. This hypothesis is further supported
by the marked infdtration of neutrophils into the cervical stroma at term and demonstration
of their subsequent degranulation.
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1.2: MYOMETRIUM
Alterations in myometrial activity occur concurrently with cervical ripening and dilatation,
the two being facets of the same process which leads to delivery of the fetus. The factors
that regulate the timing of parturition must therefore act on both uterine areas. The aim of
the studies described in this thesis was not to investigate the mechanisms of myometrial
contractions but the alterations in production of mediators examined in the cervix, decidua
and placenta could be expected to affect the myometrium. The physiology of myometrial
contractions is therefore considered below and the changes at the time of parturition
discussed.
1.2 i: Structure of the myometrium
Myometrium consists of smooth muscle fibres embedded in an extracellular material that is
mainly composed of collagen, this connective tissue matrix facilitates transmission of the
contractile force generated by the muscle fibres. In contrast to striated muscle, smooth
muscle fibres exist in irregular bundles, this organisation enables the contractile force of
the myometrium to be exerted in any direction and ensures that the uterine morphology can
alter to accommodate a fetus of varying size and position44. The contractile unit of muscle
is composed of actin and myosin which slide along each other to generate contraction by
the formation of cross-bridges between the myosin heads and the actin molecules.
Myosin (molecular weight about 500kDa) acts as both a structural protein and as an
enzyme which utilises the chemical energy of ATP to generate the mechanical force of a
contraction. The myosin molecule contains a head, a region where the ATPase sites are
located and where interaction with actin occurs and a tail region. Myosin consists of two
'heavy" chains (around 200kDa) and two pairs of "light" chains (15 to 20kDa)44. It is the
phosphorylation and dephosphorylation of these light chains that regulates the interaction
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between myosin and actin. The latter is a protein with molecular weight of 45kDa.
Monomers of actin polymerise to form long thin filaments.
1.2 ii: Myometrial contractions - intracellular events.
For contraction to occur, the myosin light chains must be phosphorylated prior to their
interaction with the actin molecules45'46. This reaction is catalysed by myosin light chain
kinase (MLCK). This enzyme is, in turn, activated by the combination of calcium with
calmodulin47, the binding of these two agents causes a configurational change in
calmodulin exposing a hydrophilic domain that interacts with MLCK46. When calcium is
removed from the system dephosphorylation occurs rapidly leading to muscle
relaxation1-. Relaxation can also occur by the action of myosin light chain phosphatase
which removes the phosphate group from myosin light chains48. There is a strong
positive correlation in human myometrium between the levels of intracellular calcium and
the rate of myosin light chain phosphorylation47. Stimulation of myometrial cells in
culture with oxytocin produces wave-like changes in the levels of intracellular calcium as
shown by fluorometryIn order for a contraction to occur intracellular calcium levels
need to increase from 10"7M to lO5 M49.
The system of myometrial contractility is controlled via a subtle network of interacting
second messengers. Calcium is available within the cell either following its release from
vesicles in the intracellular sarcoplasmic reticulum which is the main intracellular calcium
store, or after entry into the cell across extracellular channels. Release of intracellular
calcium from the sarcoplasmic reticulum is promoted by inositol 1,4,5-triphosphate
(InsP3) acting to open a calcium channel. Phospholipase C acts on phosphatidylinositol
4,5-biphosphate (PIP2) to hydrolyse it releasing InsP3 and 1-2-diacylglycerol (DAG).
The uptake of calcium (and therefore its removal from availability to activate MLCK) into
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the sarcoplasmic reticulum is facilitated by cyclic AMP via the activation of protein kinase
A (PKA). PKA also inhibits contractions by phosphorylating MLCK thereby decreasing
its affinity for the calcium-calmodulin complex. In addition to its release from intracellular
stores calcium can also enter the myometrium cell across the cell membrane via receptor or
voltage mediated channels. Depolarisation of the membrane to the required extent
activates the voltage regulated channels allowing calcium influx into the cell. The plasma
membrane also contains calcium/sodium ion 'pumps' which remove calcium from the
intracellular space during relaxation of the muscle cell. Exogenous agents such as
hormones or drugs acting on the myometrial cell do so via cell membrane receptors that
are coupled via G-proteins to enzymes such as adenylyl cyclase which produces cAMP
from ATP or phospholipase C converting PIPt to InsP3 and DAG. Adrenaline, for
example can act via (3-receptors to increase intracellular cAMP causing muscle relaxation
or via a-receptors to increase InsP3 and decrease cAMP leading to contraction.
1.2 ii: Myometrial contractions - intercellular events.
Calcium can enter myometrial cells via voltage dependent channels when the resting
potential of the membrane is altered as occurs when waves of depolarisation spread
between myometrial cells. This spread of depolarisation is facilitated by intercellular
connections or gap junctions that have low electrical resistance50-51 and which also
enhance metabolic coupling between cells5-. Gap junctions are composed of six identical
proteins, connexins, arranged in a hexameric array which are functional when paired
across an intercellular membrane 49. They were first described in 196750 and identified
by Garfield in human myometrium in 197753. The myometrial gap junction protein is
coded for by the connexin 43 gene54 which is found on chromosome 6. Agents such as
(3-adrenergic agonists that relax the myometrium are capable of closing gap junctions49.
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The regulation of changes in the gap junctions around the time of parturition is discussed
further below.
Oxytocin (from the Greek 'rapid birth') is a nonapeptide secreted from the posterior
pituitary and is structurally similar to vasopressin, the other nonapeptide secreted from this
site. Both are formed from large precursor polypeptides in the supraoptic and
paraventricular nuclei of the hypothalamus from whence they are transported to the
pituitary gland via the axons of hypothalamic neurones bound to carrier proteins
(neurophysins) and are then stored in the pituitary prior to their release 10. The major
actions of oxytocin are to cause expulsion of milk by means of the neurogenic reflex, the
'milk letdown response' and to stimulate of uterine contractions. It also weakly mimics
the effects of vasopressin, such as inhibition of water diuresis, an important consideration
if large amounts of oxytocin are to be administered exogenously to stimulate uterine
contractions. The 'Ferguson reflex'55 whereby oxytocin release would be increased by
cervical stimulation was postulated by Ferguson in 1941 but has not been proven to occur
in humans in whom vaginal distension may have a more potent effect than cervical
stretch56. Following its release into the bloodstream oxytocin is carried to the uterus
where it exerts its uterotonic effects via membrane receptors in addition to that produced
locally. Once bound to its receptor oxytocin inhibits the ATPase membrane pump which
moves calcium from the intracellular to the extracellular area 46. It also promotes the
influx of calcium from both the sarcoplasmic reticulum and the extracellular area into the
intracellular area 44. Oxytocin receptors are also found in the decidua, in increasing
numbers at the time of parturition57 and are thought to interact with other agents involved
in the onset of parturition, in particular the prostaglandins. Oxytocin receptors have also
been described in the amnion and choriodecidua of human fetal membranes at term58.
26
1.2 Hi: Modifications of myometrial structure and responsiveness
associated with parturition.
It was first noted by Braxton-Hicks in 1872 59 that from early pregnancy the uterus
exhibits uncoordinated myometrial activity. More recently a pattern of contractility termed
contractures has been observed in pregnant animals60. These contractures were initially
described in sheep from around day 60 of gestation (term being about 150 days)59. They
are prolonged low amplitude increases in intrauterine pressure and have subsequently been
demonstrated in many other species including non-human primates such as the Rhesus
monkey 6f62. They seem to be part of the intrinsic activity of uterine muscle as they
continue to occur in strips of sheep myometrium transplanted away from the uterus 63. As
pregnancy progresses contractures eventually switch to uterine contractions which are
more regular, shorter lasting and are associated with greater intrauterine pressures. In
sheep and cows this switch from contractures to contractions occurs once prior to labour
and delivery whereas in non-human primates it occurs several times commencing a few
days prior to the onset of labour. These switches demonstrate a photoperiodicity,
generally occurring when lights are switched off 64. There is also a circadian rhythm to
these switches demonstrable even when animals are kept at the same light intensity
throughout an experimental period65. The onset of parturition in many animals, including
non-human primates, is therefore associated with an alteration in the pattern of uterine
activity to produce stronger more co-ordinated contractions, which in the presence of a
ripening cervix will effect labour and delivery of the fetus. In mechanical terms it is more
efficient to cause deformation of a visco-elastic structure, such as the cervix, by applying
loads of a small amplitude over an increased length of time, such as with regular
myometrial contractions, rather than a larger load over a shorter time period66. It will,
however, be more difficult to establish such changes in the human female as to do so
would require prolonged insertion of intrauterine pressure recording devices which could
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potentially introduce infection and may not be ethically acceptable. External monitoring of
uterine activity via a tocograph is, unfortunately, not accurate enough to reliably detect
these changes.
Intercellularcommunication.
The onset of regular co-ordinated uterine activity at the time of parturition requires the
myometrial cells to function as a syncytium with rapid communication between them. In
rat myometrial strips the diffusion of 2-deoxy-D-glucose through cells is greater in
myometrium from parturient rats than from ante or post-partum ones67. Samples from the
rats in labour were also noted to have an increase in the area of gap junctions, a finding
confirmed by another study68 which showed an increase in gap junctions in the
myometrium of rats commencing six hours prior to delivery. The area of gap junctions
underwent a rapid decline post-partum. Communication of electrical signals between
myometrial cells also increased at the time of parturition. Increased propagation of
electrical excitation was shown in myometrial strips from uteri during parturition as
compared to those at earlier gestations69. In women the appearance of gap junctions in
myometrium sampled at the time of caesarean section has been described by Garfield and
Hayashi70. In myometrium obtained from women having an elective caesarean section
four of eleven samples contained demonstrable gap junctions whereas there was a
significant increase in the area of tissue containing gap junctions found when tissue was
obtained at caesarean during labour. A similar increase in the number of gap junctions
was seen in tissue from women in preterm labour as compared with those not in labour at
term. In the same study correlations were shown between the area of gap junctions and
the frequency of uterine contractions and the area of gap junctions and the stage of cervical
dilatation. It was estimated that around 250 gap junctions per cell appear at the time of
parturition in women70. Parturition is therefore associated with an increase in intercellular
28
coupling via gap junctions which will decrease the impedance to the flow of electrical
current between the cells and which also facilitates the diffusion of metabolites between
cells. The formation of this functional syncytium at the time of labour explains the gradual
synchronisation and co-ordination of the myometrium that is seen preceding and during
labour.
Oxytocin and oxytocin receptors.
There has been some controversy over the alterations in oxytocin levels during pregnancy
and parturition, indeed oxytocin physiology has been described as 'a graveyard of
scientific reputations'64. Initial studies in monkey71 and human72 females prior to and
during labour did not demonstrate convincing alterations in oxytocin levels. In 1991
Fuchs et al readdressed this issue56. They suggested that the measurement of oxytocin
levels may not have been accurate in previous work for several reasons such as the low
physiological levels of oxytocin, the limitations of previously used assays and the rapid
degradation by oxytocinase of oxytocin in stored plasma. In their study they performed
serum sampling at one minute intervals over a thirty minute period in women prior to
labour and in the first, second and third stages of labour. They found that oxytocin was
released in a pulsatile manner and that there was a significant increase in the frequency of
these pulses during labour and a further rise in their frequency during the second and third
stages of labour. There was also a less marked increase in the amplitude and duration of
the pulses in the second and third stages of labour.
The response of the myometrium to oxytocin is dependent not only on the absolute serum
levels of oxytocin but also on the concentration and affinity of the tissue receptors for
oxytocin. The uterus demonstrates increasing sensitivity to oxytocin as pregnancy
progresses, for example in the non-pregnant state lOOmU of oxytocin is required to
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produce a contractile response in the myometrium, whereas at term the same response can
be elicited by 1 or 2 mU of oxytocin73. This increased sensitivity could be mediated by an
alteration in the receptors for oxytocin in the myometrium. Oxytocin specific binding sites
have been described in human myometrium and decidua73'74 A specific G protein
receptor for oxytocin was described in 1992 containing seven trans-membrane domains75.
When myometrial strips were taken from uteri at the time of hysterotomy or caesarean
section at varying gestations it was found that the concentrations of oxytocin receptors
rose markedly as gestation progressed. In the second trimester the concentrations were
six times those found in the non-pregnant state, at 37 to 41 weeks they were 80 times
higher and in early labour there was a further 2.5 increase in the pre-labour levels 74.
When tissue was obtained from caesarean sections in the later stages of labour (after 7cm
dilatation) much lower concentrations, around 2.5 times the early pregnancy levels, of
receptors were found. One explanation for this was postulated to be due to the lower
levels of oxytocin receptors in the isthmus of the uterus as compared with the fundus and
corpus. Tissue collected from caesarean sections in the later stages of labour may have
been taken from an incision lower in the uterus with lower levels of receptors than the
higher regions. The affinity of oxytocin receptors for the hormone was not found to alter
during gestation. An increase in the mRNA for the oxytocin receptor has also been
demonstrated in human myometrium at the time of parturition with levels over 300 times
higher than those found in the non-pregnant myometrium76. This study also
demonstrated that the distribution of the mRNA for the receptor was heterogeneous in the
myometrial cells. Similar findings of increased mRNA for oxytocin at the time of labour
have been reported in sheep77 and rat78 myometrium. The decidua also contains oxytocin
receptors73-74 which also increase in number, but not affinity, from early to late
pregnancy. Decidua parietalis obtained from the uterine surface was found to have a
greater concentration of receptors than the decidua vera from the surface of the chorion74.
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An increase in the number of oxytocin receptors is also seen in the fetal membranes, both
amnion and chorio-decidua, during labour58.
There is therefore an increase in the frequency of oxytocin pulses and an increase in the
myometrial and uterine responsiveness to oxytocin, via an increase in the number of
receptors at the time of parturition. There may also be an alteration in the G protein
coupling of the receptor at this time which would further increase the uterine response to
oxytocin1-.
1.3: THE FETAL MEMBRANES.
The fetal membranes consist of the inner amnion and the outer chorion. The latter is in
close association with the decidua and cells derived from this layer are often termed
choriodecidual. The tensile strength of the fetal membranes is due to their connective
tissue component which has a high concentration of collagen79 which as in the cervix is
predominantly types 1 and III80. The amnion is thinner than the choriodecidua but it is
stronger81
In the majority of women the membranes rupture late in the first stage of labour but in
around 10 per cent they rupture at term prior to the onset of established labour8-.
Furthermore, it is estimated that 40 per cent of preterm labours are preceded by rupture of
the membranes83. In one study in which membranes that had ruptured before term were
compared with those that had ruptured at term it was found that the former were thinner
near the rupture site with a lower modulus of elasticity near the placenta84. It was not
apparent however whether these changes occurred before or after the membranes had
ruptured at this site. A later study85 describes an area of altered morphology in the
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membranes which forms part but not all of the rupture site. As this area is smaller than the
ruptured area it was suggested that it existed prior to and indeed may have been the focus
for the membrane rupture. The area of altered morphology contained thicker connective
tissue layers with a thickened and swollen spongy layer seen between the membranes.
Despite this layer, in this area the membranes showed an overall decrease in thickness of
35% due to the marked thinning of the decidual and trophoblast layers. It is proposed that
in this area of altered morphology the increase in separation of the two membranes means
that they act as separate components thus having decreased strength as compared to their
action when functioning as a unit. This study excluded any membranes with evidence of
infection which is a factor that may be associated with abnormal membrane rupture.
Contact with group B streptococci or with Staphylococcus aureus will decrease
membrane integrity as measured by in vitro outcomes, such as bursting tension, elasticity
and work required to rupture the membranes. This effect is enhanced by the addition of
neutrophil elastase86.
Rupture of the fetal membranes may therefore occur at an area with altered collagen
composition, infection may act on this site or on a normal area to cause distortion of the
collagen. The role of collagenases, in particular those derived from neutrophils in causing
this distortion remains to be more fully elucidated.
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REGULATION OF PARTURITION.
Many and various factors have been implicated in the onset and establishment of labour
and delivery. There would appear to be a complex interaction of local factors which act in
a cascade with internal feedback mechanisms to culminate in cervical dilatation, regular
myometrial contractions and delivery. In some animals, such as the sheep, the mechanism
for the initiation of parturition has been much more clearly elucidated than in the human.
In sheep it is known that alteration of fetal steroid production acts via ovine placental
steroid production to cause increased prostaglandin production from the fetal cotyledons
andchorioallantois87. In the human female, however, such a clear pathway has not been
proven and the mechanism of parturition cannot be assumed to follow this model. It is
much more difficult to obtain information as to the levels of prostaglandins and other
hormones at various stages of normally developing pregnancies in women than in
experimental animals. In many species, but not in women, a decrease in serum
progesterone or in the progesterone : oestrogen ratio is seen immediately prior to the onset
of labour.
Prostaglandins, in particular PGE2 and PGF2« occupy a pivotal role in this system and
their local concentrations may be at least partially under progesterone control as will be
discussed further below. In addition to the prostaglandins, it seems that other local
effectors participate in the cascade leading to parturition. These are the cytokines, which
are involved in local inflammatory responses and also in altering cell populations and
activities.
There are therefore many agents to be considered in a discussion of the events leading to
parturition. In the following it is proposed to focus on the alterations in local levels of
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prostaglandins, their interaction with the cytokine IL-8 in recruiting neutrophils into
uterine tissues and the possible control over this system exerted by progesterone.
REGULATION OF THE ONSET OF PARTURITION.
1.4: Prostaglandins
1.4 i: Structure and action of prostaglandins.
Arachidonic acid is the precursor of several families of compounds that exert diverse
biological effects in many systems including the reproductive organs. These include
prostaglandins, thromboxanes and leukotrienes as well as the hydroperoxy and hydroxy
fatty acid derivatives. These agents are not typical of endocrine hormones as they are
produced in almost all tissues rather than in specialised glands, they are not stored to any
great extent and they generally exert local effects10. The prostaglandins were named by
von Euler in 1935 as a term for prostatic extracts and their configuration was determined
in 1966 by Nugteren88. They are a family of related C20 carboxylic acids which contain a
cyclopentane ring from which two aliphatic side chains protrude ending in a carboxyl and
a methyl group. Prostaglandins are divided into the A, B, C, D, E, F and J series.
Prostaglandins G and H are unstable endoperoxides that are intermediates in prostaglandin
biosynthesis. In addition are prostacyclin (PGE) and thromboxane (TXA2) which are
derived from the same endoperoxides but which do not fit into the simplified scheme of
nomenclature88.
The two series of most relevance in reproduction are the E and F series (figure 1.1).
These each consist of three members i.e. Ei, E2, E3, Fiu, F2a and F3tt. The subscript
numerals in this classification refer to the number of double bonds in the side chains.
These two series of prostaglandins differ from one another in that the PGEs have a C-9
keto oxygen and a C-ll hydroxyl group in the cyclopentane ring whereas the PGFs
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Figure 1.1: The synthesis and structure ofprostaglandins.
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contain a hydroxyl group at both positions10. Of these compounds it is PGEo and PGF2a
which have the most biological and clinical importance. Prostaglandins of the ' 2 series
are derived from arachidonic acid (5, 8, 11, 14-eicosatetraenoic acid). This is either
ingested in the diet or formed from linoleic acid. It is derived as a precursor for
prostaglandin synthesis from membrane phospholipases. As prostaglandins are not stored
to any appreciable extent in tissues their rate of release is regulated by the availability of
arachidonic acid and thus by the actions of the phospholipases that liberate it from
membrane phospholipids. The main phospholipase is phospolipase A2 but phospholipase
C can also act to release arachidonic acid in conjunction with diacylglycerol lipase.
Synthesis.
The conversion of arachidonic acid to prostaglandins is via the action of prostaglandin
synthetase which is a membrane bound multi-enzyme complex. One component of this is
cyclooxygenase (COX) or prostaglandin endoperoxide synthetase which catalyses the
conversion of the substrate into the unstable intermediates PGG2 and PGFb by
oxygenation. This step requires the removal of a hydrogen ion at C13 and the addition of
an oxygen molecule at Cll10>88. These intermediates are then converted into the
prostaglandin series by prostaglandin endoperoxide isomerases in the case of PGE or
reductases for PGF or into prostacyclins or thromboxanes by prostacyclin or thromboxane
synthetases respectively. Other metabolites of arachidonic acid such as the leukotrienes
and the hydroxyeicosatetraenoic acids are formed in a pathway which utilises
lipooxygenases rather than cyclooxygenase in the initial step.
There are now known to be two forms of the COX enzyme (otherwise known as
prostaglandin endoperoxide synthase PES), COX-1 and -2. The former is a constitutive
enzyme that is present in most tissues. COX-2 is a rapidly induced and short-lived form
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of the enzyme89 the message for which can be induced by phorbol ester and inhibited by
glucocorticoid89'90. It has been demonstrated in amnion where its expression rises
rapidly after treatment with IL-1 (391 and has also been demonstrated
immunocytochemically around the vessels of first trimester decidual vessels89.
Pharmacological inhibition of prostaglandin synthesis can be achieved using the non¬
steroidal anti-inflammatory drugs (NSAIDs). These agents inhibit the action of
cylooxygenase and thus reduce prostaglandin synthesis. It has been found however that
their effects are less potent in inhibiting COX-2 as compared with their effects on COX-1.
Indomethacin, for example, has an ID50 which is 22 times less for COX-1 than for COX-
29-. The finding of this transient inducible enzyme for prostaglandin synthesis has many
implications for understanding the mechanisms of parturition. It seems likely that the
rapid changes in uterine prostaglandins and their synthesis that are postulated to occur at
this time could be modulated by induction or inhibition of this enzyme. In laboratory
studies of prostaglandins non-steroidal agents such as indomethacin are often used to
antagonise their production, however their lower efficacy against COX-2 means that this
suppression of prostaglandin synthesis may not be absolute.
Metabolism.
The major site for prostaglandin metabolism in all species is the lung although local
mechanisms for degradation also exist in some tissues88. The initial steps in the
catabolism of prostaglandins Eo and F^a are mediated by 15-hydroxy prostaglandin
dehydrogenase (PGDH) and A13-reductase to produce the biologically inactive 15-keto-
13,14-dihydro prostaglandin metabolites. Two types of dehydrogenase have been
described which use either NAD+ or NADP+ as cofactors and which have greater
affinities for PGE2 or PGF2a respectively10.
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General effects ofprostaglandins.^
i: Vascular: In general PGEs will cause vasodilatation whereas PGFs promote
vasoconstriction. Prostacyclin (PGE) is a potent vasodilator whereas thromboxane
(TXA2) is a vasoconstrictor.
ii: Platelet aggregation: TXA2 decreases cAMP levels and thus promotes platelet
aggregation. Conversely PGEs raise intracellular cAMP levels and inhibit aggregation.
Vascular endothelial cells generate PGE which inhibits platelet aggregation protecting
vascular walls from such aggregates.
ii: Bronchial system: PGEs relax and PGFs constrict the smooth muscle present in
bronchi and trachea.
iv: Gastrointestinal effects: Prostaglandins inhibit gastric secretion but increase intestinal
secretions and motility. They also alter the electrolyte balance in the intestinal cells. They
may thus be protective against gastric ulceration but can cause marked diarrhoea.
These general effects can be of relevance when considering the therapeutic uses and
potential side-effects of prostaglandins.
1.4 ii: Prostaglandin production by uterine tissues and alterations at
parturition.
Prostaglandins are widely accepted as playing a key role in the onset of parturition46'89.
This conclusion arises from three main avenues of research, namely that the administration
of exogenous prostaglandins results in uterine activity and cervical ripening at any
gestation 93-94, that there is an increase in the production of prostaglandins by uterine
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tissues during pregnancy and that an increase in the concentrations of prostaglandins in
amniotic fluid, blood and urine occurs during pregnancy and, particularly, at the time of
parturition 95-97
The effects of prostaglandins in the uterine tissues will be governed, as elsewhere, by the
rate of their synthesis and degradation. It is the rapidly induced COX-2 isoenzyme which
may be of most relevance to short term alterations in the synthesis of prostaglandins.
Their catabolism is initially by prostaglandin dehydrogenase (PGDH) and so alterations in
the levels of this enzyme will also affect the concentrations of prostaglandins available
locally.
PGF^a is a potent uterotonic agent both in vitro and in vivo. PGE2, also a uterotonin,
causes marked cervical softening and ripening and is widely used clinically for this
purpose as discussed in Chapter 1193.98 Blocking of prostaglandin synthesis with
indomethacin has been shown to abolish contractures in monkeys thereby promoting
uterine quiescence99.
Human amnion and chorion produce mainly PGEo whereas the decidua can produce both
this and PGF2a- An increase in the production of PGE2 and PGF2a in vitro by fetal
membranes, placenta and decidua at term has been described100'101. More specifically
after spontaneous labour there is an increase in the production of PGE2 and PGF2CX by the
amnion, a lesser increase in the decidual production of these prostaglandins and a marked
increase in the release of PGF metabolite by the chorion103. This increase in
prostaglandin production by human uterine tissues at term has been suggested to derive
from a fetal signal excreted via the fetal kidneys into the amniotic fluid where it could
affect the production of prostaglandins by the amniotic membranes89.103. The role of the
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prostaglandin produced by the fetal membranes has yet to be determined, in particular its
potential effect on the adjacent decidua. Although the amnion produces substantial
amounts of PGEt the chorion has been shown to contain high levels of PGDH (the main
catabolising enzyme)10-'104,105 jn one [n vjtro study of intact amnion and chorion it
was shown that PGE2 could cross these membranes at a similar rate to sucrose 10(1
supporting a possible in vivo effect of amniotic prostaglandins on the decidua or
myometrium. A later study, however, showed that while both the amnion and chorion
could produce PGE2 only a small proportion of that added to the amnion side of a
perfusion chamber could cross to the decidual side106. There is therefore debate as to
how much influence the PGE2 that is undoubtedly produced by the amnion can exert on
the decidua and myometrium.
The levels of PGDH activity in the fetal membranes has been compared in different areas
of the uterus using both immunoassay for enzyme activity and immunocytochemistry.
The levels of activity are highest in the region of the cervix in the non-labouring uterus but
are significantly lowered in this area after the onset of labour 107. A reduction in the levels
of the catabolic enzyme present in this tissue would provide a local mechanism for an
increased effect of the prostaglandins in the lower uterine segment and the cervix.
The increase in levels of prostaglandins in uterine tissues could alternatively or
additionally be the result of an increase in the liberation of arachadonic acid mediated by
phospholipases or an increase in the action of the cyclooxygenase enzymes or to both of
these effects46. In a study of the enzyme kinetics of PGHS in human amnion a significant
increase in the Vmax was noted in amnion obtained after spontaneous deliveries as
compared to that from caesarean delivery108. COX-1 gene expression has been
demonstrated in human endometrium and decidua using reverse transcription PCR109, in
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this study endometrial tissue was found to express much higher levels (two to three times
higher) of mRNA than decidual tissue obtained at elective caesarean section. This study
did not demonstrate any COX-2 RNA in decidua or indeed in endometrium, a finding
previously reported in a study showing that COX-2 expression in vitro occurred only in
response to inducing agents ^ ^ ancj confirmed by a study which demonstrated PGHS-2
by immunocytochemistry and in situ hybridisation in amnion and chorion but not in
decidua. These findings are in keeping with the proposed role of COX-2 as a rapidly
inducible enzyme which can cause marked but short-lived and easily modulated changes in
the uterine levels of prostaglandins.
The cervix produces PGE2, PGI2 and lesser amounts of PGF2«- Production of these
prostaglandins by the cervix has been shown to increase at term111 and receptors for both
PGE2 and PGF2a have been demonstrated in the cervix112. The levels of COX-2 double
in the rat cervix biopsied in spontaneous labour113.
Although the pharmacological effects of prostaglandins in ripening the cervix are
undisputed there has been much debate about the physiological effects of prostaglandins in
causing cervical ripening. Indirect evidence of the effects of prostaglandins on the process
of cervical ripening comes from a study in which the administration of aspirin, which
blocks prostaglandin synthesis, delayed parturition and also prevented cervical
ripening114. There have been conflicting reports on the effects of prostaglandins on
collagenase activity in the cervix but a study using improved methodology to detect
collagenase activity found no alteration in this after treatment with sulprostone (a
prostaglandin analogue) despite the cervical ripening produced in the treated group. It was
also found that there was no difference in the levels of collagen degradation products
detected in the cervix after prostaglandin treatment as compared with those in a placebo
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group115. In animal studies, prostaglandins have been found to increase the production of
GAGs. in particular the production of hyaluronic acid from fibroblasts and this is
associated with a decrease in collagen production and an increase in circulating levels of
chondroitin sulphate 116. The effects on the cervix of prostaglandins administered in vivo
are considered further in Chapter 2.
The precise method of action of the prostaglandins on uterine tissues and in particular the
signals for their production remain to be fully clarified. There appears to be much
interaction between the various areas of the uterus and in their production of eicosinoids.
For example, the vaginal administration of PGE246 leads to an increase in plasma levels of
PGF metabolite, suggesting that increased levels of PGE2, administered to the cervix
increases the production of PGF2« either by the cervix itself or elsewhere. It has also
been found that PGE2 increases the expression of intercellular adhesion molecules in
endothelial cells, a finding which may indicate a role for this prostaglandin in recruitment
of leucocytes into the cervix prior to ripening117.
Although prostaglandin production from uterine tissues has been demonstrated to be
increased following spontaneous labour it is possible that this is an effect rather than a
cause of labour. This argument was expanded by MacDonald and Casey 118 who found
that fluid from the forebag of amniotic fluid (i.e. that presenting in front of the baby's
head) contained higher concentrations of PGE2 and PGF2a than that obtained from behind
the presenting part. They concluded from this that the increase in prostaglandins
measured during labour was an effect of the trauma of cervical dilatation rather than a
causative factor. However, as discussed in a review by Kelly89 the area of decidua
exposed during cervical ripening may undergo activation and selective induction of PG
synthesis around blood vessels and thus there could be particular amplification of
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inflammatory signals in the region of the cervix and the forebag of membranes. This area
of controversy highlights the important issue that although an increase in the production
by uterine tissues of many factors can be demonstrated following parturition this does not
necessarily mean that their production has increased prior to and with a causative role in
the initiation of labour.
Role ofoestrogen andprogesterone.
In the myometrium oestrogen increases the responsiveness of a-adrenergic receptors
which leads to an increase in production of the uterotonin PGF2cx whereas progesterone
stimulates ^-adrenergic receptors causing a preponderance of prostacyclin synthase and
eventual relaxation of myometrial cells via cyclic AMP46'1^ Further evidence of the
actions of progesterone in modulating prostaglandin production has been elucidated
following the use of antiprogestins and is considered in detail below. Oestradiol can
stimulate cervical prostaglandin production following progesterone exposure and has been
used clinically to cause cervical ripening120.
1.5: CHEMOKINES
As discussed above, the exact mechanism by which prostaglandins facilitate cervical
ripening is not yet known. However it seems that although PGE2 does cause ripening this
is not due to a direct effect on the collagen degradation in the cervix. The actions of
prostaglandins on the cervix can be postulated to be via a series of intermediary
substances. In recent years attention has focused on the possible role of cytokines in this
process. These intermediaries act as local signals in inflammation and can have both
stimulatory and inhibitory effects. In the following review the role of interleukin-8 will be
concentrated on.
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Interleukin-8 (IL-8) is a member of the chemokine family. This is a group of structurally
and functionally related cytokines which all contain four conserved cysteine residues
which form two intra-chain disulphide bridges. They can be sub-divided into two families
according to whether the first two cysteine residues are adjacent (CC proteins) or
separated by an amino acid (CXC or a- chemokine proteins) ^1. IL-8 is a member of the
latter family as are platelet factor 4 (PF4) and (3-thromboglobulin. Monocyte
chemoattractant peptide-1 (MCP-1) is a member of the CC group which has also received
recent interest as having a possible role in the initiation of parturition. Many of the genes
coding for a-chemokines have been localised and assigned to chromosome 4q 12-21.
1.5 i: Interleukin-8
Interleukin-8 (IL-8) was first described1-- as a peptide, also known as neutrophil-
attractant peptide-1 (NAP-l) which was released from monocyte cultures stimulated by
lipopolysaccharide. It has since been found to be released by many other cell types 123,124
including endothelial cells, fibroblasts, some epithelial cells and also by neutrophils
following phagocytosis1-5. The latter finding suggests a feedback mechanism whereby
the effects of IL-8 in the target tissue can be amplified.
The initial description of IL-8 was of a 72 amino acid peptide with a molecular weight of
8383122 but it has since been found to exist in other forms. It is produced from a 99
amino acid precursor which is processed to release a 79 amino acid peptide. Another
biologically active form has also been described which contains 77 amino acids126. In
concentrated solution or on crystallisation IL-8 exists as a dimer which is stabilised by




As indicated by its synonym one effect of IL-8 is to attract neutrophils. In addition to this
it can activate these cells. It has also been found to act as a chemoattractant for T cells,
basophils and smooth muscle cells 124 and to cause endothelial cell proliferation in blood
vessels 127. The extravasation of neutrophils takes place by their adherence to and
subsequent diapedesis through the endothelial wall of blood vessels. For this to occur the
neutrophil first rolls along the endothelial cell surface, a process mediated by endothelial
P-selectin. It then adheres to the endothelial cell by means of an interaction between a
CD11-CD18 integrin heterodimer on the neutrophil surface with endothelial intercellular
adhesion molecule (ICAM-1). Chemoattractants, such as IL-8, facilitate this adhesion by
inducing the translocation of CD 11-CD 18 from its intracellular stores to the surface of the
neutrophil. It also causes the shape change and shedding of L-selectin from the neutrophil
surface which are prerequisites for neutrophil extravasation128. It has been proposed that
IL-8 does not attract neutrophils by creating a simple diffusion gradient but rather that it
binds to the endothelial cell walls of small venules (but not arterioles) promoting
neutrophil adhesion to endothelial cells and directly stimulate their emigration128.
Following the extravasation of neutrophils into tissues IL-8 causes their activation. This
produces a change in their shape, exocytosis of intracellular enzymes from their storage
granules and a respiratory burst129. The shape change is partially caused by the formation
of large thin cytoplasmic lamellae which alter the transmission of light by neutrophil cell
suspensions once they are activated130. Neutrophils contain two types of storage granules
the azurophil and the specific granules. The contents of the azurophil granules include
elastase, myeloperoxidase and lysozyme while the specific granules contain collagenase,
lactoferrin, Bjo-binding proteins and lysozyme. The contents of these granules can be
released without phagocytosis occurring. The third event in the activation of neutrophils
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is the generation of a respiratory burst. This results from the activation of NADPH-
oxidase, which is a trans-membrane complex which on assembly (this can occur within 2
seconds of neutrophil activation) transfers electrons from cytosolic NADPH to
extracellular oxygen1-9. This respiratory burst results in the formation of hydrogen
peroxide and superoxide radicals which are involved in the killing of pathogens.
IL-8 thus acts as a classical chemotaxin in that it both attracts and activates neutrophils
causing all of these characteristic events to occur 124,128,129 [t has a[so been shown to
have chemotactic action on T-lymphocytes131.
Regulation ofinterleukin-8production.
11-8 production is induced by LPS106 and also by other cytokines, including IL-1 (a and
(3) and TNFa 124,132 These cytokines have been shown to stimulate production of IL-8
in endothelium, epithelium and in fibroblasts 133. Dexamethasone is a potent inhibitor of
IL-8 production by monocytes 53T24and other cell types including fibroblasts 124,134
Interleukin-8 receptors.
Two specific IL-8 receptors have been described termed IL-8 receptor A (RA or 1) and B
(RB or 2)135"138 or alternatively CXCR1 and CXCR2139. IL-8 RA is a 350 amino acid
molecule which has a configuration characteristic of a G-protein linked receptor with
seven trans-membrane domains. IL-8 RB has 77% homology with the RA receptor and
consists of 355 amino acids. Both these receptors have been shown to be present in large
numbers on the human neutrophil 137,138 jhe genes for these receptors have been
mapped to chromosome 2q35.
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The effects produced by IL-8 are initiated by its binding to the specific cell surface
receptors, IL-8 R1 and 2 which are coupled to G-proteins which dissociate into their a
and Py subunits when the ligand is bound. The a subunits then activate phospholipase C
which leads to the generation of inositol triphosphate (IP3) and diacylglycerol (DAG). IP3
diffuses into the cytosol and facilitates calcium release from intracellular stores and DAG
activates protein kinase C.
IL-8 receptors types 1 and 2 have been described in human fetal membranes, placenta and
myometrium. The levels in placenta and amnion were noted to be increased in samples
taken after spontaneous labour as compared with those obtained at elective caesarean 141.
IL-8 can also be bound by the human erythrocyte chemokine receptor which also binds a
wide variety of other chemokines, including MCP-1. This receptor has been shown to be
the Duffy blood group antigen which is also a receptor for the malarial parasite
Plasmodium vivax ,35. It does not appear that the binding of IL-8 to this erythrocyte
receptor has any effect on the red blood cell and so it has been proposed that this receptor
acts to bind excess IL-8 in the blood and thus act as a clearance mechanism for high levels
of IL-8 in the circulation135.
Biological Effects ofInterleukin-8.
In rabbits intradermal injection of IL-8 induces plasma exudation and a massive local
infiltration of neutrophils but not of other leukocyte cells142'143. This accumulation of
neutrophils is particularly marked around the venules and is strongly enhanced by the
concomitant administration of PGEo142"144. In the absence of this vasodilator the
threshold for infiltration of neutrophils is about 10-11 mol IL-8, with the addition of PGE2
this threshold becomes around 10~14 mol IL-8 per site142'143. In addition to lowering the
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threshold level of IL-8 necessary to cause neutrophil infiltration the presence of PGE2 also
leads to a marked increase in the number of accumulating neutrophils and in the volume of
the associated plasma exudation144. A similar effect is seen following the injection of IL-8
into human skin145. A perivascular neutrophil infiltration is demonstrated that is time-
dependent and persists for several hours. This is similar to animal studies in which the
effects of IL-8 persist for up to eight hours143'144, suggesting that IL-8 is resistant to
inactivationfor at least this time period. IL-8 can bind to glycosaminoglycans in tissues
and its chemotactic activity is increased following binding to heparan sulphate 128.
A further biological role for IL-8 has been postulated following the finding that in vitro
and in vivo it acts as a potent angiogenic factor. When IL-8 was implanted into a rat
cornea, which is normally avascular, it caused an angiogenic response in all ten corneas
studied and produced no evidence of non-specific inflammation 137.
Interleukin-8 is therefore a chemokine which has been shown to aid the emigration of
neutrophils from blood vessels and to activate them in tissues, causing a shape change, the
release of storage granules they contain and a respiratory burst. It has a prolonged effect
in tissues, due to its resistance to inactivation and to its binding to glycosaminoglycans.
Its effectiveness in causing neutrophil movement is significantly increased in the presence
of PGE2. IL-8 is thus an attractive proposition as a mediator in the process of cervical
ripening and in the onset of parturition. As discussed above neutrophils are intimately
invol ved in the cervical changes at parturition and PGE2 is known to play a key role in the
mechanisms operating at this time. The possible steroid control of IL-8 production in
reproductive tissues would mean that its concentration could alter at the time of labour.
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lnterleukin-8 in uterine tissues: Endometrium.
Human endometrium, which becomes decidualised during pregnancy, consists of
glandular epithelium and stroma. Both of these cell types have been shown to produce IL-
8 in vitro. This production was significantly increased after addition of either TNF-a or
IL-la to the culture medium and this increase was associated with an increase in IL-8
mRNA production146. Kelly etal confirmed this production of IL-8 by endometrial cells
and also demonstrated that it was significantly decreased by the addition of either
progesterone or dexamethasone to the culture medium 147.
Using immunohistochemical techniques IL-8 in the human endometrium has been
localised to the perivascular areas of the endometrium 148.149. jhe specific
immunostaining did not occur in all vessels of the endometrium and was found in both the
proliferative and secretory phases of the menstrual cycle with the more recent study 149
demonstrating an increase in immunostaining for both IL-8 and PGE2 premenstrually
supporting the hypothesis of a role for neutrophil migration in the onset of menstruation.
This localisation was not endothelial but was associated with the smooth muscle cells in
the vascular wall.
Choriodecidua.
Decidual cells can be found on the chorionic surface of the fetal membranes and when
these cells were obtained from elective caesarean sections at term they produced high
amounts of IL-8 in culture150. The addition of progesterone to the culture medium
significantly inhibited the production of IL-8 whereas the concomitant addition of the
antiprogesterone mifepristone overcame this effect. The production of IL-8 was also
stimulated by the bacterial product lipopolysaccharide (LPS). A separate study confirmed
that group-B streptococcus stimulates IL-8 production by chorion cells 151. These studies
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suggest that a decrease in the effects of progesterone or the presence of significant
bacterial invasion of the decidua could increase levels of IL-8 leading to an increase in the
numbers of neutrophils present and to their activation. A study of the expression of IL-8
mRNA, however, using decidua, amnion and chorion from term and preterm labours in
the presence and absence of chorioamnionitis, did not find a difference in the mRNA
expression between any of these tissues 152. These tissues were all collected after
delivery and so the changes at the onset of parturition may have been masked by a
subsequent inflammatory cascade. The production of IL-8 by choriodecidual cells has
also been shown to be inhibited by dexamethasone 147.
In another study the production of IL-8 by choriodecidual cells was confirmed in samples
of both decidual and chorionic cells obtained from placentae at the time of elective
Caesarean section. In both cell types production was increased significantly and in a dose
dependent manner by the addition of either IL-lp or TNF to the culture medium. This
increase was associated with an increase in mRNA for IL-8153. In this study Dudley etal
proposed that a cytokine network exists in gestational tissues with intercommunication
between maternal and fetal tissues producing a cascade of cytokines. IL-1 and TNF have
been shown to stimulate PGE2 production by chorion, amnion and decidual cells145'154
and may thus amplify the effectiveness of IL-8, the production of which they also
increase. These findings were corroborated in a further study of choriodecidua and
amnion in which production of IL-8 by both tissues was demonstrated and it was shown




IL-8 mRNA has been demonstrated in fetal membranes and it has also been found that the
level of this is increased by stretching the membranes in vitro using mechanical force.
This study also demonstrated an increase in IL-8 receptors in decidua (but not amnion-
chorion) following the application of a mechanical stretch 156. It was therefore suggested
that the physical stretching caused by the expansion of the intrauterine contents may
provide a mechanism via IL-8 production to favour the initiation of parturition.
Amnioticfluid
The levels of IL-8 in amniotic fluid have been studied in samples acquired by
amniocentesis 133,157,158. j( has been suggested that while most samples from mid-
trimester and term patients do not contain detectable IL-8, a greater number of samples in
the term group do contain detectable IL-8133-157. a more recent study however showed
IL-8 to be present in the amniotic fluid of all women tested at term, whether they were
labouring or not159. In one study using samples tested from women in threatened preterm
labour all of those with positive microbiological amniotic fluid culture had quantifiable
levels of IL-8 whilst of those with negative amniotic fluid cultures higher IL-8 levels were
found in samples from those who delivered preterm than in those who did not157.
Amniotic fluid levels of IL-8 increase during term labour, even when there was no
bacteriological invasion of the amniotic fluid133-157.
Amniotic fluid IL-8 levels therefore increase during parturition, are associated with
positive amniotic fluid microbiological culture and are associated with an increased risk of
preterm delivery in the presence of sterile amniotic fluid cultures. In preterm labour, the
levels of amniotic fluid IL-8 were shown to be predictive of histological chorioamnionitis
50
158 and may thus have a potential use as an indicator for the likely success of tocolysis in
this clinical situation.
The levels of other inflammatory cytokines, TNFa and IL-1 and -6, in amniotic fluid have
been shown to be inter-related and to correlate with histological signs of inflammation in
the placenta160. IL-1 and -6 were found to be present in all the samples tested from
women after spontaneous rupture of the membranes, whereas TNFa was present only in
some of the samples. The presence of these inflammatory agents after membrane rupture
may however be a result of contact of the fluid with cervical or vaginal secretions.
Placenta.
Placental tissue culture in any stage of pregnancy produces IL-8 in increasing amounts
with advancing gestation or in the presence of chorioamnionitis161. IL-8 has been
localised immunohistochemically to the trophoblast cells of the placenta with no staining
seen in endothelial or mesenchymal cells.
Cervix.
Cultures of fibroblasts from the cervices of pregnant rabbits produce IL-8162. This is
increased by IL-1 a and (3 and is inhibited in a dose dependent manner by the addition of
progesterone. This inhibition of IL-8 production is reversible by the addition of
mifepristone. These changes are all associated with similar changes in the levels of
mRNA for IL-8.
Human cervices from first trimester pregnancies and from non-pregnant, pre- and post¬
menopausal women all produce IL-8 in culture. This production was significantly
increased by the addition of phorbol myristate acetate (PMA, a protein kinase C activator)
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except in the post-menopausal group. Progesterone did not inhibit this stimulation. There
was no difference in the production by cervices from women in the first trimester who had
received a PGE analogue prior to sampling and those who had not43.
In biopsies of cervices of women at term IL-8 production has been demonstrated. This
production is increased as compared to non-pregnant control biopsies and is further
increased in biopsies obtained after vaginal delivery163.
In both guinea pigs164 and rabbits165 the direct application of IL-8 to the cervix causes
softening and dilatation. In rabbits this is associated with a significant increase in the
water content, the glycosaminoglycan concentration and the mean number of neutrophils
of the cervices. There is a decrease in the collagen content of the cervices. These findings
were found in both pregnant and non-pregnant animals. In guinea pigs the effects of IL-
1(3 and TNF-a were also studied. It was found that the local application of these
cytokines to the cervix of the guinea pig caused histological changes similar to those found
in physiological cervical ripening. TNFa, however, produced a more severe
inflammatory type reaction with infiltration of lymphocytes and macrophages in addition
to the neutrophil invasion seen in all of the cervices treated with cytokines. Of the three
cytokines, only IL-8 caused a significant alteration in the cervical extensibility as measured
by mechanically testing to determine its elastic properties164. In a study where both IL-8
and dehydroepiandrosterone sulphate (DHEAS) were applied to rabbit cervices, it was
found that both treatments reduced the collagen content of the cervix (as assessed by
staining with picrosirus red) but that this decrease was greatest when the two were used in
combination. Influx of neutrophils into the cervical tissue was noted after IL-8 application
but again this was greater when IL-8 and DHEAS were applied concomitantly 166.
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The cervix is therefore capable of producing IL-8 in both human and animal models.
When IL-8 is applied to the cervix in animals it causes changes equivalent to physiological
ripening, including neutrophil invasion.
Plasma
An increase in plasma levels of IL-8 during pregnancy as compared with the non-pregnant
state has not been found133. An increase in serum IL-8 has however been demonstrated
in women at term with histologically confirmed chorioamnionitis as compared with serum
from non-affected women. This was a significant increase and was compared with other
markers of infection such as white cell count, C-reactive protein and the cytokines IL-1
IL-6 and TNF-a which did not show a consistent rise in the presence of chorioamnionitis
167 In preterm women with chorioamnionitis a similar increase in plasma IL-8 has not
been demonstrated, whereas in this group an increase in IL-6 has been shown 168.
1.5 ii: Monocyte chemotactic peptide-1 (MCP-1).
This is a 76 amino acid protein that was initially called lymphocyte derived chemotactic
factor (LDCF). It is a C-C cytokine (i.e. there is no residue between the first two
cysteines in the protein) and is a heterogeneous protein existing in both a and (3 forms. It
was first described in 1989 on being obtained from lymphocyte culture169 and as its name
implies is able to attract blood monocytes which are also capable of its production in large
amounts. In addition to its effects on monocytes it is chemotactic for basophils,
eosinophils and lymphocytes but not for neutrophils. In vivo, however, its effects on
monocytes are the most marked. Its chemotactic effects seem to be limited to blood
macrophages, tissue macrophages being unresponsive170. MCP-1 also causes an increase
in monocyte secretion of IL-1 and IL-6 171. IL-1 in particular is known to stimulate IL-8
production and so release of MCP-1 could act as an indirect stimulant of IL-8 production.
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As with IL-8 its production by cells has been shown to be stimulated by IL-1, TNFa and
LPS 124
1.6: WHITE CELL POPULATIONS IN THE PREGNANT UTERUS.
The changes in the immune environment of the uterus at all stages of gestation are
complex and the results of studies are at times contradictory. It does appear however that,
both in early and late pregnancy there are altered immune responses in the uterus. In early
pregnancy these changes may protect the fetus from rejection by the maternal immune
system, whereas in later pregnancy a cascade of inflammatory events may precipitate
labour and the ultimate expulsion of the fetus.
The leucocyte populations of the uterus alter during pregnancy. These populations have
mainly been studied by the identification of their cell surface markers which are classified
according to the CD (cluster of differentiation) type17-. The common marker for all
leucocytes is CD45 which can exist in RB, RA and RO forms. Leucocytes are abundant
in the first trimester decidua, with over 30% of stromal cells expressing the leucocyte
common antigen348. These decidual leucocytes consist of three main types: macrophages,
granulated lymphocytes and T lymphocytes.
Macrophages
There are significant numbers of tissue macrophages present throughout pregnancy in the
placenta and decidua which can elaborate cytokines, such as IL-1 and TNF-a and also
PGE21 -4,160,173,174 These cells may thus have a central role in the proposed
inflammatory cascade of parturition, their activity resulting in an increase in IL-1, TNF
and thus IL-8 production. In the human cervix, a ten-fold increase in the number of
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macrophages present was noted in immunohistochemicai studies of biopsies from term as
compared with first trimester pregnancies175. This increase in numbers could be pivotal
in amplifying the proposed inflammatory cascade leading to cervical ripening and
dilatation.
The prostaglandins produced by decidual tissue appear to be derived from a macrophage
population176-177, in contrast to the endometrium in which the source of prostaglandins is
the stromal cells178. Lopez Bernal and Watson used flow cytometry to separate decidual
cells from fetal membranes and then labelled them immunocytochemically to determine
their antigen markers. The subsequent analysis of prostaglandin (PGE and PGF)
production from these cells showed that CD45 positive cells (i.e. bone marrow-derived)
produce more prostaglandins than CD45 negative cells and that it is the macrophage
subgroup (labelled with HLA-DR) which produce the most prostaglandins179. The PGE2
produced may have direct effects, for example on the myometrium and could also act
synergistically with IL-8 to facilitate neutrophil recruitment into the uterine tissues.
Lymphocytes
During early placentation the number of large granular lymphocytes (LGLs) in the decidua
increases markedly.146 These are cells of an unusual phenotype which may aid in the
protection of the fetal tissue from immune surveillance. They account for up to 75% of
leucocytes in the first trimester decidua349. LGLs are strongly positive for CD56, an
antigen expressed by natural killer (NK) cells but not for the other NK antigens, CD 16 or
CD3 nor the T lymphocyte antigens CD3, 4 or 8. Despite their NK lineage these first
trimester LGLs do not lyse trophoblast cells350. Their number increases markedly in the
first trimester and then shows a significant decrease as pregnancy advances174. Decidual
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CD56+ cells from early pregnancy have been shown to be capable of producing a large
amount of IL-8 and to express IL-8 mRNA180.
The proportion of lympnocytes that are T-cells (CD3 positive) increases during
pregnancy, doubling by the third trimester174, as the proportion of CD-56 positive cells
decreases.
In addition to their altered concentrations in pregnancy, decidual lymphocytes isolated
from term human placentae respond differently to antigenic stimulation than peripheral
lymphocytes from the same women181. The decidual cells were found to produce
granulocyte-macrophage colony- stimulating factor (GMCSF) both spontaneously and on
stimulation whereas peripheral cells did not. This finding suggests that lymphocytes from
gestational tissues may respond in a different way to their immunological environment
than plasma cells and thus that the uterus may function as a separate immunological
environment.
During early placentation the number of large granular lymphocytes in the decidua
increases markedly146 These are cells of an unusual phenotype which may aid in the
protection of the fetal tissue from immune surveillance. The number of T-cells (CD3
positive) increases during pregnancy, doubling by the third trimester, whereas the number
of cells that are CD-56 positive increases markedly in the first trimester and then shows a
significant decrease as pregnancy advances. CD3 is a polypeptide marker of T-
lymphocytes and CD56 a marker for natural killer (NK) cells 17-. Decidual CD56+ cells
from early pregnancy have been shown to be capable of producing a large amount of IL-8
and to express IL-8 mRNA180.
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In addition to their altered concentrations in pregnancy, decidual lymphocytes isolated
from term human placentae respond differently to antigenic stimulation than peripheral
lymphocytes from the same women181. The decidual cells were found to produce
granulocyte-macrophage colony- stimulating factor (GMCSF) both spontaneously and on
stimulation whereas peripheral cells did not. This finding suggests that lymphocytes from
gestational tissues may respond in a different way to their immunological environment
than plasma cells and thus that the uterus may function as a separate immunological
environment.
Neutrophils
The above study which described the leukocyte populations in early and late pregnant
cervices showed an increase in the neutrophil concentrations during pregnancy but not
during labour in the cervical biopsies studied175. This indicates the possibility that the
increase in neutrophil population precedes and is not an effect of labour.
Eosinophils
An increase in the concentration of eosinophils in the cervix during pregnancy has been
noted in a study comparing biopsies from women who delivered vaginally or at elective
caesarean with those in early pregnancy and with non-pregnant controls 18~. Although the
sample studied was small, an increase in the number of eosinophils was noted after
vaginal deliveries. This may reflect the inflammatory changes in the cervix during labour
or could, as the authors of this study suggest, indicate a role for eosinophils in the onset
of cervical ripening at term.
Although the changes in maternal peripheral white cells populations may not be an
accurate reflection of changes in their concentrations or activity in uterine tissues, there are
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marked changes evident in maternal plasma at the time of parturition. A consistent rise in
the neutrophil count has been found, with a concurrent lymphopaenia as compared with
non-pregnant women 183. This lymphopaenia was found to be a result of a decrease in
almost all types of T-and B-cells studied.
1.7: THE ROLE OF PROGESTERONE IN THE ONSET OF
PARTURITION
In 1975 Csapo described the "see-saw" theory of pregnancy regulation in which there is a
balance between the factors that promote pregnancy maintenance and those which favour
its termination184 This theory related in particular to the effects of PGF2a which is an
intrinsic stimulator of uterine activity, the effects of which are decreased when the uterus
is dominated by progesterone.
Progesterone and oestradiol have been shown to affect the function of the components of
the uterus, often in opposite ways. In the guinea pig cervix, for example, oestradiol
stimulates the degradation of type I collagen whereas this effect is blocked by the addition
of progesterone-3. In the myometrium the changes associated with parturition, such as
the increase in gap junctions and the change from the contracture to a contraction pattern of
activity have been related to alterations in the hormonal environment. In monkeys, there is
a pre parturient increase in oestrogen prior to the onset of switches from contractures to
contractions61. This may be due to a combination of the effects of oestrogen which
stimulates oxytocin receptor production in the myometrium and decidua, stimulates
prostaglandin production and also stimulates the formation of gap junctions. Other factors
which may also be involved in this switch include oxytocin, the antagonism of which
decreases the frequency of contractures64 or even physical stretching of the myometrium
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as in experimental conditions expansion of the uterus with saline infusion increases the
frequency of contractures and eventually results in a switch to contractions64.
In rat myometrium there is a significant increase in nuclear oestrogen receptors and
decrease in progesterone receptors at the time of parturition. These alterations correlate
with an increase in the area of gap junctions in the myometrium, but not with the levels of
steroids in the serum68. Administration of oestradiol to immature or to mature
ovariectomised rats185 caused an increase in the numbers of myometrial gap junctions
similar to that seen in parturient animals. The gap junctions thus induced were however
only about half of the area of those demonstrated at the time of labour. Administration of
progesterone inhibited this effect of oestradiol. Indomethacin enhanced the effect of
oestradiol in inducing gap junctions. The latter finding seems paradoxical if
prostaglandins are required for the increase in gap junctions seen at labour. It may be
however that indomethacin differentially inhibits the production of prostaglandins that
suppress gap junction formation such as prostacyclin has been proposed to do. Connexin
production is thought to be upregulated by progesterone withdrawal from the
myometrium53'186 jjje increase in gap junctions at the time of labour that has been
demonstrated in many species including humans70 may therefore be due to an increase in
connexin production facilitated by decreasing local levels of progesterone and enhanced by
rising levels of oestrogen and alterations in prostaglandins present.
In many of the events in the cervix and myometrium associated with parturition,
progesterone acts to promote quiescence whereas oestradiol can act in an opposing
manner. It is thus proposed that a decrease in available progesterone levels at the time of
the onset of parturition enables cervical ripening and myometrial contractions to proceed.
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Csapo also described the delicate nature of pregnancy maintenance by progesterone in the
rat in which a gradual decrease in progesterone in the mid-trimester allowed the
continuation of the pregnancy whereas an abrupt withdrawal led to termination of the
pregnancy187. In sheep, there is a well defined pathway by which increased fetal
secretion of ACTH stimulates an increase in fetal adrenal production of Cortisol which acts
as a substrate for increased placental oestradiol production 188ri89 a recent study in
Rhesus monkeys found that the administration of epostane (which inhibits progesterone
production by selectively inhibiting 3-beta-hydroxysteroid dehydrogenase) caused cervical
ripening, uterine activity and delivery within 48 hours. This was associated with an
increase in the amniotic fluid levels of PGE2. This study also showed that the
administration of progesterone alone to these animals did not inhibit spontaneous
parturition at term190.
In humans, however, such a clear mechanism has not yet been described. It has been
shown, however, that there is an increase in the salivary oestriol / progesterone ratio in the
three weeks preceding the onset of spontaneous term labour in women191 and that this
increase does not occur in women whose labours are induced post-term192. This increase
in the ratio of these hormones in saliva is caused by an increase in oestrogen levels rather
that by an absolute decrease in the progesterone level191ri92 peripheral plasma levels
of progesterone, oestradiol, oestriol and dehydroepiandrosterone sulphate (DHEAS: a
precursor of oestrogen) were measured in women with ripe (i.e. with a modified Bishop
score193 of greater than 4) and unripe cervices prior to the induction of labour and it was
found that the group with ripe cervices had a significantly raised level of DHEAS but not
of the other steroids194. These results are similar to those obtained from rhesus monkeys
in which DHEAS levels rise in the latter stages of pregnancy with an acceleration in this
increase before parturition195. There may be an alteration in the ratio of oestrogen to
60
progesterone prior to the onset of labour in humans, possibly due to an increase in the
production of oestrogen precursors.
Recent work has shown that preterm labour is associated with an increase in
corticotrophin releasing hormone (CRH) and a fall in its binding protein, in both preterm
and term deliveries196-197. It has also been found that plasma CRH concentrations are
higher in those women who eventually deliver preterm than in those who deliver post-
term197. A 'placental clock' is proposed which acts to govern the gestational length of the
pregnancy197-198. This 'clock' could presumably be over-ridden by events such as
infection that could bypass the steroid balance and cause direct stimulation of the
inflammatory cascade leading to labour.
Progesterone Receptors.
The effects of progesterone on uterine tissues are caused via its receptors, either nuclear or
cytosolic, the structure of which is considered further in the following chapter.
Progesterone down-regulates the levels of both progesterone and oestradiol receptors199
in the non-pregnant and pregnant uterus.
The number of nuclear progesterone and oestrogen receptors in human amnion, chorion,
decidua and myometrium decreases as pregnancy advances-00"-9-. Indeed, in one
study-00 there were no detectable receptors in the term tissues studied. A possible
explanation suggested was that these specific receptors are replaced by less specific
binding sites in these tissues at later gestations. This lack of nuclear progesterone
receptors in placenta and membranes was also found in another study of tissue obtained
from elective caesarean sections prior to labour at term-01. This group did, however, find
detectable progesterone receptors in the decidua and myometrium. These receptor levels
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contrasted with the high levels of progesterone found in placenta and fetal membranes, the
possibility being suggested that the lack of receptors at these sites allowed progesterone to
reach the deciduaand myometrium to maintain uterine quiescence.
In a more recent and detailed study of the receptors in the specific cell types of the
endometrium and decidua-0- progesterone receptors were demonstrated in the nuclei of
decidual stromal cells and in the walls of spiral arteries throughout pregnancy but were
down-regulated in the epithelial cells. Oestradiol receptors were down-regulated in all the
endometrial cell types at each gestation and increased following mifepristone treatment
indicating that their down-regulation was due to the action of progesterone.
Understanding of the effects of progesterone on prostaglandin metabolism has been
improved by the antagonist mifepristone and a full discussion of these effects is
considered below. In summary the effects of the antigestagen are to increase
prostaglandin production and decrease its metabolism by PGDH. The effect of
progesterone in many reproductive tissues is to inhibit the production of IL-8. A decrease
in the local action of progesterone, either due to a fall in its proportion relative to
oestrogens or to a decline in the number of available receptors could thus lead to an
increase in the levels of prostaglandin Eo and IL-8 in the uterine tissues. An increase in
these levels would favour neutrophil recruitment into the uterine environment, including
the cervix, where they could then promote the events leading to cervical ripening. This
would occur in an environment of increased inflammatory activity in which other
cytokines, such as MCP-1, IL-1 and TNF, elaborated by lymphocytes and macrophages
could act in a positive cascade promoting the events of parturition.
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INTRODUCTION.
It is possible to use pharmacological or mechanical means to interrupt pregnancy at any
gestational stage. To accomplish this the events of normal term parturition must be
imitated such that the cervix softens and dilates and myometrial contractions are produced.
In early pregnancy the alternative is to physically empty the uterine cavity by surgical
methods such as vacuum aspiration or the less commonly used dilatation and evacuation.
Both these techniques use physical dilatation of the cervix, usually with a series of dilators
of increasing circumference. Regardless of the stage of interruption of pregnancy the
degree of softening of the cervix is of paramount importance. In surgical procedures
preoperative softening of the cervix decreases the risk of damage to the cervix. In medical
terminations in the second trimester it is advantageous to have improved cervical
compliance to reduce the duration of the process and also reduce the risk of uterine
rupture116. In the third trimester the induction of labour also necessitates cervical
dilatation and, as will be discussed below, the degree of cervical ripeness prior to labour
induction is predictive of the ease of that induction. When considering the dilatation of the
cervix at any stage of pregnancy there is an essential difference between forced dilatation
where force is applied along the length of the circumferential fibres against the strength of
the fibres and the ground substance and the dilatation achieved by the action of uterine
contractions in which the force is from above at right angles to the fibres separating them
"like a trellis"11.
This review will focus mainly on methods of promoting cervical ripeness, with reference
also to the production of uterine contractions in the third trimester. The effects of the
antiprogesterones, in particular mifepristone, are central to the elaboration of the
hypothesis that progesterone antagonism will lead to cervical ripening and plays a role in
64
the onset of normal parturition. These agents are considered together in the final section
of this chapter.
2.1: TERMINATION OF PREGNANCY.
If pregnancy is interrupted before the fetus is viable (currently adjudged to be at 24
weeks), the pregnancy is regarded as having been terminated, rather than labour having
been induced. This may legally be performed, in Great Britain according to the 1968
Abortion Act, if there is a substantial risk of fetal anomaly or if the mothers well-being is
at risk if the pregnancy continues or if the well-being of existing children would be
compromised by the continuation of the pregnancy. Although the legalisation of abortion
has greatly reduced the maternal morbidity and mortality of the procedure there are still
associated complications. In the period of 1988 to 1990 one death was recorded as a
consequence of a termination of pregnancy which was due to a cervical tear during a mid-
trimester surgical procedure thus emphasising the potential hazards of forced cervical
dilatation-03. In uteri removed immediately following cervical dilatation tears of the
internal os were found around 40% of the specimens examined-04.
Cervical ripening may also be used prior to surgical evacuation of retained products of
conception in a non-viable pregnancy. This may be of particular benefit in a primigravida
whose cervix will often be less distensible during mechanical dilatation than that of a
parous woman.
Cervical ripeningprior to surgical techniques.
The techniques developed are either physical employing intracervical devices or
pharmacological using prostaglandins. The more recent use of the antiprogesterone
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mifepristone is discussed below. Dilatation can be traumatic to the non-compliant cervix
causing trauma or lacerations205 and has been implicated in the aetiology of an
incompetent cervix, which causes mid-trimester pregnancy losses and preterm delivery.
Difficult dilatation of the cervix is also associated with uterine perforation, necessitating
laparoscopy or even laparotomy and with an increase in perioperative blood loss206.
2.1i: Mechanical cervical ripening.
The use of intracervical dilators has been practised for over 100 years, the first such
devices being prepared from seaweed116. There are three types of intracervical tents
currently available207. The laminaria tent is composed of sticks of seaweed which act as
an osmotic dilator which expands as it absorbs water to exert a considerable force per unit
area on the cervix208. This is no longer used in the UK in view of the length of time it
takes to act. Dilapan is a synthetic form of this compound which is claimed to have a
faster action, acting in two to four hours compared with four to twelve hours116.
Lamicel, another synthetic product, is a poly-vinyl alcohol polymer impregnated with
magnesium sulphate which acts as a sponge absorbing water from the cervix. Unlike the
former two devices it does not exert a physical force on the cervix207 but may act by
altering the matrix of the cervix209. The use of all these devices effectively decreases the
cervical resistance to subsequent dilatation210-211 and also decreases the incidence of
complications such as bleeding or uterine perforation211. The mechanism of action of
these tents may not be due simply to a mechanical effect as it has been found that
following insertion of laminaria tents the plasma levels of PGFoa metabolite are increased
suggesting that the mode of action may involve increased synthesis of prostaglandins.
Histologically after dilatation with Lamicel the changes are similar to those seen in
physiological cervical ripening with a decrease in the collagen, an increase in the water
content and infiltration of inflammatory cells 212.
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Lamicel tents have been compared with the prostaglandin analogue gemeprost (16, 16-
dimethyl-transA2 PGEj methyl ester, Cervagem) pessaries prior to surgical termination of
pregnancy but conflicting results have been reported. In an open study both treatments
made cervical dilatation easier to perform as compared with placebo with no difference
between the two interventions. The prostaglandin pessaries caused more pain following
their insertion than the Lamicel-13. In a later blinded study, however, it was found that
cervical dilatation was easier following the administration of gemeprost than Lamicel with
no difference in their side-effect profile-14.
2.1 ii: Pharmacological cervical ripening.
The potential role of prostaglandins in cervical ripening has been discussed in the previous
chapter. Prostaglandins have been utilised to terminate pregnancies for the past 30 years
either in conjunction with surgery as a preoperative ripening agent or to effect medical
termination of pregnancies, particularly at later gestations116. Pre-operative treatment with
prostaglandins has been shown to soften the cervix leading to easier dilatation and
decreased peri-operative blood loss215"218.
PGF2a
Both intravenous and intrauterine infusions of PGF2« will cause abortion in some women
they are administered to but even with large doses only around half or less of those treated
will abort, the intravenous route being rather more effective. Administration of these large
doses caused marked rises in intrauterine pressure but did not always lead to cervical
dilatation. These regimes were associated with severe gastrointestinal side-effects219. In
1976, improved results were reported after administration of extraovular PGF2a in a
'double impact' regimen in which an initial prostaglandin dose was used to destabilise the
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regulatory mechanisms of the uterus followed by further boluses as necessary. Patients
required sedation prior to this procedure--0.
pge2.
The local or systemic administration of PGE] or PGE2 has now replaced PGF2a in the
management of pregnancy termination. In the first or mid-trimester of pregnancy the
primary prostaglandin is less effective than its synthetic analogues which have been
designed to hinder inactivation by prostaglandin dehydrogenase. Examples of these
analogues include sulprostone (16-phenoxy-tetranor-PGE2-methyl sulphonamide) given
intramuscularly, gemeprost (16, 16-dimethyl-transA2 PGEi methyl ester, Cervagem)
given intravaginally or misoprostol (a PGEj analogue) given orally or intravaginally. The
latterhas the advantage of being cheap and has been shown to be equally as effective as
gemeprost in producing cervical ripening--1.
In the first eight weeks of pregnancy use of these preparations will result in about 90%
success in effecting termination of pregnancy avoiding the need for anaesthesia and in¬
patient hospital admission. Some patients, however may experience the predictable
gastrointestinal side-effects caused by prostaglandins and some will have severe uterine
pain116. The use of mifepristone as an adjunct to medical termination of pregnancy is
discussed below.
At eight to twelve weeks of gestation most clinicians will employ surgical termination of
pregnancy. The use of prostaglandins preoperatively will however increase the initial
dilatation of the cervix, the ease with which it can subsequently be dilated and reduce the
blood loss during the procedure215"218. These effects have been demonstrated with
vaginal PGE2215, gemeprost pessaries216'218 and more recently vaginal or oral
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misoprostol, a PGEi analogue217. In 1984, the Medical Advisory Committee of the
International Planned Parenthood Federation recommended that these agents should be
used routinely prior to suction termination116.
At later gestations the use of PGE2 either vaginally in the form of gemeprost pessaries or
by the extra-amniotic route222 will produce termination in most cases. The use of PGE2
by either route rather than PGF2« is associated with improved cervical softening and is
less likely to cause uterine rupture as compared with intraamniotic PGF2a
The histological changes associated with the administration of prostaglandins have been
reported in several studies218'224'225. Gemeprost administration prior to taking a cervical
biopsy at the time of surgical termination in the first trimester was found to cause a
significant reduction in the polymerised collagen concentration of the cervix (as measured
by the optical densitometry of Picrosirius red staining) and a modest neutrophil influx as
compared with placebo administration. No change in the GAG content of the cervix was
noted following prostaglandin administration in this study218. Microscopy of the cervix
following PGE induced mid-trimester termination showed dispersed collagen fibrils in an
increased amount of ground substance with neutrophil invasion noted in samples of the
cervix obtained from more proximal regions225. This effect of prostaglandin
administration on the collagen concentration has been shown to be associated with an
increase in the activity of collagenase and elastase in cervical biopsies. The levels of these
enzymes increase with the length of time after PGE administration that biopsies were
taken224. In this study an increase in the hyaluronic acid concentration was described in
around half of the cervices examined. No alteration has been found in the collagen
structure of the amnion following mid-trimester termination of pregnancy using a vaginal
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PGEi analogue, suggesting that the uterine tissues can respond differently to the local
administration of prostaglandins2-5.
The histological effects of prostaglandin E or its analogues on the cervix therefore closely
resemble the collagen dissociation and inflammatory infiltrate seen in physiological
cervical ripening giving a good basis for its use for this purpose in the first and second
trimesters of pregnancy and also supporting the role of endogenous prostaglandins in the
normal process of cervical ripening.
2.2: CERVICAL RIPENING AND INDUCTION OF LABOUR.
2.2i: Historical considerations
Many methods have been tried over hundreds of years to induce labour. These have been
extensively reviewed by Thiery231. The first recorded attempts used manual dilatation of
the cervix which was superseded by the use of intracervical tents, such as the laminaria.
Mechanical methods to induce labour also included the insertion of bougies or catheters
into the cervix or the extra-amniotic space. An alternative was to infuse large amounts of
fluid into the vagina or uterine cavity. The procedure of amniotomy was first utilised to
promote the onset of labour in the mid- 18th century. Both high (or hindwater) and low
amniotomy techniques were described but neither was consistently effective and as they
were associated with a high incidence of intra-uterine infection their use was discontinued
for many years. In the last forty years the use, particularly of low amniotomy, has once
again become part of obstetric practice, most often in conjunction with oxytocin infusions
as first described in 1968 227 High amniotomy is very rarely performed now but a Drew-
Smythe catheter may still be occasionally employed for this purpose.
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The earliest non-surgical methods of inducing labour used cloths which were soaked in
plant extracts and then packed into the vagina. The administration of ergot, also used as
an abortifacient, was revived during the early 19th century but was discontinued due to the
severe risks of hypertonus. The discovery of ergometrine in the 1930s led to a re-
evaluation of its use in labour induction but it is now solely used to control third stage
haemorrhage.
During the 19th century most attention was focused on the mechanical methods of
inducing labour but in the early twentieth century a 'medical induction' was proposed by
Watson 228 This method involved the administration of castor oil, quinine and pituitary
extract. This was further combined with a hot bath and a hot soap enema. Although the
first two elements and baths and enemas are no longer used, the purification of pituitary
extract to produce oxytocin was a major milestone in the development of pharmacological
methods to induce labour. Indeed those responsible for the characterisation and
purification of oxytocin and antidiuretic hormone were awarded a Nobel prize in 1955.
Oxytocin was initially used in continuous infusions but the use of a titrated regimen as
described by Turnbull and Anderson227 in combination with amniotomy improved its
efficacy and decreased the risk of uterine hypertonus. At this time use of the
prostaglandins to induce labour was also being reported229. The initial work reported in
1968 used PGFoa with the similar action of PGE2 being reported in the following
year230.
'Natural' methods to induce labour have also been advocated, for example nipple
stimulation and sexual intercourse. Nipple stimulation has been shown to provoke uterine
contractions by causing release of oxytocin from the posterior pituitary but it has been
suggested to have a risk of uterine hypertonus231. A study of 300 women of at least 39
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weeks gestation who performed this for 3 hours per day showed a significant reduction in
the incidence of post-term pregnancies with no alteration in the rate of caesarean
section23-. Sexual intercourse has theoretically been proposed to increase the likelihood
of labour occurring due to the prostaglandin content of semen and the suggestion that
female orgasm is associated with oxytocin release but this has not been formally evaluated
as a method of labour induction231.
There have therefore been numerous methods utilised in the attempt to induce labour over
centuries of obstetric practice. As the physiological mechanisms of cervical ripening and
dilatation and the control of myometrial contractions are more clearly understood such
methods can hopefully be refined to mimic the normal physiology of parturition as closely
as possible to minimise the risks of side-effects and the chance of the procedure failing.
2.2 ii: Indications for and risks of labour induction.
As the methods described above have been developed and refined it has become apparent
that none are without risks to the mother and to the fetus. The use of either prostaglandins
or oxytocin can cause uterine hyperstimulation resulting in hypertonic contraction of the
myometrium. This can contribute to fetal hypoxia and, if prolonged, necessitate
emergency caesarean delivery. Oxytocin and its synthetic derivatives have weak anti¬
diuretic hormone actions and thus administration of large amounts over time in fluid may
provoke fluid retention and pulmonary oedema. Prostaglandins, even when administered
vaginally, can cause gastrointestinal side-effects, such as vomiting and diarrhoea and
uncomfortable uterine contractions.
In addition to the side-effects inherent in the use of these agents the process of induction
of labour carries additional drawbacks. The procedure may take a variable length of time
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during which the mother will be an in-patient in the maternity unit, in primigravidae in
particular it may take at least 24 hours for labour to become established after the initial
attempt to ripen the cervix. It may also be that the procedure will fail to induce labour
within a given time span or with a given regimen of drugs. In such cases clinicians must
then decide whether to abandon the attempted induction or to proceed to caesarean section.
It is therefore of vital importance that, in addition to the development of safe and effective
methods of inducing labour, the conditions in which labour should be induced are
carefully evaluated. There are many clinical scenarios in which the risks to the mother or
to the fetus of the pregnancy continuing outweigh the potential risks of induction or of
delivery of a possibly preterm infant. Such a decision will be made in a situation where it
is on balance safer to induce labour but where the condition of neither the fetus nor the
mother requires the rapid and less stressful delivery of a caesarean section.
In many cases the risks to mother or fetus of the pregnancy continuing are fairly clear.
However, many inductions are performed for the reason that the pregnancy is 'post-term'
and this indication has received much recent attention. The definition by the World Health
Organisation of a post-term pregnancy is one which exceeds 42 completed weeks or more.
There has been evidence to suggest that perinatal mortality is slightly increased after this
time-33. The question of whether to induce labour after 41 weeks or whether to monitor
the pregnancies and only deliver those in which there is evidence of compromise has been
addressed by several studies, the largest being reported by the Canadian Multicentre Post-
term Pregnancy Trial Group 234 This group studied 3407 women at gestations of over
41 weeks and randomly allocated them to either having labour induced or to serial
antenatal monitoring with Caesarean delivery being performed in the presence of any
evidence of fetal compromise. There was no significant difference in the perinatal
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mortality rate between the two groups nor in the neonatal morbidity. There was a
significant reduction in the rate of caesarean sections in the induced group but this may be
due in part to the rather rigid policy of performing caesarean rather than inducing labour if
fetal compromise was suspected-35. The low rate of perinatal loss of two in over three
thousand cases reflects the low rate of perinatal mortality in developed countries which at
41 weeks is estimated at 2 per 1000 rising to 3 per 1000 at 42 weeks and 4 per 1000 at 43
weeks333-336'-37. These figures are however based on small numbers of cases and may
not be a true representation of the figures. 333'333 This low rate of an outcome measure is
one reason that the use of meta-analysis, such as in the Cochrane database is a significant
advance in the evaluation of clinical trials. Using this technique to examine randomised
controlled trials comparing elective induction after 41 weeks with conservative
management, it was found that induction decreased the incidence of perinatal death in
normal babies (relative risk 0.23; confidence interval 0.76 - 0.98)338. In practical terms it
has been calculated that this means inducing 500 women to prevent one perinatal death
occurring335. This meta-analysis indicates that routine induction of labour is not
associated with any major adverse events for mother or fetus, reduces the already small
risk of perinatal death and may be associated with a reduction in the caesarean section
rate333-339.
In view of the potential problems of labour induction it is therefore essential that before
induction is embarked upon the reasons for this are carefully evaluated and the potential
risks and benefits of the procedure explained to the mother.
2.2 iii: Cervical ripening prior to labour induction.
Induction of labour requires progressive cervical dilatation and regular uterine
contractions. It has been found that the success of induction relates to the 'ripeness' of the
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cervix prior to the onset of the induction procedure. The ripeness of the cervix can be
quantified by scoring of various criteria on vaginal examination, such as the system
described by Bishop in 1964 which was originally designed for use in multiparous
patients193. Scores were assigned according to the cervical dilatation, percentage
effacement, consistency and position and by the level of descent of the fetal head out of a
total of 13. Modifications of this system have been proposed by several groups including
Calderetal -40 (shown below) in which a modified score is obtained by quantifying the
cervical length rather than expressing it as percentage effacement and giving less emphasis
to the position of the cervix. The total score in this system is 12:
0 1 2 3
Dilatation
(cm)
< 1 1 - 2 2-4 >4
Length (cm) >4 2-4 1 -2 < 1
Consistency Firm Average Soft
Position Posterior Mid
Anterior
Level * -3 -2 -1; 0 Below
spines
* Level of presenting part in relation to the maternal ischial spines
In the initial proposal of a cervical score Bishop showed that in multiparae there was a
correlation between this score and the length of time to the spontaneous onset of
labour193. Calder et al subsequently described a group of 125 primigravid women
undergoing induction of labour by amniotomy and oxytocin infusion in whom there was a
significant increase in the length of time to delivery and in the rates of caesarean section,
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maternal pyrexia and birth asphyxia in those women whose initial modified Bishops score
was less than 3241. It has been known for over 30 years that the presence of an unripe
cervix increases the uterine work needed to effect dilatation three to four fold242. It thus
seems that production of uterine contractions alone is not necessarily sufficient to
successfully and safely induce labour particularly in the presence of an unripe cervix. It
has been suggested more recently that the presence of fetal fibronectin in vaginal
secretions may act as a reliable predictor of the ease of labour induction, in terms of
interval to delivery and caesarean section rates, independent of the Bishops' score243.
Methods to ripen the cervix prior to the onset of uterine contractions have therefore been
studied. Although these methods may also result in some women in myometrial
contractions and labour their primary purpose is to ripen the cervix to the extent that has
been associated with a more successful outcome of subsequent induction.
The techniques employed to ripen the cervix are similar in principle to those described
above used to terminate pregnancy in the first trimester. When such methods are used in
the third trimester, however, fetal well-being must also be considered in addition to that of
the mother.
Mechanical devices andcervical ripening.
The oldest methods of attempting to ripen the cervix are by digital means or by the
insertion of devices into the cervix, such methods were described by Hippocrates as
described in a review by Trofatter 244 These methods have been refined into the insertion
of either a balloon catheter or a hydroscopic dilator such as Lamicel or Dilapan into the
cervix. A balloon catheter can be inserted into the cervix and the balloon inflated above
the level of the cervical os, with the catheter then being withdrawn until the catheter is held
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against the internal os. Additional traction can be applied by the use of a weight attached
to the end of the catheter244. While this method may be effective at promoting cervical
ripening it is a rather awkward method and has largely been replaced by more recent
developments. The use of synthetic hygroscopic dilators, such as Lamicel placed in the
cervix does result in gradual cervical ripening93'244. It is debatable as to whether the
effect of these devices in promoting cervical ripening is a result of the mechanical force
exerted as they swell or of the resultant increase in the local production of prostaglandins
or to a combination of these effects93'245. Although they have a small effect on cervical
ripening the use of Lamicel has been shown in several studies to be less effective than
prostaglandins at increasing the cervical ripeness as assessed by the pelvic score and to be
less likely to result in labour onset during the ripening period93. Meta-analysis of trials of
mechanical methods for cervical ripening concluded that "the data limited as they are, do
not suggest that the insertion of various mechanical devices into the cervix, or the extra-
amniotic space, is a useful approach to ripening the cervix prior to the induction of
labour"93- This negative conclusion may be due, at least in part, to the lack of large
studies with well defined outcome measures addressing the effects of mechanical devices.
Such devices, however, may still have a place in obstetric practice, for example in patients
in whom the use of prostaglandins is contra-indicated .
Prostaglandins and cervical ripening.
The initial clinical study of the use of prostaglandins for induction of labour reported in
1968 used intravenous PGF2a ~9- In 1973 it was reported that the use of a lower dose of
prostaglandin than that needed to induce labour had a marked effect on cervical
ripeness246. In subsequent years studies have addressed the optimal dose, route and
regimen of administration. Meta-analysis of all such randomised controlled trials confirms
that the use of either prostaglandin E or F2« by aH the studied routes (oral, vaginal,
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extraamniotic or intracervical) results in a significant increase in the cervical score and an
increased chance of delivery during the ripening procedure as compared with placebo93.
These beneficial effects are offset by an increase in the incidence of uterine hypertonus
with the use of prostaglandins. Analysis of the five trials which used PGF2a showed that
this compound is effective at improving the cervical score, at producing delivery during
the ripening period but also carries a risk of uterine hypertonus. There are only two
studies comparing the effects of PGE2 with PGF2a directly and these do not suggest a
significant difference between the two agents but PGE2 is five to ten times more effective
than PGF2« and a lower dosage can thus be used that is associated with fewer side-
effects93'96.
PGE2 can be administered orally but this is not as effective in producing cervical ripening
than local routes and may be expected to cause more systemic side-effects93. Local
administration may be either extra-amniotic, intracervical or vaginal. Extraamniotic
infusion of PGE is achieved by the insertion of a transcervical Foley catheter into the
extraamniotic space and the delivery of PGE2 in a gel into this space. The production of
cervical dilatation associated with mild uterine contractions means that ideally the catheter
will be expelled once the cervix is around 3cm dilated and therefore ripened in preparation
for formal induction of labour. In a study of primigravidae with unripe cervices the use of
this technique prior to amniotomy and oxytocin infusion produced a decrease in the length
of the induction period and a marked decrease in the rates of maternal pyrexia, caesarean
section and Apgar scores of < 4 at one minute after delivery247. Although this method
was effective it has largely been superseded by the use of either vaginal or intracervical
preparations due to the increased ease of administration of these preparations.
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Use of a vaginal gel or tablet to administer PGE2 is a simple method which does not
involve the inconvenience to the patient of an intra-uterine catheter. In a comparison of
the vaginal with the extra-amniotic route for PGE2 administration in primigravidae248 they
were found to be comparable in terms of their effectiveness in producing cervical ripening
and in the number of women subsequently requiring oxytocin. Women who received the
prostaglandin as a vaginal tablet required less analgesia during the period of cervical
ripening. These results are similar to those found by meta-analysis of the available trials
comparing extra-amniotic with vaginal administration of PGE2 which also found no
difference between the efficacy of the two methods in promoting cervical ripening. There
is a slightly higher likelihood of labour occurring during ripening with extra-amniotic than
with vaginal PGE2 (odds ratio 2.71 with 95% confidence interval 1.34 - 5.51). In this
analysis there was no difference in the incidence of side-effects or of maternal pyrexia
between the two routes93. The plasma levels of prostaglandin E and F metabolites
significantly increase following the administration of PGE2 by either route with a greater
increase seen following extra-amniotic administration. This increase directly correlated
with the alteration in cervical score96. The greater increase in PGFM production after
extra-amniotic administration of PGE2 may reflect an increase in the production of
PGF2a, a uterotonin, explaining the increased need for analgesia with this route of
administration.
PGE2 administration by the endo-cervical route is comparable with the vaginal route in
terms of its efficacy with a slight increase in the number of women delivering during the
ripening period following the use of endo-cervical PGE293. A smaller dose is utilised
with this method, 0.5mg compared with 1 or 2mg when given vaginally as a gel
preparation or 3mg in the tablet formulation. In a double blind comparison between the
two methods the intravaginal route was found to be more effective at increasing the
79
cervical score than the endo-cervical route with no difference in the incidence of side-
effects. This study did not report on the incidence of delivery during the ripening period.
The study groups consisted of nulliparous and multiparous patients and the intravaginai
group did contain more parous patients which may have biased the results249. Although
prostaglandins are generally safe, in addition to their potential systemic side-effects their
oxytocic action means that their is a small risk of uterine rupture following application.
This complication has been reported after all methods of prostaglandin administration 25°.
The vaginal route of administration is therefore as effective as either extra-amniotic or
endocervical administration in causing cervical ripening, although the latter two routes are
slightly, but significantly, more likely to result in the onset of labour or delivery during the
ripening period. This slight advantage of these two routes is however balanced by the
relative ease with which vaginal forms of PGE2 can be given, without a need to visualise
or cannulate the cervical os. Repeated doses of vaginal prostaglandin may be needed to
produce sufficient dilatation to allow induction to proceed. The development of a
controlled release preparation of PGE2 (Propess, Ferring, UK) may replace such repeated
doses and this preparation has been shown to produce plasma levels of PGE metabolite
comparable with those seen in spontaneous labour and to be effective in the production of
cervical ripening96-251. There have however been concerns regarding the predictability of
the prostaglandin release from the pessary in vivo and the possibility of a high incidence
of uterine hypertonus 96
Oxytocin and cervical ripening.
In view of the physiology of parturition the use of oxytocin would be expected to produce
uterine contractions but not to effect significant cervical changes other than by the action of
such contractions. Myometrial contractions in the presence of an unripe cervix require
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more work than when the cervix is ripe and so the use of oxytocin for this purpose does
not seem to offer much advantage. This theoretical view is confirmed by the few studies
that examined the effects of oxytocin on cervical ripening, the conclusion from the meta¬
analysis of these trials being that use of such treatments "serves no useful purpose....This
practice should be abandoned"93.
Oestrogens and cervical ripening
Oestradiol, oestriol and the oestrogen precursor dehydroepiandrosterone sulphate have all
been studied as potential agents to ripen the cervix. In 1977 the extra-amniotic
administration of oestradiol valerate to primigravidae was compared with placebo
administered by the same route and shown to be more effective at increasing the cervical
score, at reducing the caesarean section rate and at decreasing the incidence of maternal
pyrexia1-0. However, when a further two placebo controlled trials were also taken into
accout in a meta-analysis the use of oestrogen was not found to have a significant benefit
on cervical ripening or on the onset of labour 93.
Relaxin and cervical ripening.
Relaxin is a hormone which is produced in humans by the corpus luteum, decidua and
chorion. That in use for therapeutic purposes is derived from the corpora lutea of pigs and
has been known for seventy years to relax the pelvic ligaments of the guinea pig. In view
of its effects on connective tissue it has been proposed to play a role in cervical ripening.
In the 1950s it was claimed to cause cervical softening but paradoxically it was also
claimed to prevent preterm labour. Placebo controlled trials did not confirm any benefit on
cervical softening-5-. More recently relaxin has become available in a purified form and
has been re-evaluated as a method of promoting cervical ripening. The small studies
performed suggest a beneficial effect on cervical score and an increase in the incidence of
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labour onset during ripening93'25-. A randomised trial of 96 women, however, failed to
demonstrate any significant effect of recombinant human relaxin, administered as an
intravaginal gel, on ripening the cervix at term 253.
The current method of choice for cervical ripening prior to labour induction is therefore
PGE2. The initial route of administration was extra-amniotic and while this is effective in
producing a ripened cervix it has largely been replaced by the use of the endo- cervical and
vaginal routes of administration. The latter are both simpler to employ and involve less
discomfort for the mother. While the vaginal route has been suggested by meta-analysis
of the available data to be marginally less effective, it is the simplest method of
administration.
2.2 iv: Induction of labour.
Although the process of cervical ripening may sometimes induce labour and delivery the
methods considered below are those used with the intention of causing uterine
contractions with concomitant cervical dilatation and thus leading to vaginal delivery.
'Sweeping the membranes'.
This refers to the mechanical process of digitally stripping the membranes off the decidua
during vaginal examination. It will only be possible if there is already some degree of
cervical dilatation. This procedure has been shown to cause a significant rise in the
maternal plasma levels of prostaglandin metabolites 254 but despite its common use in
obstetric practice its use has not been formally evaluated since 1958 94.
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Amniotomy
The fetal membranes may be ruptured using the technique of either high or low
amniotomy. The latter method is almost exclusively used nowadays. Although this
procedure may induce labour it does so in an unpredictable fashion and there may be a
long delay before the onset of contractions causing a risk of ascending intrauterine
infection94. Combination of low amniotomy with oxytocin increases the effectiveness of
this method at inducing labour 94.
Oxytocin
In the late 1940s the use of pituitary extract to induce uterine contractions was studied, this
extract was further purified to give oxytocin as discussed above. This is now usually
administered intravenously and titrated against the apparent uterine activity94'--7.
Controlled delivery of a titrated dose is used to decrease the risk of uterine hypertonus and
to prevent fluid retention resulting from the administration of a significant dose of
oxytocin (which has an anti-diuretic effect) in a large volume of fluid. Analysis of
available data indicates that the use of oxytocin is associated with an increased incidence of
neonatal jaundice. It cannot be concluded whether this is in fact a causal relationship or a
reflection of increased risk of jaundice in situations in which oxytocin is used94.
Prostaglandins
In addition to their proven efficacy in ripening the cervix, prostaglandins have also been
studied as potential agents to induce labour. In a review of trials of prostaglandins for this
purpose by Keirse and Chalmers 94 it was confirmed that prostaglandin administration is
significantly more effective than placebo in effecting labour induction and delivery with a
low incidence of maternal side-effects. While both PGF2« and PGE2 have been studied
in this context it appears that the latter is at least as efficacious as the former and has a
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lower incidence of side-effects. In the United Kingdom PGE2 is now almost exclusively
used for this purpose. Topical or oral preparations have largely replaced intravenous ones
as they are equally effective with a lower incidence of systemic side-effects. The use of
misoprostol (PGEi) intravaginally for labour induction has been studied and is of interest
as it is much cheaper than the topical preparations currently available. At present,
however, misoprostol is only licensed for use orally in the prevention and treatment of
gastric ulcers. In a comparison between intravaginal misoprostol and dinoprostone
(PGE2) the oral prostaglandin was shown to improve the Bishops score significantly more
than the vaginal tablet while interval to delivery was unchanged between the two groups
and there was no difference in the methods of delivery 255. A later study, however, while
confirming the improved efficacy of misoprostol as compared with dinoprostone at
ripening the cervix and inducing labour, reported an increase in the number of caesarean
sections performed for fetal distress in the group that received misoprostol 256. It is of
note that currently no synthetic prostaglandins are used for the induction of labour with a
live fetus and it may be that their increased resistance to catabolism is a disadvantage in
this context.
When all available trials comparing the use of prostaglandins with oxytocin by any route
were collated using meta-analysis257 it was found that the use of prostaglandins carried a
higher probability of delivery within 24 and 48 hours but no increase in the probability of
delivery after 12 hours. Less analgesia was required after induction with prostaglandins.
Use of prostaglandins, however, had an increased risk of gastrointestinal side-effects and
of uterine hyperstimulation. When the use of vaginal prostaglandins was directly
compared with oxytocin the only significant benefit of the former was a small increase in
the incidence of delivery within 12 hours. The analysis of these trials was confounded,
however, by the wide variety of induction schedules that were followed. When the
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intrauterine pressure was studied during induction of labour in women with either vaginal
PGE2 gel or with amniotomy and oxytocin infusion it was found that the use of PGE2
was associated with a longer pre-established phase and a shorter established phase of
labour than oxytocin with lower uterine activity integrals (the intrauterine pressure over 15
minute periods) being observed in the nulliparous patients. This means that in the
prostaglandin treated group less overall uterine activity was required to attain the same
degree of cervical dilatation than in the oxytocin treated group258. This is consistent with
the effect of prostaglandins in promoting cervical compliance prior to the onset of regular
contractions which would be expected to decrease the myometrial work needed to cause
subsequent dilatation. A comparison has been performed of labour induction with
intravaginal misoprostol or intravenous oxytocin with cervical ripening with PGE2 if
needed. The women given misoprostol delivered within a shorter time interval and there
was no difference in the rate of intrapartum complications, neonatal or maternal adverse
effects between the groups despite a greater frequency of uterine tachysystole after
misoprostol administration 259. A meta-analysis of studies comparing the use of
intravaginal misoprostol with placebo which included 966 patients, confirmed the efficacy
of misoprostol for cervical ripening and that it increased the rate of vaginal delivery within
24 hours and decreased the caesarean rate260. This cheap and easily administered
prostaglandin may therefore be an alternative to current induction regimens.
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2.3: MIFEPRISTONE (RU486).
2.3 i: Mechanism of action and effects on uterine tissues.
Mifepristone (RU38486, now shortened to RU486) was first described by Philibert in
1981-61. Although its main initial clinical application was as an abortifacient -6- -63 many
other uses have subsequently been investigated, both in gynaecology, for example as a
contraceptive264 and in other areas of medicine, such as in the management of
meningiomas 265.
RU486 is a derivative of norethindrone containing a 4-(dimethylamino) phenyl group at
the 1 IB position and a 17a 1-propynyl chain. It is thought that the 17 substitution
increases its binding affinity to the progesterone receptor as compared with progesterone
and that the 1 IB branched aminophenyl group induces and stabilises the formation of inert
receptor complexes264. Mifepristone binds to progesterone and glucocorticoid receptors
with a high affinity, 5 times greater than the binding of progesterone to the rabbit uterus
receptor and 3 times more than that of dexamethasone to the rat thymus glucocorticoid
receptor. It also shows weak binding to the androgen receptor but does not bind to
oestrogen or to mineralocorticoid receptors264. Other synthetic antigestagens have since
been synthesised including onapristone (ZK98299) and lilopristone (ZK98734) which
both have fewer antiglucocorticoid effects than mifepristone. Onapristone shows stronger
synergism than mifepristone with prostaglandins and oxytocin and has a shorter half
life266-
Theprogesterone receptor
The progesterone receptor (PR) is capable of 'shuttling' between the cytoplasm and the
nucleus but resides mainly in the nucleus in normal circumstances (in contrast to the
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glucocorticoid receptor which is cytosolic). It is a ligand-activated transcription factor
which consists of four regions-64'-67. These are a DNA binding area which is
characterised by two 'zinc fingers', a hinge region which is probably involved in the
nuclear localisation of the receptor, the hormone binding domain and a transactivation area
which increases gene transcription once the hormone is bound. It seems that the glycine
residue at position 722 of the progesterone receptor is essential for the binding of RU486,
as in the chick receptor this is substituted with a cysteine and RU486 does not bind to this
receptor-64. In vivo the unbound receptor is associated with cytosolic proteins including
heat shock protein 90 (hsp90) which inactivate the receptor. Following progesterone
binding the receptor is activated (transformed) and the hsp90 is dissociated exposing the
DNA binding area. The activated hormone-receptor complexes then dimerise. These
dimers then bind to the progesterone response elements (PRE) which are transcriptional
enhancer regions of progesterone responsive genes causing increased rates of transcription
of regulated proteins.
When RU486 binds to the PR it causes a very similar transformation of the receptor-68
and dimerisation of the complexes also occurs, however the hsp90 does not seem to then
dissociate from the receptor. The dimers may still bind to the PRE of responsive genes,
but in the presence of progesterone the drug-receptor complexes are inactive, which may
be due to a difference in the structure of the receptor once bound to RU486 268 If,
however, there is no progesterone present the drug-receptor complexes may have partial
agonistic effects on the DNA transcription of regulated proteins 264. This partial agonistic
effect of RU486 has been demonstrated clinically in post-menopausal women who are
receiving oestrogen replacement269. When RU486 is administered to such women it
causes endometrial changes similar to those seen with progesterone administration,
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however if RU486 is given with progesterone to this group of women it will antagonise
the effects of the progesterone .
Pharmacology ofmifepristone.
RU486 is currently used as an oral preparation and although one study reported
intravaginal use in humans this resulted in inadequate absorption of the drug as compared
with vaginal use in rats and monkeys-70. Following oral administration of RU486
metabolism in the splanchnic circulation results in a bioavailability in humans of 40%
whereas in monkeys the bioavailability is 15%. Clearance in humans is slow, around
0.55L/kg/day which is less than in other animals such as monkeys (36L/kg/day) or rats
(72L/kg/day)264. Part of the reason for the decreased clearance in humans is that in
humans mifepristone binds with a high affinity to orosomucoid (al acid glycoprotein)271.
It does not however bind to either sex hormone binding globulin (SHBG) or to
corticosteroid binding globulin (CBG). The maximum plasma concentrations of RU486
in women are reached about one hour after oral administration. The pattern of kinetics
seen varies with the dose of mifepristone used, after low doses of 50mg to lOOmg first
order kinetics are displayed with a half-life of 20 to 25 hours 264,272 but at higher doses of
lOOmg to 800mg two phase kinetics are seen with a redistribution phase lasting 6 to 10
hours followed by a plateau in serum levels for at least 24 hours 273. During this plateau a
dose-dependent change in serum levels is not seen but metabolite levels do increase with
higher doses. These metabolites also exhibit some antagonistic effects which, although
weaker than those of RU486, may have biological effects due to their relatively high
concentration in serum 273. Metabolites are formed by a 2 step demethylation of the CI 1
ring and hydroxylation of the 17-propynyl side chain followed by further hydroxylation
and acetylation. Excretion of drug and metabolites is mainly faecal 274.
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Figure 2.1: The mechanism of activation of steroid hormone receptors
 
Antiglucocorticoid Effect
Mifepristone shows a dose-dependent inhibition of the negative feedback effect of Cortisol
on ACTH secretion meaning that increasing levels of peripheral Cortisol can overcome the
antagonistic effects of mifepristone 275. With a relatively low dose of mifepristone
(6mg/kg) this effect is most marked during the morning hours when the negative feedback
of Cortisol on the hypothalamic-pituitary is inhibited leading to increased circulating
Cortisol levels276. When 600mg of mifepristone is administered to women to induce
termination of pregnancy, the subsequent rise in peripheral Cortisol levels is observed
throughout the day. Short term courses of RU486 have not been shown to cause
symptoms of glucocorticoid deficiency 277. In Rhesus monkeys a low dose of lmg/kg of
mifepristone was sufficient to cause elevation of plasma ACTH whereas higher doses of
5mg/kg and lOmg/kg also caused increased plasma Cortisol and arginine vasopressin
levels278. The effect on vasopressin is postulated to be due to inhibition of the
glucocorticoid provoked rise in the osmotic threshold for vasopressin release 279. In these
monkeys mifepristone administration did not affect the plasma levels of FSH, LH, GH or
TSH280. Use of mifepristone has been reported in patients with Cushings
syndrome281'282 who have increased ectopic ACTH secretion or carcinomas secreting
Cortisol. In such patients, who have a fixed rise in their Cortisol levels, mifepristone
reverses most of the symptoms of Cushings syndrome. This benefit is not reported in
patients with Cushings disease in whom Cortisol secretion is variable.
Mifepristone andprostaglandins.
The effects of mifepristone on prostaglandin production and metabolism are relevant to
many of its potential uses in reproductive medicine. As described above, endogenous
prostaglandins are implicated both in first trimester interruption of pregnancy, whether
spontaneous or induced, and in the initiation of labour. It has long been postulated that
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progesterone has a key role in the maintenance of pregnancy. In the early 1970s,
Csapo219-283 proposed a 'see-saw' theory for pregnancy regulation whereby a balance is
maintained during pregnancy between progesterone and tocomimetic substances, such as
PGF2a and oxytocin. His hypothesis was that at the initiation of parturition it is the
withdrawal of progesterone which stimulates the events leading to labour by promoting
levels of prostaglandins and other oxytocics. Antagonism of progesterone by an
exogenous agent, such as mifepristone, might therefore be expected to promote
termination of pregnancy at any stage.
Prostaglandins such as PGE2 and PGF2«> which are of most relevance in the context of
the pregnant uterus are metabolised by 15-hydroxyprostaglandin dehydrogenase (PGDH).
The catabolism involves initial oxidation of the alcohol group at C-15 by PGDH, followed
by reduction of the double bond at C-13 and then further oxidative steps. Prostaglandin
metabolism mainly occurs in the pulmonary cells but PGDH also occurs in other tissues,
such as endometrium 284 and decidua 104,285 suggesting it has a role in the control of local
prostaglandin concentrations. The short half life of this enzyme of 47 minutes would
provide a relatively rapid control mechanism of local prostaglandin concentrations.
PGDH has been suggested to be under progesterone control as an increase in levels of
progesterone cause a corresponding increase in PGDH activity286. Progesterone control
of local prostaglandin levels by an increase in their metabolism could provide a mechanism
for the maintenance of uterine quiescence during pregnancy until the time of parturition.
Antagonism of this effect by mifepristone would thus favour events leading to termination
of pregnancy or parturition by increasing locally available levels of prostaglandins.
The levels of PGDH in first trimester human decidua have been shown to be markedly
reduced following mifepristone administration when assessed by either assay for enzyme
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activity or by the level of immunohistochemical staining intensity287. PGDH is
immunolocalised in the decidual stroma and gland cells and in the endothelial cells of the
decidual blood vessels. The effect of mifepristone in decreasing the staining intensity for
PGDH appears to be most marked around the blood vessels. This decrease in the
catabolic enzyme following mifepristone administration in the first trimester of pregnancy
is accompanied by an increase in immunostaining for PGE2, also in decidual glands and
small vessels and with a parallel decrease in PGEM immunostaining 287.
In vitro endometrial cell cultures treated with mifepristone exhibited increased PGF2«
and PGE2 production which was inhibited in a dose-dependent manner by progesterone.
In these cell cultures progesterone led to increased conversion of prostaglandins to their
13,14-diydro-15-keto metabolites288. A similar effect was observed in cultures of
decidual cells289. In the guinea pig uterus pretreatment with mifepristone leads to
decreased PGDH levels in subsequent tissue culture but no alteration in the prostaglandin
production by these tissues290. Similar findings have been reported for women in the first
trimester of pregnancy. Culture of decidual tissue collected from women who had been
given mifepristone prior to first trimester termination of pregnancy showed increased
PGF2a production and decreased PGFM (the metabolite of PGF2a) levels compared with
control tissue 291. While it is apparent that mifepristone does affect prostaglandin
production and metabolism by uterine tissues, its clinically observed effects do not seem
to be solely mediated via this effect. For example, in a further study292 women were
treated with mifepristone prior to termination of pregnancy in the first trimester and one
group were also given indomethacin (a prostaglandin synthase inhibitor). As expected
from previous work, mifepristone pre-treatment increased the in vitro production of
PGF2a by decidual cells and this increase was significantly reduced by concomitant
indomethacin administration. However, the observed uterine activity (as measured by an
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intrauterine pressure recorder and expressed in Montevideo units), increased after
mifepristone treatment, regardless of indomethacin administration. Similar findings have
been reported in studies of varying tissues, species and prostaglandin synthase inhibitors.
In the cervix, as further discussed below, the effects of mifepristone on cervical ripening
in the late pregnant rat are not reversed by diclofenac administration-93 nor is the effect of
mifepristone in causing increased cervical softening and dilatation in women in the first
trimester of pregnancy reversed by the concomitant administration of naproxen (a
cyclooxygenase inhibitor) -94.
Mifepristone therefore increases production of prostaglandins by uterine tissues and
decreases their metabolism, however inhibition of this action by cyclooxygenase inhibitors
may not prevent most of the events provoked by mifepristone. One reason for this could
be that, as discussed above, there are at least two forms of the cyclooxygenase enzyme:
COX-1 and COX-2. The latter is less inhibited by agents such as diclofenac and may
mediate at least some of the actions of mifepristone that are not inhibited by currently used
cyclooxygenase inhibitors. Alternatively, the observed effects of mifepristone on uterine
contractility and cervical ripening may be mediated by other pathways involving local
factors such as cytokines or relaxin. In the late pregnant monkey, oral administration of
mifepristone led to an increase in the amniotic fluid levels of 6-keto-PGFia, PGFM,
PGF2« and PGEM which increased in that order over time-95. This increase was not
observed, however, until at least 40 hours after mifepristone administration by which time
an increase in uterine contractile activity was already evident. This observation is in
contrast to the finding in the same study that in spontaneous labour intra-amniotic
prostaglandins and their metabolites increase before the onset of regular uterine activity.
These results suggest that the alteration in prostaglandin metabolism provoked by
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mifepristone may not necessarily result in the sequence of events observed in normal
labour.
Mifepristone and interleukin-8
Interleukin-8 (IL-8) is a chemokine which was initially described as 'neutrophil attractant
peptide'. As discussed above, it is hypothesised to have a role in the onset of parturition
by acting synergistically with PGEo to attract neutrophils into uterine tissues, such as the
cervix. It also activates neutrophils and thus could facilitate collagen dissociation such as
is seen during cervical ripening. IL-8 has been demonstrated in several uterine tissues,
including choriodecidua150, endometrium147, cervix43 and placenta161. In vitro,
production of IL-8 by cultured choriodecidual cells is inhibited by progesterone, this
inhibition being overcome by the addition of mifepristone150. Similar results have been
described from cultures of rabbit cervical fibroblasts162 whose production of IL-8 in
culture is also inhibited by physiological levels of progesterone, an effect which is
overcome by the addition of mifepristone. In human endometrial cells, IL-8 production is
also inhibited by the addition of medroxyprogesterone acetate and dexamethasone to the
cell cultures147. The IL-8 gene has been shown to contain a glucocorticoid response
element124 and it has been hypothesised that the inhibitory effect of progesterone could be
effected via the glucocorticoid receptor or that it could act on the gene via its own
intracellular receptors 89.
These in vitro results suggest that in vivo mifepristone may be capable of overcoming an
inhibitory effect of endogenous progesterone on IL-8 production. Its use would therefore
lead to increased local levels of IL-8 which could act synergistically with prostaglandins
(the levels of which are also increased by mifepristone) in the recruitment of neutrophils
into uterine tissues.
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Effects ofantiprogesterone on uterine tissues: Endometrium
In women, administration of varying doses of mifepristone during days 6 to 8 of the luteal
phase of the menstrual cycle causes menstrual bleeding within 72 hours and results in
changes in the endometrial histology consistent with progesterone withdrawal296'297.
This is due to a direct action on the endometrial progesterone receptors as is shown by a
study in which pregnancy was mimicked by the administration of hCG during the luteal
phase followed by the concomitant administration of RU486. In these women menstrual
bleeding still occurred following the RU486 treatment298. Interestingly, in contrast with
monkeys, in humans mifepristone causes irregular shedding of the endometrium so
implantation may still occur following its use 2".
Decidua
In the early pregnant uterus, mifepristone directly blocks the supportive action of
progesterone on the decidua leading to bleeding and interruption of placental function.
The decrease in hCG that is observed following RU486 administration is probably
consequent to this disruption of chorio-decidual function and contributes to luteolysis,
further decreasing the hormonal support for the early pregnancy 264.
In the termination of pregnancy at less than six weeks gestation, administration of
mifepristone prior to vacuum aspiration leads to a dose dependent decrease in the level of
cytosolic progesterone receptors and an increase in the levels of cytosolic and nuclear
oestrogen receptors. The effect on receptor levels was greater after 36 hours than after 12
hours300. In late pregnant macaque monkeys, treatment with mifepristone also caused an
increase in decidual oestrogen receptors which it was noted does not occur during
spontaneous labour301. In these animals mifepristone administration does not alter the
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maternal plasma concentration of oestrogen but it leads to increased levels of progesterone
after 72 hours 295.
Some of the effects of mifepristone on the decidua may therefore be mediated in alterations
in local levels of steroid receptors. Alterations in local receptor concentrations could in
turn modulate differential effects of progesterone and oestrogen on uterine tissues without
a change in peripheral hormone levels being observed.
Myometrium.
Treatment with mifepristone increases the contractile response of the uterus in early
pregnancy after 24 to 36 hours, both in terms of the basal tonicity and in the establishment
of contractions. This effect is particularly marked if prostaglandins are administered
following pretreatment with mifepristone, which facilitates increased contractility and
more co-ordinated contractions302. Administration of oxytocin in early pregnancy does
not give rise to similar co-ordinated activity regardless of whether or not mifepristone is
administered. This may be due to lack of functional oxytocin receptors in early decidua74.
In late pregnant macaque monkeys, administration of mifepristone led to an increase in
uterine activity as compared with control animals. However, the contractions stimulated
by mifepristone were of a long duration and high amplitude and occurred with low
frequency as compared with those of normal labour which occur with high frequency,
have a short duration and a much greater amplitude 295. Another study in macaques also
describes mifepristone as causing increased uterine activity and a 'hyperexcitable' uterus
but not the regular uterine activity seen in normal spontaneous labour303. The
administration of mifepristone to these animals does however greatly improve the
effectiveness of oxytocin at inducing labour. Mifepristone alone was found to cause
95
delivery in two of 19 treated monkeys, oxytocin alone led to one out of seven treated
monkeys delivering whereas 12 out of 14 animals who received mifepristone and oxytocin
in combination delivered304. It seems, therefore, that at least in non-human primates
mifepristone does not cause sufficient myometrial activity to establish labour but that it
does increase the sensitivity of the myometrium and its responsiveness to oxytocin. The
mechanism by which this could occur may involve the gap junctions between the
myometrial cells. These intercellular communications are composed of connexin 43 and
are responsible for increased electrical coupling between myometrial cells. In guinea pigs
treated with subcutaneous onapristone (another antigestagen) there was an increase in the
myometrial responsiveness to oxytocin which was associated with an increase in the
immunolocalisation of gap junctions in the myometrium but not with an increase in
oxytocin receptors 305. Similarly, in the late pregnant rat, administration of subcutaneous
mifepristone led to a significant increase in the area and number of myometrial gap
junctions from 24 to 48 hours following treatment306. All of these treated rats delivered
within 72 hours of mifepristone administration compared with no deliveries of the control
animals. The time interval for all pups to be delivered was however longer than that seen
in spontaneous labour, possibly due to lack of endogenous uterotonic agents at this stage
of pregnancy.
Antagonism of progesterone, therefore, may act on the myometrium by increasing
intercellular communication via gap junctions but not by altering the oxytocin receptor
levels resulting in increased myometrial responsiveness to endogenous or exogenous
stimulation but not to the establishment of effective uterine activity. This postulate is
presented by Garfield et al 306 as "Perhaps after RU486 treatment, the myometrium is
prepared for labour with gap junctions and appropriate receptors for stimulants but lacks
the necessary stimulation provided by oxytocin or excitatory prostaglandins".
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Cervix
Mifepristone causes cervical softening and dilatation of the cervix in the first trimester of
pregnancy even if termination of the pregnancy does not occur. Its clinical use for this
purpose is discussed further below. In guinea pigs, administration of onapristone
(ZK98299) in late pregnancy led to cervical ripening which was associated with
histological changes similar to those seen in spontaneous ripening, such as oedema,
dissociation of collagen and infiltration of leucocytes into the cervical stroma307.
In the late pregnant rat, the administration of mifepristone leads to preterm delivery293'306,
this is associated with an increase in cervical hydration and levels of hyaluronic acid. This
effect is not inhibited by the cyclooxygenase inhibitor diclofenac which does however
prevent the animals delivering preterm when administered with mifepristone293. This
suggests either that the mechanism of action of mifepristone in causing these effects is not
solely mediated through prostaglandins or that other synthetic pathways producing
prostaglandins unaffected by diclofenac are involved.
Several studies have reported the effects of mifepristone on the cervices of non-human
primates near term. The normal gestational length in these animals is 167 days ± 3 days.
In one such study295 20mg/kg/day mifepristone was administered orally for three days to
macaque monkeys at gestations of 125 to 133 days. There was no evidence of
progressive cervical effacement and dilatation despite an increase in uterine activity in
these animals. However, in a separate study of the same species304 at day 160 of
pregnancy a significant increase in cervical dilatation was noted following oral
administration of 25mg mifepristone. This alteration was not associated with a significant
increase in the number of animals delivering but concomitant administration of oxytocin
with mifepristone did lead to a significant increase in the number of monkeys delivering as
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compared with the control group and with animals given mifepristone or oxytocin alone.
These findings were confirmed by a further study in which oral or intramuscular
mifepristone administration at gestations of 150 to 158 days caused cervical ripening but
not delivery in macaque monkeys 303.
In the human cervix in the first trimester in vivo administration of mifepristone did not
alter the subsequent in vitro bioconversion of radiolabeled arachodonic acid to
thromboxane, PGE2 or PGF2« as compared with placebo308 again supporting the
hypothesis that the effect of mifepristone on the cervical structure is not solely mediated
through prostaglandins. When other metabolites of the lipooxygenase chain were
examined the administration of mifepristone was not found to alter the production of
cervical 12-hydroxyeicosatetraenoic acid (HETE) or leukotrienes and so its action does not
seem to be mediated by alterations in these substances-83.
In early pregnancy, the administration of mifepristone to women leads to a decrease in the
ratio of a-2 to (3-adrenoceptors309 in the cervix, a similar effect to that observed in
rabbits310. This ratio is high during normal pregnancy and has been implicated in
maintaining the tonus of the internal cervical os 311. The administration of mifepristone to
women prior to vacuum aspiration has not been shown to affect either the spontaneous
activity or the contraction frequency of cervical smooth muscle in vitro 31-. In this study
there was no effect demonstrated on the in vitro inhibition of cervical smooth muscle
contractions by PGE2 in the cervices pre-treated with mifepristone. The action of
mifepristone on the cervix does not seem, therefore to be associated with alterations in
stromal smooth muscle behaviour despite the alteration in proportions of adrenoceptor
types. These receptor changes could potentially affect blood vessel contractility and it may
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be that alterations in the control of vascular smooth muscle are of more importance in the
control of cervical ripening than effects on the stromal smooth muscle.
2.3 ii: CLINICAL USES OF MIFEPRISTONE.
Mifepristone has therefore been shown to have varied actions on pregnant and non¬
pregnant tissues. At least some of these effects are mediated by an increase in the
production and a decrease in the catabolism of prostaglandins, in particular PGE2 and
PGF2a- The concomitant increase of local levels of IL-8 by antagonism of the inhibitory
effects of progesterone could lead to a significant effect on the recruitment of neutrophils
into uterine tissues. Activation of these neutrophils would release matrix
metalloproteinases, such as collagenase capable of degrading the extracellular matrix of
these tissues. Other actions of mifepristone relate to its effects on myometrial sensitivity
to tocomimetic substances, such as oxytocin, which is increased possibly via an effect on
intercellular gap junctions.
Mifepristone And Termination OfPregnancy.
Since 1982 various doses and regimens of mifepristone administration have been studied
to determine their effectiveness in interrupting early pregnancy. There are several
advantages of an effective method of medically terminating pregnancy. In developing
countries where surgical abortions are a major factor in maternal mortality and morbidity,
an effective medical alternative would decrease the risks from surgery and its potential
sequelae such as sepsis or haemorrhage313. In the developed countries medical abortion
offers an alternative to women who may not wish or may not be suitable for anaesthesia
and surgical termination.
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Initial studies of the potential use of RU486 for pregnancy termination with doses varying
from 140mg to 1600mg over up to 7 days administration314-317 reported a success rate of
64 to 85%. This is significantly less than the rate achieved by vacuum aspiration of the
uterus and so did not present a satisfactory alternative. The failure rate of mifepristone in
inducing abortion increases with rising gestation315'317. In one study in which women of
up to 55 days amenorrhoea or of 56 to 70 days amenorrhoea were given 200mg or lOOmg
mifepristone daily for four days in the nine patients at gestations greater than 56 days only
three had successful termination of pregnancy compared with 29 of the 35 patients with
less than 55 days amenorrhoea317. In a study comparing three dosage regimens of
mifepristone (lOOmg; 50mg or 20mg for seven days) the effectiveness in the three groups
was 73%, 66% and 64% respectively. It was found that for each treatment group the
chance of successful termination of pregnancy was significantly increased with lower pre-
treatment hCG levels316. There may also be individual variations in the metabolism of
mifepristone between women, in particular in its binding by orosomucoid271 although
serum levels of this protein are the same in women who did and who did not have a
successful termination of pregnancy with mifepristone318.
Although the efficacy of mifepristone at inducing termination of pregnancy is not equal to
that of vacuum aspiration this efficacy has been improved by combining mifepristone with
various prostaglandins, such as the intramuscular PGE2 analogue sulprostone302, the
vaginal PGEi analogue gemeprost 262,319 an(j oraj pQEj analogue misoprostol320. It
has been found that combination of mifepristone with a prostaglandin, such as gemeprost,
is more effective at causing complete abortion than gemeprost alone. In a study of 301
women with less than 56 days of amenorrhoea, complete abortion occurred in 87% who
were given gemeprost alone compared with 98% of those who received mifepristone in
addition. Pre-treatment with mifepristone also decreased the analgesic requirements of the
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women following prostaglandin administration319. Similar results have been shown in
large French 262 and British 321 multi-centre trials in which combination of prostaglandin
with mifepristone resulted in complete abortion rates of 96% and 94% respectively.
Subsequent work322 has found that a lower dose of gemeprost (0.5mg) is of equal
efficacy at inducing abortion as the higher dose (lmg) initially investigated. The other
advantage of combining mifepristone with a prostaglandin is that the decreased dose of
prostaglandin required leads to a decrease in the mainly gastrointestinal side-effects that
are associated with the use of prostaglandin analogues. The analgesic requirements of
women undergoing termination of pregnancy are also reduced when mifepristone is
concomitantly administered with a prostaglandin analogue263-319. The combination of
mifepristone with a prostaglandin also increases the gestation at which successful
termination of pregnancy can be induced. Mifepristone alone markedly decreases in
effectiveness after seven weeks amenorrhoea317, whereas in combination with a
prostaglandin it remains effective at up to nine weeks of amenorrhoea 32 f In the second
trimester of pregnancy mifepristone reduces the dose of prostaglandin required to cause
termination of pregnancy and decreases the time taken from prostaglandin administration
to abortion 323.
Mifepristonefor cervical ripening prior to vacuum aspiration.
Administration of mifepristone in early pregnancy causes cervical softening in many
species including guinea pigs307 and rats293. This is associated with similar
morphological changes in the cervix to those observed during spontaneous cervical
ripening at term 293. This effect is beneficial in promoting termination of the pregnancy
and has also been examined further as a means of preparing the cervix prior to surgical
dilatation. The cervix, particularly in nulliparous women, is dilated prior to the
performance of intrauterine operative procedures including vacuum termination of
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pregnancy. Such dilatation can be traumatic to the non-compliant cervix causing trauma or
lacerations205. Difficult dilatation of the cervix is associated with uterine perforation,
necessitating laparoscopy or even laparotomy and with an increase in perioperative blood
loss206. Pre-operative treatment with prostaglandins has been shown to soften the cervix
leading to easier dilatation and decreased peri-operative blood loss215-218.
Prostaglandins, however, when given systemically can cause marked gastrointestinal side-
effects and even local administration can cause these effects and uterine pain as a result of
contractile activity.
In addition to causing termination of pregnancy in the first trimester of pregnancy,
mifepristone was also noted to cause marked cervical softening294. This effect has been
demonstrated following the administration of doses of mifepristone ranging from 50mg to
600mg at time intervals from 12 to 48 hours prior to vacuum aspiration of the
uterus294'308'31 1,324-327 Mifepristone decreases the initial cervical resistance to dilatation
(as objectively measured with a mechanical dilator)325 and increases the initial cervical
dilatation311. In addition mifepristone causes improved cervical compliance during
subsequent dilatation which has also been reported subjectively311 and objectively308'325,
After 600mg of mifepristone 48 hours preoperatively the force required to dilate the cervix
to 9cm was 9.5N compared with 24.5N after administration of placebo326. One of the
benefits of pre-operative treatment with prostaglandins prior to suction termination is a
decrease in subsequent peri-operative blood loss. In a large multi-centre study311
comparing placebo with 25mg, 50mg or lOOmg of mifepristone given 12 and 24 hours
pre-operatively although mifepristone improved the clinical assessment of cervical
compliance, it did not significantly alter peri-operative blood loss. The significant
improvement in cervical compliance was less than that previously reported for
prostaglandins by the World Health Organisation328'329 A further study, however,
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directly compared by blinded randomisation mifepristone (200mg administered 36 hours
preoperatively) with gemeprost (16, 16-dimethyl-trans A-2 PGEi methyl ester,
Cervagem) and placebo for preoperative cervical ripening prior to vacuum aspiration in the
first trimester of pregnancy327. The findings were that compared with placebo, both
treatments significantly improved the baseline dilatation of the cervix and the subsequent
objectively measured force required to dilate the cervix. The intraoperative blood loss was
significantly decreased by both treatments compared with placebo with no difference
between their effectiveness. The use of prostaglandins was associated with significantly
more abdominal pain than mifepristone or placebo. Mifepristone could be expected to
cause preoperative bleeding as a result of its abortifacient effect and this has been observed
in some studies. The effect, however, would seem to be time dependent as 62% of
women experienced preoperative bleeding following the administration of mifepristone 48
hours before surgery330 compared with 20%325 when it was given 24 hours
preoperatively. This is as would be expected as with increased time there will be an
increase in the effect of mifepristone on the decidua leading to uterine bleeding.
Mifepristone, when given prior to first trimester termination of pregnancy thus causes an
increase in cervical dilatation prior to dilatation and a subsequent improvement in the ease
of dilatation of the cervix. Administration of mifepristone can be on an out-patient basis
unlike prostaglandin pessaries which are used during in-patient admission Due to the
logistics of the timing of ward admissions and scheduling of theatre lists there may be
insufficient time between the administration of prostaglandin pessaries and their maximal
effect. As mifepristone can be administered at least 12 hours prior to surgery and is
effective over a relatively wide time-span it could provide a more convenient method of
cervical preparation. The benefit of mifepristone in decreasing cervical resistance could
also be utilised prior to other procedures such as insertion of intrauterine devices or
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hysteroscopy. However, it may not be appropriate for use prior to endometrial sampling
as it may alter endometrial histology.
Mifepristonefor induction ofdeliveryfollowing intrauterine death.
The induction of delivery following an antenatal intrauterine death is a distressing
experience for parents and for the staff involved. It can be achieved by combinations of
prostaglandin analogues (e.g. cervagem), amniotomy and oxytocin administration but can
be difficult and slow to induce. In a study of 94 women with an intrauterine death at a
mean gestation of 198 days randomised to receive 600mg of mifepristone or placebo,
delivery of the fetus occurred within 72 hours in 63% of those who received mifepristone,
compared with 17.4% after placebo331.
This success rate is less than that observed after prostaglandin administration in a similar
situation of 91 to 100%. There may be a role for mifepristone in cases where
prostaglandins are contraindicated or when treatment is preferred initially on an out-patient
basis or as an adjunct to prostaglandin use to shorten the length of time to delivery.
Mifepristonefor the induction of labour.
In the rat-93'306 and the sheep305 administration of mifepristone induces preterm labour.
However there are substantial differences between these species and primates in the site of
progesterone synthesis and the mechanisms by which parturition occurs. In non-human
primates mifepristone promotes cervical ripening at term but does not lead to delivery of
the fetus due to the lack of co-ordinated uterine activity303'304. Following its
administration to monkeys there is an increase in uterine contractility that has been referred
to as 'hyperexcitability'303 but the establishment of regular tonic uterine contractions that
are associated with spontaneous labour does not occur-95'303. It has been shown,
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however, that in combination with oxytocin mifepristone will significantly increase the
numbers of monkeys delivering at term304. It thus seems that mifepristone administration
at term will cause cervical ripening and facilitate the subsequent induction of labour with
oxytocin. In rats and guinea pigs this effect on the myometrium is associated with an
increase in the number of intercellular gap junctions305-306. In humans therefore it is
reasonable to propose that mifepristone could cause cervical ripening at term and while not
necessarily inducing labour could facilitate its' induction by other agents such as
prostaglandins or oxytocin.
The safety of mifepristone for pregnancy induction is dependent on whether it is
transferred across the placenta and on its potential effects on the fetus. In the late second
and third trimester of pregnancy in monkeys intravenous injection of mifepristone was
followed by rapid establishment of a steady state equilibrium with a gradient between
mother and fetus possibly limiting flux32. These results suggested that mifepristone
initially crosses the placenta by simple diffusion with the subsequent development of a
gradient between mother and fetus. It was also noted that the efficiency with which
RU486 crosses the placenta was significantly decreased in the third as compared to the
second trimester of pregnancy. In women in the second trimester of pregnancy, a single
dose of 600mg RU486 was found to give a maternal : fetal ratio of circulating
mifepristone levels of 9:1. The ratio of the metabolite RU42633 was 17:1. This dose
caused no alteration in fetal progesterone, oestradiol or Cortisol levels but an increase in
fetal aldosterone levels was noted which was only just significant in this small study of 6
women333.
There has been one study reported of the administration of mifepristone to women at term
to induce labour 334 This was a double-blinded placebo controlled trial in which 120
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women at gestations of 37.5 to 41.4 weeks were randomised to receive either placebo or
200mg of mifepristone orally for two days. In women who had not delivered four days
after treatment administration labour was induced. Significantly more of the women who
had received mifepristone went into spontaneous labour than those in the placebo group.
Treatment with mifepristone also caused a significant decrease in the number of women
with an unfavourable cervix after four days, in the length of the subsequent labour and in
the total amount of oxytocin required during labour. There were no serious maternal side
effects after mifepristone administration. Fetal distress was not increased after
mifepristone treatment nor was the rate of operative delivery. There were no differences
in the neonates of the treated and placebo groups in terms of birth weights, Apgar scores
blood pH nor in the incidence of hypoglycaemia. This study, however was of a
heterogeneous group of women in terms of their parity 65% and 60% of the treated and
placebo groups respectively being nulliparous.
There is therefore theoretical and practical support for the use of mifepristone as an agent
for cervical ripening at term and a need for further study of its effectiveness for this
purpose in defined groups of women including the evaluation of lower doses than that
found to be effective in the study described above 334
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2.4: CURRENT CLINICAL PRACTICE.
There is wide variation between different centres and indeed between different clinicians in
the approach to pregnancy interruption. The following are therefore broad statements
intended to summarise current practice.
Termination ofpregnancy.
The preferred method used will depend on the gestation of the pregnancy, on the womans'
wishes, on the methods available and on the clinicians judgement of the most suitable
method to be used. If surgical methods are employed most clinicians will use pre¬
operative cervical ripening, at least in primigravid patients. This may be with
prostaglandin analogues or less commonly with tents or more recently with mifepristone.
The most effective medical technique for termination of pregnancy utilises mifepristone
followed by a prostaglandin analogue. At less than seven weeks gestation either medical
or surgical methods are possible but medical methods are particularly effective and
perhaps preferable. Between seven and twelve weeks the effectiveness of medical
termination decreases and so surgical methods may be recommended if appropriate. As
the risks of surgery increase with advancing gestation after twelve weeks medical methods
are of increasing value.
Cervical ripening.
Prostaglandin Eo is the agent of choice at present for this purpose with units varying in
their choice of either intracervical or vaginal preparations, the latter being rather simpler to
apply. Extra-amniotic prostaglandins are rarely employed at present. Prostaglandin
analogues were not previously used in the third trimester due to concerns about their fetal
effects but recent work suggests that misoprostol when given vaginally is effective and
107
safe for this purpose. Mifepristone has been reported in small studies to be beneficial for
improving cervical ripening prior to formal labour induction.
Induction oflabour.
Although labour can be effectively induced with prostaglandins the current standard
method of induction is by low amniotomy followed by titrated oxytocin infusion. The
infusion is started either at the time of amniotomy or at a variable time after it depending
on the parity of the patient and the existing uterine activity.
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Chapter III:
CLINICAL STUDY: THE EFFECTS OF 50mg AND 200mg OF
MIFEPRISTONE ON CERVICAL RIPENING AND LABOUR INDUCTION
IN PRIMIGRAVIDAE AT TERM WITH UNFAVOURABLE CERVICES.
3.1: Introduction.
3.2: Methods.
3.2 i: Patient recruitment.
3.2 ii: Study procedure.
3.2 iii: Labour induction.







3.6: Tables and Figures.
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3.1: INTRODUCTION
Induction of labour involves promoting softening and dilatation ("ripening") of the cervix
and producing effective myometrial contractions. It has been shown that induction is more
likely to have a successful outcome if the cervix can be ripened prior to the onset of
contractions, whether spontaneous or augmented96'193. PGE2 is now widely used to
prepare the 'unfavourable' cervix for parturition11-'247-335. However, prostaglandin
preparations may cause problems of uterine hyperstimulation336 or may fail to produce
sufficient cervical ripening for labour induction to proceed.
Mifepristone (RU486) is a potent progesterone and glucocorticoid antagonist acting on the
progesterone receptor264. Since it was first described by Philibert in 1981261 its' main
clinical application has been as an abortifacient although it has been noted that its'
administration causes marked cervical softening in the first trimester, either in conjunction
with prostaglandins promoting medical abortion319 or when used alone before vacuum
aspiration of the uterus327, 311. Mifepristone shows synergism with prostaglandins in
causing termination of pregnancy in the first or second trimester319- 323. It seems
reasonable, therefore, to propose mifepristone as an agent for cervical ripening in the third
trimester, particularly in conjunction with prostaglandins. In primates, mifepristone has
been demonstrated to be efficacious, in combination with oxytocin, in achieving cervical
dilation and induction of labour304. In humans, Frydman et al have shown that
administration of 200mg mifepristone on 2 consecutive days to women at term
significantly increased the number entering labour and decreased the prostaglandin
requirements of the remainder, as compared with placebo 334
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Our study aimed to evaluate two doses of mifepristone (50mg and 200mg) as compared
with placebo for their effect on cervical ripening and subsequent induction of labour in
primigravid women whose cervices were initially very unfavourable for induction. We
also evaluated the maternal and neonatal safety of mifepristone when used for this
purpose. Mifepristone is also a potent glucocorticoid antagonist264 and as it is known to
cross the placenta33-'333 we particularly wished to assess whether there was an increased
risk of neonatal hypoglycaemia following its' antepartum use.
3.2: METHODS
This study was a placebo controlled double-blinded trial in which two single oral doses
(50mg and 200mg) of mifepristone were compared with placebo in a dose escalation study
to assess their efficacy and safety for the induction of labor in unfavorable primigravidae at
term. The study was designed such that in the first part the efficacy of a dose of 50mg
mifepristone was compared with placebo. It was then determined on the basis of the an
interim efficacy analysis of this dose compared with the placebo whether a higher or a
lower dose of mifepristone should be used in the second part of the study. Twenty-five
women were included in each treatment arm in this first part and on the basis of the interim
efficacy analysis an increased dose of 200mg was used in the second part of the study. In
the second part of the study twenty-five women received this higher dose of mifepristone
and a further five were randomised to receive the placebo (the placebo groups from both
parts of the study were pooled for the final analysis). The sample size was calculated to
detect a 40% difference in the number of patients who went into spontaneous labour or
who had a Bishops score greater than or equal to 6 between patients receiving mifepristone
and patients receiving placebo with a power of 90% at the 5% significance level.
Randomisation was by pre-determined randomisation code, patients were allocated a
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number, and therefore treatment, in strict numerical order as they entered the study. The
study had ethical approval from the Lothian Research Ethics Reproductive Medicine Sub-
Committee.
Patient Recruitment
The inclusion criteria for the study were that patients were primiparous women aged 18 -
40 with an indication for labour induction and a normal live single cephalic presentation.
The subjects were all of gestations between 37 weeks to 41 weeks and 4 days. Labour
induction was scheduled 72 hours following treatment administration so this maximum
gestation ensured that no patient was induced at a gestation later than 42 weeks. (There is
a small rise in perinatal mortality after this gestation-35) Gestational age was assessed by a
first trimester ultrasound scan. Women were not included in whom there was an obstetric
or medical reason to induce labour within 72 hours. Patients who met the above criteria
had a cervical assessment performed and were offered the option of inclusion in the study
if they had a modified Bishop score-47 of 4 or less (Table 1). Following written informed
consent the patient was blindly randomised to receive either mifepristone or placebo. The
placebo tablets were identical to those containing mifepristone.
Patients were excluded who showed signs or symptoms of the onset of labour or of
placental insufficiency. They were also excluded if they had any contraindication to a
vaginal delivery, if a previous attempt had been made to induce labour or if the membranes
had ruptured. Medical contraindications to inclusion were renal failure, hepatic disorder,
adrenal insufficiency, a history of abnormal coagulation or treatment with anticoagulants
or diabetes mellitus. Patients who during their pregnancy had received chronic
corticosteroid treatment (including inhaled preparations) or a treatment, that may have
interfered with the mode of action of mifepristone, such as aspirin, were not included.
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Study Procedure.
Before taking the study medication a maternal medical and gynaecological history was
taken and a general, abdominal and vaginal examination performed. A modified Bishops'
score (BS)-47 was assigned according to the state of the cervix as described in table 3.1.
A cardiotocograph was obtained, entry to the study being conditional on a reactive tracing.
After entering the study the women were reviewed as out-patients after 24 and 48 hours.
Labour induction was scheduled for 72 hours post treatment if the patient was not in
labour by that time. Fetal well-being was assessed by the women keeping a 'kick-chart'
(on which she recorded the time it took to feel the baby move or kick ten times) for each
24 hour period and by a further cardiotocograph being performed at each review visit. At
the 24 and 48 hour reviews maternal blood pressure and pulse were recorded, the vaginal
examination was repeated and a Bishops score calculated.
Labour Induction
If labour had not occurred within 72 hours after taking the allocated treatment the woman
was admitted for induction of labour. If the cervix was not 3cm dilated and fully effaced
(i.e. favourable for artificial rupture of the membranes, ARM) then an initial dose of lmg
PGEo gel was inserted into the posterior fornix of the vagina. The cervix was reassessed
after 6 hours and (unless labour was established) a further dose of 1 or 2mg of PGEo
given intra-vaginally. The examination was repeated 4 hourly and when appropriate an
ARM was performed. Oxytocin was administered as clinically indicated following the
ARM. Labour management thereafter was at the discretion of the labour ward medical
staff. The fetal heart rate was monitored continuously once labour was established.
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At delivery a cord blood sample was obtained for blood gas analysis, biochemical and
haematological parameters and for assay of Cortisol, ACTH and mifepristone levels.




Neonatal blood glucose was monitored 1,3 and 12 hours post delivery by means of a heel
prick sample tested with BMStix. Neonatal weight, pulse and temperature were recorded
after 24 and 48 hours as were any adverse clinical findings
Maternal observations
Maternal pulse, temperature and blood pressure were recorded 24 and 48 hours following
delivery and again adverse events were noted. A further sample of maternal blood was
taken 24 hours after delivery. Both mother and baby were reviewed one week and one
month following delivery, again standard observations were recorded and any adverse
events noted.
Statistical Analysis
Data were stored on computer database, analysis was performed using the Statistical
Analysis Software (SAS) package. (SAS Institute Inc., Cary, North Carolina, USA).
Differences between the treatment groups were compared using the t-test for continuous




These are outlined in table 3.2. Those in the placebo group had a significantly lower
booking weight than those in either treatment group (p = 0.01 for the 50mg treatment
group and 0.02 for the 200mg treatment group). This was not significantly related to the
efficacy outcomes The patients in the 50mg mifepristone group had a slightly higher pre-
treatment Bishops' score (median of 4 compared to 3) and this was accounted for in the
efficacy analysis. The median Bishops' score in the 200mg group was 3. In all three
treatment groups the most common reason for inclusion was prolonged pregnancy (that is
of duration greater than 40 weeks) (table 3).
Efficacy
The main outcome measures are summarised in table 3.4. Cervical ripening was deemed
to be successful if spontaneous labour had ensued or if the BS was > 6 prior to induction
of labour 72 hours after the treatment administration. This was the case for 64%, 48%
and 30% of the patients treated with 200mg, 50mg mifepristone and placebo respectively.
This difference was significant for the 200mg group (p=0.01) with an odds ratio of 4.15
(95% confidence interval 1.34, 12.84). In the 50mg treatment group the difference was
not significant when the pre-treatment BS was included in the analysis but the odds ratio
was 2.36 (95% confidence interval 0.66, 8.37). The numbers of patients in spontaneous
labour after 72 hours were 9 (36%), 8 (32%) and 7 (23.33%) in the 200mg, 50mg and
placebo groups respectively.
The subsequent course of labour is summarised in table 3.5 and the modes of delivery in
Graph 1. Similar numbers of women in all three groups were given PGE2, had an
115
artificial rupture of the membranes and received oxytocin. The amount of oxytocin
required was 1095mU, 5198mU and 5780mU for the 200mg, 50mg and placebo groups
respectively. This represents a significant reduction in the requirement by the former
group. Significantly fewer women who received 50mg of mifepristone had a caesarean
delivery than those who were given placebo (p=0.033, %2=4.55), however in the group
given 200mg of mifepristone there was no difference from the placebo group in the
number requiring caesarean section. In the 200mg treatment group 8 of the 9 caesareans
were performed for fetal distress and the other one for failure to progress. In the placebo
treated group 3 of the 8 caesareans were for distress and 5 for failure to progress.
Only one patient in the 200mg mifepristone group and three in the placebo group required
manual removal of the placenta. Post partum haemorrhage (blood loss > 500ml) was
reported in 2, 1 and 6 patients who received 200mg mifepristone, 50mg mifepristone and




There was a wide range of maternal minor adverse events reported in all three treatment
groups, most of which were complications of pregnancy, such as haemorrhoids or
headache. There were no marked differences across the groups in the reporting of these.




There were no episodes of antepartum fetal distress following recruitment to the study.
All of the patients had satisfactory CTGs and normal fetal movement at each antenatal
assessment.
In labour, fetal distress was considered as severe if it required medical intervention (such
as fetal blood sampling) or delivery of the baby. This was the case for 12 (48%), 6 (24%)
and 4 (13.33%) in the 200mg mifepristone, 50mg mifepristone and placebo groups
respectively.
Neonatal Safety.
Blood was taken from the umbilical vein at delivery, the blood gas parameters, ACTH and
Cortisol values from these samples are summarised in table 3.6. Samples were not
obtained from all deliveries due to logistical problems in an investigator being present at
delivery and due to technical problems with the equipment to analyse blood gases. The
pC>2 was slightly higher and the base excess slightly lower in the 200mg mifepristone
group, however there were no statistically significant differences between the groups in
any of the cord gas parameters. The analysis of ACTH and Cortisol in the cord blood
showed a wide range of values with no significant differences between the three groups in
their values or the ratio between them, however, there is a trend for the ACTH to be lower
and the Cortisol to be higher across the groups from 200mg to 50mg mifepristone to
placebo. There were no differences between the groups in the renal or liver function tests
nor in haematological or coagulation parameters. The mean levels of mifepristone in the
cord blood were 0.020mg/l (sd=0.034) and 0.036mg/l (sd=0.046) after 50mg and 200mg
of mifepristone respectively. Graph 2 illustrates the relationship between the length of
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time to delivery after mifepristone administration and the cord blood levels of
mifepristone.
The Apgar scores of the babies were recorded at 1 minute and 5 minutes in all the babies
and at 10 minutes in 8 babies. The scores are summarised in table 3.7 from which it can
be seen that there was very little difference between the treatment groups.
Monitoring for hypoglycaemia in the neonates after delivery was by means of a BM stick
test of a heel-prick sample 1, 3 and 12 hours following delivery. Hypoglycaemia was
defined as a BM reading of < 2.2, this was the case in a total of 10, 11 and 10 infants of
mothers who received 200mg, 50mg and placebo respectively. Only one infant in the
study population was admitted to the Special Care Unit as a result of hypoglycaemia, the
mother of this infant had received placebo. Neonatal jaundice was reported in 7 (28%), 2
(8%) and 2 (6.7%) of the infants in the 200mg mifepristone, 50mg mifepristone and
placebo groups respectively. All of these cases resolved spontaneously.
3.4: DISCUSSION
Mifepristone was deemed to have successfully caused cervical ripening in primigravid
women at term with initially unfavourable cervices if after 72 hours the woman was in
spontaneous labour or the cervix had become favourable (Bishops' score > 6). By these
criteria 200mg mifepristone had a significant effect on cervical ripening, while the effect of
50mg was just below significance level, as compared with placebo. An improvement in
the Bishops' score confers an increased chance of successful labour induction193 which
may be of particular benefit to this group of women. These findings confirm those of
Frydman et al 334 who gave 200mg of mifepristone on two consecutive days to women at
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term . In their study, using a higher dose of mifepristone than reported here, 54% of
those treated with mifepristone went into labour spontaneously and a further 23% had a
Bishops' score greater than 4 in the four days following treatment administration
compared with 18% and 24% in the placebo treated group. The higher number in that
study entering labour spontaneously, as compared with our data, is most probably a result
of the higher dose administered, it may also be related to the extra day allowed before
labour induction began or to the fact that some multiparous women were included in the
study group. As the effect of 50mg mifepristone in our study only just failed to reach
significance levels it seems likely that a slightly increased dose, such as 75mg or lOOmg
may also significantly ripen the cervix and that doses greater than 200mg could have a
more pronounced effect.
In the first trimester of pregnancy, mifepristone promotes cervical ripening311 and acts by
way of the decidua 264 to effect termination of the pregnancy. The concomitant
administration of prostaglandins significantly improves the efficacy with which abortion is
induced319. In the second trimester, after intrauterine death, mifepristone was found to
significantly increase the incidence of miscarriage as compared with placebo331. As
pregnancy progresses mifepristone becomes less efficacious at inducing abortion but its
action in promoting cervical ripening is maintained-64. This effect has previously been
noted in Rhesus monkeys, in whom mifepristone alone induced cervical ripening but did
not produce sufficient myometrial activity to effect delivery303. In combination with
oxytocin, however, mifepristone was effective at inducing delivery in these monkeys304.
It is thus to be expected, as is shown in this study, that the most pronounced effect of
mifepristone in the third trimester will be in causing cervical ripening and increased
sensitivity to oxytocin rather than labour induction.
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The cervical changes following mifepristone administration have clinical implications but
in addition this finding may help to elucidate the processes whereby cervical ripening and
the onset of labour occur spontaneously. The effect of antiprogesterones in causing
cervical softening indirectly supports the role of progesterone in the maintenance of
pregnancy, as has long been postulated184. During cervical ripening there is an influx of
neutrophils into the cervical matrix-- and an increase in neutrophil specific collagenase35.
Progesterone may prolong pregnancy by the suppression of intermediary factors. For
example, production of the neutrophil attractant IL-8 in vitro is inhibited by
progesterone147450 jn gUinea pigs the administration of IL-8 or IL-lp vaginally resulted
in cervical ripening with associated histological changes164. The ripening action of
mifepristone on the human cervix demonstrated here may be mediated by such cytokines
or by an alteration in local prostaglandin production and catabolism. In first trimester
decidua, mifepristone administration causes a decrease in prostaglandin dehydrogenase
(the principal catabolic enzyme) and an increase in PGE2 around blood vessels-87-337. If
mifepristone causes similar changes in the third trimester cervix this would provide a
mechanism whereby the blood vessels could become more permeable for neutrophil
extravasation.
As with prostaglandins, it would seem preferable to administer mifepristone vaginally if
this method could maintain the ripening effects demonstrated with oral dosage. In one
study in the first trimester of pregnancy -70 it was found that intravaginal administration of
mifepristone did not lead to termination of the pregnancy, this was thought to be due to
insufficient absorption of the drug. However, it may be, as discussed above, that in the
third trimester a systemic effect on the decidua is not integral to the action of mifepristone
and that this route could provide a local ripening effect on the cervix. It may be that a
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suitable preparation of mifepristone could be administred vaginally if a suitable
formulation could be developed to cause local effects on the cervix.
In labour following mifepristone administration a marked reduction was seen in the mean
total oxytocin dose required, although there was no alteration in the number of women
requiring augmentation. A similar finding was reported by Frydman et al 334 This
decreased requirement may arise because mifepristone administration leads to a more
compliant cervix, thus reducing the myometrial work needed to effect dilatation. A further
possibility is that mifepristone increases the baseline contractility of the myometrium thus
reducing the oxytocin requirement. In the late pregnant guinea pig305 administration of
onapristone, (another antiprogesterone), improved the sensitivity of the myometrium to
oxytocin by increasing the number of intercellular gap junctions which facilitate
intercellular communication. A similar effect on human myometrial gap junctions could
explain the decreased oxytocin dose described in our results. In a small study in early
human pregnancy302 mifepristone caused a slow rise in uterine contractility but no change
in the response to oxytocin, it may be that the sensitising effect of mifepristone on the
myometrium becomes more pronounced with increasing gestation. In our study the
women were initially given only lmg PGE2 following treatment administration due to
concerns that increased uterine responsiveness and synergism between the two agents
could lead to a risk of hyperstimulation. However, there were no episodes of
hyperstimulation reported in any group. At the out-patient antenatal assessments
following mifepristone administration very little uterine activity was observed
tocographically.
In addition to efficacy, the other main outcome measures of the study were fetal and
neonatal safety. Mifepristone has already been used extensively in women at higher doses
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than employed here without major concerns regarding its' safety. Our data showed no
serious maternal side effects.
Previous studies of placental transfer in the late second and third trimester of pregnancy in
monkeys33- showed that a steady state equilibrium was relatively quickly established with
a gradient between mother and fetus possibly limiting flux. It was also noted that the
efficiency with which RU486 crossed the placenta was significantly decreased in the third
as compared to the second trimester of pregnancy. In women in the second trimester of
pregnancy, a single dose of 600mg RU486 was found to give a maternal : fetal ratio of
circulating mifepristone levels of 9:1 .The ratio of the metabolite RU42633 was 17:1. This
dose caused no alteration in fetal progesterone, oestradiol or Cortisol levels but an increase
in fetal aldosterone levels was noted which was only just significant in this small study of
6 women333. In our study the values of ACTH and Cortisol do not show any significant
differences across the groups nor do any of the other biochemical or haematological
markers analysed. As would be expected the levels of mifepristone in the cord blood
samples were higher in the group treated with 200mg mifepristone than in those given
50mg. The levels of mifepristone in cord serum are inversely correlated with the length of
time after administration that delivery occurs.
Fetal and neonatal well-being were assessed at each stage of the study. There was no
antepartum evidence of fetal distress following mifepristone administration, as assessed by
CTG and by maternal record of fetal movement. Intrapartum distress was assessed
clinically and was more often diagnosed in the women who received 200mg of
mifepristone than the other two groups. In this group of women there was an increase in
caesarean deliveries for fetal distress and a decrease in the number performed for failure to
progress, although there was no overall increase in the number of caesarean sections
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performed. In the group of women who received 50mg of mifepristone there was a
reduction in the number of caesarean deliveries. No difference was found in the cord pH
values between the three groups nor in the Apgar scores. These findings may be related to
the small numbers in each group undergoing caesarean section but they could reflect an
effect of the higher dose of mifepristone on fetal distress, possibly related to the
antiglucocorticoid action of this substance. There is a decreased incidence in each group
receiving mifepristone in the number of women requiring caesarean section as a result of
failure to progress in labour as compared with placebo. It may be that labour induction
following mifepristone administration results in a more efficient process thus decreasing
dystocia in the subsequent labour.
In addition to its antigestogen action, mifepristone is also a glucocorticoid antagonist and
indeed has been used in the treatment of Cushings' syndrome-81. There is therefore a
theoretical risk that following delivery the neonates could become hypoglycaemic, if there
is a decrease in neonatal glucocorticoid action. In this study, we therefore measured the
blood glucose levels of the babies 1, 3 and 12 hours post-partum. There were no
differences between the groups in terms of clinically significant hypoglycaemia. The only
baby in the study group who needed admission to the neonatal unit with hypoglycaemia
had received placebo.
3.5: CONCLUSION
These results therefore confirm previous work that mifepristone does promote cervical
ripening, in this case in term primigravidae with unfavourable cervices. Two doses,
200mg and 50mg were studied and it was the larger dose that had a significant effect on
improving cervical ripening. However, this dose was also associated with an increase in
clinical suspicion of fetal distress, an effect not seen with the lower dose. It seems likely
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that a dose such as lOOmg could provide the beneficial effects on cervical ripening with a
lower incidence of fetal distress but the possibility of fetal distress must be carefully
evaluated in further studies of mifepristone.
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3.6: TABLES AND FIGURES.
Table 3.1: MODIFIED BISHOP SCORE
Score 0 1 2 3
Dilatation (cm) <1 1 -2 2-4 >4
Length (cm) >4 2-4 1-2 <1
Consistency Firm Average Soft
Position Posterior Mid; anterior
Level sp -3 sp -2 sp -1; 0
From Calder et al 247
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Table 3.2: PATIENT CHARACTERISTICS
PLACEBO MIFEPRISTONE MIFEPRISTONE
50mg 200mg
AGE (years) 26.2+ 5.9 25.8 + 4.5 25.6 ±3.3
mean ± SD
GESTATION 40+6 40+5 40+6
(weeks + days) (3.6) (5.5) (5.1)
mean (sd days)
BOOKING WEIGHT (kg) 62.2 ± 8.9 71.8 ±13.6 69.8 ±13.3
mean ± SD




a) TOP 2 1 4
b)miscarriage 4 5 1
c) ectopic 0 1 0
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POSTTERM 27 (90%) 18 (72%) 23 (92%)
HYPERTENSIVE
DISORDER
1 (3.3%) 5 (20%) 1 (4%)
OTHER 2 (6.6%) 2 (8%) 1 (4%)
TOTAL 30(100%) 25(100%) 25(100%)









7 (23.33%) 8 (32%) 9 (36%)
INDUCED WITH A
BS >6




9 (30%) 12 (48%) 16 (64%) *
* p=O.Ol compared with placebo
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20 (66.7%) 20 (80%) 16 (64%)
*
p< 0.05 compared with placebo
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P02 (mmHg) n=6 n=6 n=12
mean (SD) 32.3 (11.0) 30.3 (6.0) 38.9 (36.5)
range 22.5 - 53.3 24.0 - 39.8 9.0 - 137.3
pC02 (mmHg) n=6 n=6 n=12
mean(SD) 39.5 (9.6) 40.9 (40) 41.4 (10.5)
range 24.0 - 52.0 34.3 - 45.3 13.1 - 52.0
pH n=16 n=21 n=14
mean (SD) 7.3 (0.1) 7.3 (0.1) 7.3 (0.1)
range 6.9 - 7.4 6.9 - 7.4 7.1 - 7.4
BASE n=5 n=6 n=12
EXCESS)mmol/L)
mean (SD) -4.7 (5.8) -5.3 (2.1) -7.7 (5.5)
range -14.6 - -0.7 -7.9 - -2.3 -22.2 - -1.7
ACTH (mU/L) n=25 n=21 n=19
mean (SD) 51.5 (91.5) 41.8 (43.9) 20.7 (22.6)
range 3-433 3-208 3-84
CORTISOL n=24 n=21 n=19
(mmol/L) 484.5 (223.2) 498.6 (158.9) 522.1 (190.2)
mean (SD) 234- 1037 295 - 894 211 -885
range
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1 minute number 30 25 25
median (range) 8(1 -9) 8(2-9) 8 (3 -9)
5 minutes number 30 24 25
median (range) 9(5- 10) 9 (8 - 9) 9(7- 10)
10 minutes number 4 2 2
median (range) 9 (9 - 9) 9(9-9) 9(9-9)
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SVD ASSISTED VAGINAL CAESAREAN
MODE OF DELIVERY
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Graph 3.2: Mifepristone levels in cord blood obtained at the time of delivery compared
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Graph 3.3: Mean neonatal blood glucose levels 1,3 and 12 hours after delivery following
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In order to examine the in vitro tissue production of IL-8 and to assess the effects of
various steroid treatments on this cultures of tissue explants were used. The advantage of
this method of tissue culture is that it maintains the tissue architecture to a greater extent
than cell culture and so is a closer mimic of the physiological relations between various
cell types. Culture in this manner is also less prone to contamination by infection as is the
case with the longer term cell cultures. The tissues studied in this way were placenta,
decidua and cervix. The details of their collection and incubation are given below. In
general, the tissues were collected and then immediately transported to the laboratory in
sterile 0.9% saline. Under sterile conditions in a tissue culture hood the specimens were
prepared for culture in the various regimes described below. As IL-8 is known to be
produced by many cell types, including monocytes and activated neutrophils care was
taken to carefully wash all the tissue explants at least three times in PBS prior to culture.
Obvious blood vessels, which were particularly seen in the placental explants, were also
dissected out prior to culture. The basic culture medium was 'complete' medium which is
RPMI 1640 (Dulbecco) supplemented with fetal calf serum and a combination of
antibiotics (see appendix for full details). The steroids used were all diluted with complete
medium from solution in ethanol. After being dissected into appropriately sized sections
the explants were placed on CellGraft capillary matting, to aid removal of culture medium,
in the wells of 24 well plates. These were placed in an incubator at 37°C in 5% CCL.
Medium removed during culture was stored at -20°C until the immunoassays were
performed.
All of the studies described below were approved by the Lothian Region Ethics
Committee.
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4.1 i: Culture of placenta explants
Placentae were collected from women at elective caesarean section or after spontaneous
delivery at term (37 to 41 weeks gestation. n=5 in each group). No woman had been
exposed to prostaglandins or oxytocics prior to delivery, although all patients routinely
received lOiu oxytocin (Syntocinon, Sandoz) at caesarean or 5iu of oxytocin and 500/<g
of ergometrine (Syntometrine, Sandoz) at vaginal delivery, prior to the delivery of the
placenta. Immediately following delivery, a piece of villous tissue approximately 1 to 2
cm in diameter was dissected out of each placenta from a central cotyledon, avoiding any
obvious large stem blood vessels or areas of calcification and this was transported to the
laboratory in sterile 0.9% saline.
Under sterile conditions the basal plate of the placenta was dissected off and large vessels
were dissected out. Pieces of placenta measuring approximately 5mm3 were cut from the
remaining tissue and washed three times in phosphate buffered saline (PBS, Dulbecco) to
remove maternal and fetal blood cells. One piece was placed in each well of a 24 well
plate on sterile capillary matting (CellGraft) containing 1 ml of culture medium (RPMl
1640 with fetal calf serum. L-glutamine, penicillin, streptomycin and gentamicin). Forty-
eight explants were prepared in this manner from each placenta, these were divided into
four treatment groups, each comprising twelve replicates. The four treatments used were
control (i.e. no antigestagen added to the culture medium) and the antigestagens
mifepristone (RU486) (10"6M), onapristone (10'^M) or lilopristone (10_f3M). The plates
were incubated at 37°C in 5% COo in humidified air. After 24 hours, the medium was
collected, replaced with the same treatment and collected again after a further 24 hours.
This medium was stored at -20°C until the assay for IL-8 was performed.
136
After 48 hours the medium was pipetted off each well and stored as described above. The
samples were then washed twice with PBS and then each was treated with lml of IN
NaOH overnight. The protein content of each was then estimated using the BioRad assay
according to the manufacturers instructions (see appendix for full protocol). This assay is
a colorimetric assay which estimates the total protein concentration in tissue by
comparison with a standard curve prepared from serial dilutions of bovine serum albumin.
The IL-8 content of the culture medium was determined by radioimmunoassay (see
appendix) using an in-house rabbit anti-IL8 antibody and the IL-8 produced per //g of
protein was thus calculated.
4.1 ii: Culture of decidual explants
Decidua was collected from four elective caesarean deliveries at 37 to 41 weeks gestation
after uncomplicated singleton pregnancies. After delivery of the placenta decidua was
obtained by curettage of the non-placental area of the uterus (decidua parietalis). This
decidua was either immediately placed in sterile saline for transport prior to culture.
Twelve sections of approximately equal size (about 3mm-) were dissected from each
sample of decidua, these were placed in four treatment groups so that each treatment group
contained three replicates. All the explants were individually placed in 1ml of complete
culture medium. The explants were cultured for 72 hours with medium being replaced and
stored at 24 hour intervals. The first group. A, was the control group and received no
additional treatments during culture. This treatment regimen for groups B. C and D is
summarised below. This regimen was used as it is known that manipulation of explants
and their culture can increase the basal production of cytokines therefore the production of
IL-8 was initially suppressed using dexamethasone and progesterone prior to the effects of
culture with progesterone and mifepristone being evaluated.
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0 - 24h 24 - 48h 48 - 72h
A Control Control Control
B Prog 10~6 + Dex 10 7 Control Control
C Prog 10"6 + Dex 10-7 Prog 10 6 Prog 10 6
D Prog 10~6 + Dex 10"7 Prog 10 6 Prog 10 6
+ RU486 5x 10-7 + RU486 5x 10"7
After culture the medium was stored at -70°C until immunoassay was performed. The
tissue sections were dried in air before being weighed.
4.1 iii: Culture of cervical explants.
The study group consisted of thirty women of less than 9 weeks amenorrhoea who were
to have a suction termination of pregnancy. None of the women included had had any
previous pregnancies. Informed consent was obtained from all those who participated.
The women were randomised into five treatment groups, each consisting of six women, to
receive mifepristone at 6, 12, 24 or 36 hours or no treatment prior to the termination. The
surgeons performing the terminations were blinded to the treatment allocation of the
women. Women were not included if they had serious medical conditions, were less than
16 years old or were otherwise unable to give informed consent. At the time of suction
termination a biopsy of the cervix was taken using punch biopsy forceps and was
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transported in complete culture medium for incubation. The biopsies thus obtained
measured about 3mm by 5mm. These samples were obtained in conjunction with studies
being undertaken with the support of an MRC Project Grant (G9406438PA).
The cervical biopsies were cultured in 0.5ml culture medium for 24 hours at 37°C in 5%
CC>2 in humidified air.. The medium was pipetted off and analysed by
radioimmunoassay. The biopsies were then weighed and the production of the
prostaglandins PGE2, PGF2U > their metabolites and the cytokines IL-8 and MCP-1 was
calculated by radioimmunoassay as detailed below.
4.2: IMMUNOHISTOCHEMISTRY
4.2 i: Technique.
The technique of imunocytochemistry involves detection of the desired antigen with a
specific primary antibody, this localisation is then amplified by a secondary antibody
directed against the first. This secondary antibody will be from a different species to the
first. In the method described below an enzyme is then used together with a chromagen
whose colour alters when the enzyme catalyses a reaction. The most commonly used
enzymes are horseradish peroxidase (HRP) and alkaline phosphatase, the former was
used in all the staining procedures described here. The peroxidase may be linked to a third
antibody directed against the secondary antibody (and from the same species as the first
antibody enabling the secondary antibody to act as a link between them) as in the PAP
(peroxidase - antiperoxidase) method, where three molecules of peroxidase are complexed
with two antiperoxidase antibodies. Alternatively, an avidin and biotinylated horseradish
peroxidase complex may be used338-339 in the ABC method described below. This
method is more sensitive and requires a shorter incubation period than the PAP method as
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well as ensuring less background staining. This method utilises the high affinity of avidin
for biotin (10'^ M-l). Both the secondary antibody and the peroxidase can be biotinylated
and then be linked together by avidin. The ABC complex thus binds via the avidin to a
biotinylated secondary antibody, so the peroxidase is indirectly bound to the antigen to be
detected. Addition of an electron donating chromagen, such as DAB (3-diaminobenzidrine
tetrahydrochloride) and peroxide facilitates the enzyme reaction causing oxidation and
colour change of the DAB. Other potential chromagens, such as AEC (3 - amino -
ethylcarbazole) could be used but DAB has advantages in that it is not alcohol soluble and
remains well localised to the site of precipitation.
Background staining.
Staining of the tissue at sites other than those containing the desired antigen may occur for
several reasons. These are often due to the formation of an immune complex at sites other
than those containing the targeted antigen. This may be due to binding of either the
secondary antibody or the ABC complex directly to the tissue. Endogenous peroxidase
present in the tissue may catalyse the third stage enzymatic stage and cause colour change
in the DAB at the site of endogenous enzyme. The secondary antibody may bind to
epitopes in the original tissue as well as to the primary antibody from the species it was
raised against. To decrease the likelihood of background staining thus occurring, certain
steps were provided in all the following protocols. Prior to the addition of antibodies the
tissue was exposed to dilute hydrogen peroxide to saturate any endogenous peroxidase
rendering it inactive and therefore decreasing the incidence of background staining.
Normal serum of the species from which the second antibody was raised was added prior
to antibody application to decrease non-specific secondary antibody binding. Following
incubation with the DAB sections are immersed in tap water to stop the reaction and then
stained with haematoxylin, dehydrated and mounted as described in the protocols.
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Controls
Each staining procedure was performed using a tissue and a reagent control:
Positive tissue control: A tissue, in this case, tonsil known to contain the desired antigen
and therefore expected to stain positively. Tonsil has previously been demonstated to
produce many cytokines, including IL-835-, in vivo and is known to contain the leucocyte
populations being studied.
Negative tissue control: Sections of the tissue being stained which are treated in exactly the
same manner except that they receive either non-immune serum or immunoglobulins from
the species providing the primary antibody in its place in the protocol. These sections
should therefore exhibit minimal staining.
4.2 ii: General protocol.
1. Fixation: Frozen sections: These were fixed in 10% neutral buffered formalin (NBF)
for 10 minutes and then washed in PBS prior to staining.
Paraffin sections: These were fixed in NBF for 24 hours then washed
twice in 70% alcohol, dehydrated in sequential increasing concentrations of alcohol and
xylene and embedded in paraffin wax.
2. Peroxidase block: Sections were immersed in 3% hydrogen peroxide diluted in distilled
water for 10 minutes at room temperature to saturate endogenous peroxidase. They were
then washed twice in PBS.
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3. Non-immune block: Using normal serum from the same species as the secondary
antibody to decrease background staining. Sections were not washed prior to the next
step.
4. Application ofthe primary antibody or negative control: The antibodies used were either
monoclonal (i.e. raised from the same cell line and targeted against a specific epitope on
the antigen) or polyclonal and therefore directed against several epitopes of the targeted
antigen. The negative tissue controls were treated with either immunoglobulins or serum
from the same species as the primary antibody. Tissues were protected from drying out
during incubation with the primary antibody by covering them with cover slips, using a
humidity chamber or covering with Cling Film. Following incubation, tissues were
washed, ensuring that the negative tissues were washed separately in PBS with Tween.
5. Application of the second non-immune block: In the IL-8 protocol a second block was
employed at this stage using identical means as the first one.
6. Application of the secondary antibody. The biotinylated antibody was applied and
washed off (with PBS Tween) after a suitable incubation period.
7. Application ofABC - IIRP: The complex was mixed from the commercially available
kit (Vectastain or Vectastain Elite, Vector Laboratories), allowed to stand for 30 minutes
according to the manufacturers' instructions and then applied to the tissues. It was washed
off with PBS(Tween).
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8. DAB application: Again, this was prepared according to instructions from a
commercially available kit. After an 8 minute application the reaction was stopped by
immersing the tissue in tap water.
9. Counterstain and mounting: Haematoxylin was used as counterstain, after washing off
excess the tissue was dehydrated with alcohols and then immersed in xylene prior to
mounting.
4.2 iii: Specific protocols.
Detailed protocols for the immunohistochemistry are given in the appendix.
IL8
The method utilised for immunocytochemistry is as previously described by Critchley et
a] 148 polyclonal rabbit antibody was produced in-house (kindly supplied by Dr R.
Kelly) and demonstrated specific immunoreactive binding to sites on frozen tissue only. It
was used in conjunction with a biotinylated swine anti-rabbit secondary antibody (E353,
DAKO, Glostrup, Denmark) and the ABC peroxidase system (Vectastain ABC kit, Vector
laboratories, Burlinghame, USA). The non-immune block was performed with normal
swine serum. The chromagen was DAB (Vector, SK - 4100). The negative control in this
protocol was the IL-8 antibody preabsorbed with IL-8 protein. This was produced by
overnight incubation of the IL-8 antibody with an excess of IL-8 protein (provided by
Schering). Tonsil tissue was used as a positive tissue control as abundant IL-8 is found in
the vascular regions in this tissue.
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CD45
This antigen, also known as leukocyte common antigen (LCA) was used as commercially
available mouse monoclonal antibody (DAKO) labelling the RB epitope (see above).
Paraffin fixed sections were used for this protocol. A biotinylated horse anti-mouse
secondary antibody ( Vector) was used and the ABC-HRP complex for the third stage, as
in the IL8 protocol. Prior to the application of the primary antibody, a non-immune block
was performed using horse normal serum (Vector 4002).
CD68
This was also a commercially produced mouse monoclonal antibody (Mac CD68, DAKO)
raised against Gaucher's cells which was used in conjunction with a biotinylayed horse
secondary antibody (Vector), horse normal serum (Vector 4002) and an ABC peroxidase
detection system (Vector). In this protocol a trypsin digestion stage was included prior to
the first non-immune block. The tissue sections were paraffin fixed following collection.
Neutrophil elastase
A commercial mouse monoclonal antibody to a - neutrophil elastase (DAKO) was used
with horse biotinylated secondary antibody and horse normal serum (Vector 4002) and the
ABC peroxidase detection system ( Vector) as before.
4.2 iv. Tissue preparation for immunohistochemistry.
Placentaltissue
Tissue samples of placentae were collected after elective caesarean section at term (37 to
39 weeks gestation) from singleton pregnancies uncomplicated by diabetes or
hypertensive disorders. Sections from each placenta, including the basal plate, were
dissected, immediately embedded in OCT (Miles Inc., Elkhart, IN, USA.) and placed in
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an isopentone tray which was surrounded by liquid nitrogen. The frozen OCT block was
then stored at -70°C prior to cutting into approximately 5j,im sections using a microtome.
Sections for paraffin sections were placed in 10% neutral buffered formalin and processed
as described above.
First trimester villi were collected from four women during surgical termination of
pregnancy and processed in the same manner.
Decidual tissue.
Decidual tissue was collected at elective caesarean section by curettage of the non-placental
area of the uterus (decidua parietalis) as described in preparation for tissue culture. This
was placed in 10% formalin (for paraffin fixed sections) or frozen in embedding medium
(OCT, TissueTek, Miles Inc., Elkhart, USA) in a block placed in isopentone which was
in turn placed in liquid nitrogen (for frozen sections). The frozen OCT blocks were then
stored at -70C until 5pm sections were cut with a microtome. First trimester decidua was
collected for immunocytochemistry at the time of surgical termination of pregnancy and
frozen as described above for IL-8 immunocytochemistry.
4.2 v: Image analysis of decidual samples.
Ten fields from each decidual sample stained for CD45 were analysed using image
analysis. The fields were visualised with an Olympus BH2 microscope (x 20 objective)
and analysed as previously described17 with Colour Vision software (Improvision, UK).
A digital image of the field was thus obtained for analysis. Areas containing no cells were
deleted from the computer image. The software package discriminated areas of brown
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(positive) from blue (haematoxylin)) staining measuring all areas in pixels. The
proportion of positive staining cell area compared with total cell area was thus calculated.
4.3: RADIOIMMUNOASSAY
This technique is used to determine the concentration of a given substance in a solution by
comparison with a standard curve created from solutions of known concentrations.
Antibody radiolabeled with '-5I is added to the sample solution and a second antibody
conjugated to a magnet is added. The magnetic complex thus created is precipitated by
placing the test tube on a magnetic plate (see appendix for protocol). Excess solution is
discarded and the radioactive count in the remaining pellet is counted using a multigamma
counter and the concentration of the substance tested for calculated by comparison with the
standard curve. The standard curve is prepared by assay of serial 1:2 dilutions of a
known concentration of the test antigen and then plotting a curve of the radioactive count
emitted after assay. Each assay includes a test of the total count which contains only the
radiolabeled antibody, the non-specific binding (NSB) found by testing buffer and label,
to assess any binding of the buffer to the label and the B0 found by saturating the
antiserum with label. In these studies all the immunoassay results were calculated using
Assay Zap (Biosoft, Cambridge).
Immunoassay For IL-8.
A rabbit antibody, which was raised against the intact 72 amino acid IL-8 peptide
synthesised using fluorenyl methoxy carbonyl (FMOC) chemistry, was used in a
radioimmunoassay as has been previously described147. A 1 in 60 000 dilution of the
antiserum was used. Recombinant IL-8 was used for the standard curves. A top standard
of 25ng/ml was diluted by two and serial dilutions of two were continued to give ten
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standards. The assay was performed overnight with a 'non-stick' buffer containing serum
albumin and tween (see appendix) to minimise the non-specific binding. A magnetic anti-
rabbit antibody was then added and the tubes used then placed on a magnet. The tubes
were then counted using a mutiganna counter for for 60 seconds and analysed using
AssayZap.
The assay has cross reactivities of < 0.25% against IL-1, IL-2, IL-6 and IL-10. The intra-
assay variation was 7% and between-batch assay variation was 12%.
Immunoassay for MCP-1.
This was by radioimmunoasay as described for IL-8. The antibody was raised against the
intact 77 amino acid MCP-1 and recombinant MCP-1 (R and D Systems) was used as the
standard.
Immunoassay for PGE / M and PGFIM.
These assays are as described in previous publications340'341. Antiserum and label were
both mixed with assay buffer (see appendix) prior to use. Samples were moxed using
mox B solution (see appendix) immediately after thawing. The standard curve was
constructed using ten serial x2 dilutions of a top standard (5120pg/ml). After overnight




REGULATION OF INTERLEUKIN - 8 PRODUCTION IN THE TERM
HUMAN PLACENTA DURING LABOUR AND BY ANTIGESTAGENS
5.1: Introduction.








Interleukin-8, (IL-8) has been shown both to attract and activate neutrophils34-. It is a 72
amino acid chemokine that has subsequently been demonstrated to be released by many
cell types, including fibroblasts343, macrophages, endothelial cells and even
phagocytosing neutrophils1-5. IL-8 is also present in and released by many uterine
tissues, including placenta161, choriodecidua150 and cervix43. The influx of neutrophils
has been postulated to be an integral part of the onset of parturition as described above,
particularly in the cervix, where the collagenase involved in ripening appears to be derived
from peripheral neutrophils which increase in number in the cervix during this
process2'2-'35. The presence of IL-8 in these diverse reproductive tissues and its known
synergism with prostaglandin E2 (PGE2) in attracting neutrophils to skin sites144-344
suggests a wider role for IL-8 in the initiation of labour than in cervical ripening alone.
Furthermore, IL-8 production in other uterine tissues, such as cervix43, choriodecidua150
and endometrium147 is suppressed by progesterone. This effect may be reversible by
antigestagens, such as mifepristone150 which may have an inducing effect on the initiation
of labour.
The aim of this study was therefore to examine the release of IL-8 by term human placenta
prior to and after labour had ensued. The regulation of IL-8 production by three
antigestagens was studied to asses a possible regulatory role in the induction of the labour
process. Furthermore, the localisation of IL-8 in the first and third trimester placenta was
determined using immunohistochemical techniques. The localisation of cells showing
positive staining for CD-45 (pan-leucocyte marker), CD-68 (monocyte-macrophage
marker) and neutrophil elastase was also examined.
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5.2: SUMMARY OF METHODS.
These are described in detail in Chapter 4 and are summarised below.
PlacentalExplants
Placentae were collected after spontaneous and caesarean delivery at term (n=5 in each
group). After transport to the laboratory they were cultured for 24 and 48 hours in
complete medium to which was added mifepristone (RU486) (lO^M), onapristone (10"
6M) or lilopristone (10~6M), a fourth group was the control i.e. no antigestagen added to
the culture medium. The plates were incubated at 37°C in 5% CCL in humidified air. The
production of IL-8 after 24 and 48 hours by each group was analysed by
radioimmunoassay. The protein content of each placental tissue sample was assayed
using the BioRad method as described in Chapter 4.
Data analysis.
The IL-8 production was expressed as ng per )ig of protein. The results obtained were
tested for significance using a parametric test. Fishers protected least significant
difference (StatView) and significance at the level of p< 0.05 was determined.
Immunocytochemistry
Tissue samples of placentae were collected after elective caesarean section at term (37 to
39 weeks gestation) from singleton pregnancies uncomplicated by diabetes or
hypertensive disorders. Frozen and paraffin sections were prepared from these samples.
First trimester villi were collected from four women during surgical termination of
pregnancy and processed in the same manner. Sections were stained for IL-8, CD45,
CD-68 and neutrophil elastase positive cells.
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5.3: RESULTS
Production Of'Interleukin-8 By Placenta
All the explants of placental tissue released interleukin-8 into the culture medium,
irrespective of the presence or absence of labour or treatment with antigestagens.
The culture medium was replaced after 24 hours and in all samples IL-8 release increased
in the second 24 hours of culture. This increase was significant (p<0.05) for the control
samples from both elective caesarean and spontaneous deliveries and also for the
caesarean samples treated with onapristone and the spontaneously delivered placentae that
were treated with mifepristone or with lilopristone.
After spontaneous delivery, for each treatment group and at each time point, all the
placental explants produced more IL-8 than the explants collected from women not in
labour. As illustrated for the control groups in graph 1, this was a significant increase (p<
0.05) at both time points.
The effects of three antigestagens, onapristone, mifepristone and lilopristone on IL-8
production in both types of placenta were also examined and are shown in graph 2. In the
spontaneously delivered group those treated with onapristone produced significantly more
IL-8 than the control samples at 24 and 48 hours while in the electively delivered group it
was lilopristone at 24 hours which caused a significant increase in production over control
samples (p< 0.05 in each case).
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Localisation OfInterleukin-8 In Placenta.
In the third trimester villi IL-8 positive immunostaining was found to be localised in the
perivascular walls of fetal vessels as shown in figure 5.1 . A negatively stained section of
third trimester placenta is shown in figure 5.2 . In the first trimester IL-8 was shown
peripherally in the developing syncytiotrophoblast of the villi (figure 5.3 ).
White cell populations in the placenta.
Few cells in the third trimester placentae studied showed positive staining for CD-45,
those seen were mainly localised in the blood pools outside the trophoblast tissue (figure
5.4). There were CD-68 cells localised within the trophoblast tissue, mainly within the
cytotrophoblast (figure 5.5). Hardly any cells showing positive staining for neutrophil
elastase were seen and. as with the CD-45 positive cells, those present were in blood
outside the trophoblast (figure 5.6).
The populations studied were also found to be immunolocalised around vessels in the
basal plate of the placenta as in the sections shown from a spontaneously delivered
placenta. CD-45 positive cells were seen in association with this vessel (figure 5.7), both
within the lumen and within the vessel walls (figure 5.8). These cells were not
predominantly CD-68 positive (figure 5.9), but exhibited strongly positive staining for
neutrophil elastase (figure 5.10). The decrease in concentration of these cells with
increasing distance from the vessel may suggest a gradient of cells from the vessel.
Tonsil was used as a tissue control for all of the staining protocols. Positive staining was
seen in the tonsil with all the protocols used, for example IL-8 was immunolocalised to the
areas around blood vessels (figure 5.11). No staining was demonstrated in the negative
control sections of either tonsil or of placenta.
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5.4: DISCUSSION
These studies demonstrate that the human placenta produces IL-8 and that this production
is increased during labour and also by culture with some of the antigestagens studied.
An increase in IL-8 prior to the onset of spontaneous labour could facilitate recruitment of
neutrophils into the uterine environment. It has been shown that in skin sites IL-8 and
PGE2 act synergistically to increase the influx of neutrophils144'344 and it may be that
such synergism extends to the reproductive tissues where at the time of parturition there is
an increase in local levels of prostaglandins which have an established role in the initiation
and progression of labour. Once recruited into the uteroplacental tissue neutrophils could
be activated by IL-8 causing release of lytic enzymes, such as collagenase and elastase,
which may cause loosening of the tissue matrix in the cervix--35, choriodecidua157 and
fetal membranes85. IL-8 may therefore be part of a cascade of inflammatory agents,
including other cytokines and prostaglandins involved in the initiation of parturition. An
immunohistochemical study of IL-8 receptors (types 1 and 2) in the placenta has found
that these are also increased after spontaneous delivery as compared with after elective
caesarean section141. This indicates a parallel increase in the production of IL-8 and in its
functional effects via these receptors.
It is also possible that the increase in IL-8 production seen after vaginal delivery is an
effect and not a cause of labour. It may be that the mechanical stress of contractions leads
to enhancement of the capability of the placental tissue to produce IL-8. To further clarify
the role of IL-8 in parturition more detailed study of the time course of its production
during labour would be required. However, the placenta cannot be directly sampled
during spontaneous labour in women and although tissue can be obtained at emergency
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caesarean delivery performed during labour these cases may differ inherently from those
resulting in vaginal deliver)'.
There were no other obvious significant differences in the placentae to account for the
difference in production following labour, as the elective deliveries were all at term and
were not performed for placental insufficiency, growth retardation or metabolic
abnormalities. The spontaneously delivered placentae resulted from labours that were not
induced or augmented with prostaglandins or oxytocics. All women delivering vaginally
in our unit routinely receive oxytocin and ergometrine after delivery of the fetus, at
caesarean oxytocin alone is given. It seems unlikely that ergometrine would have a
significant effect on IL-8 production.
It has previously been shown that IL-8 production is down-regulated by both
progesterone 43,147 ancj dexamethasone 345. The addition of antigestagen to the culture
medium increased IL-8 production to a significant degree in the spontaneously delivered
placentae treated with onapristone and in the caesarean delivered ones treated with
lilopristone for 24 hours. Currently, antigestagens are being studied in clinical trials for
cervical ripening and induction of labour in the third trimester 334 The local antagonism
of progesterone in uterine tissues may increase IL-8 levels permitting recruitment of
neutrophils and also lead to increased local levels of PGE2 89. In first trimester decidua,
mifepristone treatment increases perivascular PGE2 levels and decreases its
metabolism-87 -337. A parallel increase m IL-8 and PGE2 levels m placenta at term would
enhance the synergistic effects of these two agents on neutrophil recruitment. A
significant increase in IL-8 production may not have been demonstrated in this study as
the amount of antigestagen used may not have been sufficient to antagonise the large
endogenous progesterone production of* t!ie plncentn. It could nlso be tfint, particularly
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after spontaneous delivery the response of the placental cells to exogenous agents has
altered such that an effect in vivo is masked.
These results confirm the findings of Shimoya et al 161 that the third trimester placenta
can produce IL-8 constitutively without in vitro stimulation by other agents. Using
immunohistochemistry we have demonstrated that cells showing positive IL-8 staining are
localised in the perivascular area. This is the same location as that described for IL-8 in
the endometrium 148. This supports the hypothesis that IL-8 may have a role in the
migration of neutrophils from blood vessels around the time of parturition. This
localisation is in contrast to that of the above study 161 which described IL-8
immunostaining in both first and third trimester placentae in trophoblastic cells and
macrophage-like cells. This difference may be due to an intrinsic difference in the samples
studied or in the antibodies used.
Leucocytes staining with CD-45, CD-68 or with neutrophil elastase were not widely seen
in the placental samples studied. The antibody against neutrophil elastase does not detect
this after degranulation of the cells and so it may be that there have been greater numbers
of neutrophils present but that they are not detected due to their rapid degranulation.
However, one would expect, if this were the case to see cells present in the tissue prior to
degranulation. The photomicrographs of the vessel in the basal plate do suggest an
emigration of neutrophils into the tissue, however this cannot be directly inferred from a
static view of a vessel in one section.
In addition to its effects on neutrophils, IL-8 has been associated with an angiogenic
action '-7. It has been shown here to be present in first trimester villi and around the
villous vessels in the third trimester. If IL-8 were to have an effect on angiogenesis as the
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placenta develops it could have a potential role in conditions involving abnormal placental
vascularisation, such as intrauterine growth retardation and pre-eclampsia.
5.5: CONCLUSION.
In summary, these studies demonstrate that the term placenta constitutively produces IL-8
which is localised principally around the perivascular area of the villi. This production of
IL-8 is increased following spontaneous labour, increases with culture time and is
stimulated to varying degrees by some antigestagens. IL-8 may have a role in the onset of
parturition by recruiting and activating neutrophils at the placental site facilitating release of
lytic enzymes, hence antigestagens may aid the induction of labour by increasing the
influx of neutrophils into the placenta. Further work is now underway to establish the
controlling mechanisms involved in the stimulation of IL-8 during labour and the potential
role of antigestagens in regulating IL-8 production and the timing of the onset of
parturition.
156
Graph 1: Interleukin-8 (IL-8) production (mean ± SEM: ng//*g protein) by explants of
placental villous tissue obtained after spontaneous (solid bars) and elective caesarean
(hatched bars) delivery and maintained in tissue culture for 24 and 48 hours. Statistical












Graph 2: Interleukin-8 (IL-8) production (mean ± SEM; ng///g protein) by explants of
placental villous tissue obtained after spontaneous (solid bars) and elective caesarean
(hatched bars) delivery, untreated (control medium, C) or treated with onapristone (O,
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Figure 5.1: IL-8 positive immunostaining in a
section of third trimester placenta following
spontaneous delivery (x20) showing staining
in the perivascular area. v= fetal vessel
Figure 5.2:11-8 negative immunostaining in a
section of third trimester placenta following
spontaneous delivery (x10).
Figure 5.3: IL-8 positive immunostaining
in a section of first trimester placenta (x20)
showing staining in the syncytiotrophoblast (s).
Figure 5.4: CD45 positive immunostaining in a
section of third trimester placenta
following spontaneous delivery (x20)
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Figure 5.5: CD68 positive immunostaining
in a section of third trimester placenta
following spontaneous delivery (x40).
Figure 5.6: Neutrophil elastase positive immunostaining
in a section of third trimester placenta
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Figure 5.7: CD45 positive immunstaining in a
section of third trimester placenta in the region
of the chorionic plate following spontaneous delivery
(x20) showing staining in the region of a vessel.
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Figure 5.8: CD45 positive immunostaining
in a section of third trimester placenta in the
region of the chorionic plate following spontaneous
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Figure 5.9: CD68 positive immunostaining in a
section of third trimester placenta in the region
of the chorionic plate following spontaneous delivery
(x20) showing little staining in the area adjacent to the vessel.
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Figure 5.10: Neutrophil elastase positive immunostaining
in a section of third trimester placenta in the region of the
chorionic plate following spontaneous delivery (x20)
showing increased staining in the region of a vessel.
 
Chapter VI:
PRODUCTION OF INTERLEUKIN-8 BY DECIDUAL TISSUE:










Decidual tissue occupies a pivotal position in the parturient uterus, being in contact with
the myometrium, adjacent to the cervix and separated only by the fetal membranes from
the amniotic fluid. Products of the decidua could therefore potentially influence and be
influenced by all of these areas.
Interleukin - 8 (IL-8) is a cytokine which has been shown to be produced by cervical
tissue 43, by choriodecidual cells obtained from the chorionic surface 147 and by placental
tissue l61. It is also present in the amniotic fluid in amounts that have been demonstrated
to be increased in association with both term and preterm labour and it has been proposed
that at least some of this IL - 8 is of decidual origin 157.
Influx of neutrophils appears to be a key event in the onset of cervical ripening and of
parturition. It has been hypothesised that PGE2 aids this influx of neutrophils, possibly
synergistically with IL-8 89 which is a potent attractor and activator of neutrophils. It has
previously been shown that IL-8 production is down-regulated by both progesterone
43,147 and dexamethasone 345. The events of parturition have been linked to a decrease in
local levels of progesterone, although this has not been conclusively demonstrated in the
human. A decrease in the effect of progesterone could lead to an increase in the
expression of IL-8 enhancing neutrophil influx and activation. Use of antigestagens such
as mifepristone (RU486) may also activate this process.
This study examines the production of IL - 8 by the decidua parietalis in contact with the
myometrium and the effects of dexamethasone, progesterone and mifepristone on this.
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The leukocyte populations present in this tissue prior to the onset of labour are studied
immunohistochemically.
6.2: SUMMARY OF METHODS
Decidua was collected from four elective caesarean deliveries. After delivery of the
placenta the decidua was obtained by curettage of the non-placental area of the uterus
(decidua parietalis) and prepared as described in chapter 4 for culture and for
immunohistochemistry. First trimester decidua was collected for immunohistochemistry
at the time of surgical termination of pregnancy.
Twelve sections from each sample of third trimester decidua were placed in four treatment
groups so that each treatment group contained three replicates, these were cultured
according to the protocol described above. The supernatant was removed after 24, 48 and
72 hours and IL-8 production determined by radioimmunoassay. The percentage change
in production for each treatment group at 48 and 72 hours as compared with the 24 hour
production was calculated for each well and the median thus obtained. Statistical
significance was tested using Fishers protected least significant difference (StatView) and
significance at the level of p < 0.05 was determined.
Sections of first trimester decidua were stained using immunohistochemistry to localise
IL-8. Sections of third trimester decidua were examined to determine the populations of
CD-45. CD-68 and neutrophil elastase positively staining cells. Ten fields from each
decidual sample stained for CD45 were analysed using image analysis as described in




All the explants of decidua parietalis obtained at elective caesarean section in the third
trimester produced IL-8. Culture with progesterone 10"^ and dexamethasone 10"^ for 24
hours (groups B, C and D) caused a decrease in this production, as compared with the
control samples which were not treated with steroids (group A) as is shown in graph 6.1.
This reduction was, however, not statistically significant (p = 0.08).
The median percentage change in production of IL-8 at 48 and 72 hours as compared with
the 24 hour production in each treatment group was calculated and is shown in graph 6.2.
There were wide variations between the decidual samples in their production of IL-8 and
also in the alteration of this in response to treatments and it may be, at least in part, a
reflection of these wide variations that none of the differences between the treatment
groups or over the two time points are significant.
Group A was the control group in which there was a non-significant increase in
production at 48 and 72 hours as compared to the 24 hour production. In group B, which
was treated initially with progesterone and dexamethasone and then with no further
steroids for the 48 hour and 72 hour timepoints there was a non-significant decrease in
production at 72 hours as compared with that at 24 hours. In group C which was treated
with progesterone 10~6 alone after 24 hours treatment with progesterone and
dexamethasone the pattern of IL-8 production is similar to that seen in group B. The
addition of mifepristone 5 x 10"^ and progesterone 10~" to the culture medium in group D
was associated with an non-significant increase in IL-8 production, as compared with the




In the first trimester decidua, positive IL-8 staining was seen in the perivascular areas, this
area was negative in tissue stained with rabbit IgG. (figures 6.1, 6.2). A similar pattern
was seen in some of the third trimester decidua with clear localisation of the staining in the
perivascular area (figure 6.3).
CD45
Cells with positive staining for this marker were evident in the third trimester decidua. A
field containing a large number of such cells is shown, (figure 6.4) By image analysis (as
described above) the overall percentage of cells staining positively for this marker was
6.7% ± 8.0. This analysis is calculated on the basis of the areaoi cells staining positively
and negatively. The tissue negative for CD45 showed no staining.
CD68
There appear to be fewer of these cells in the decidual tissue, many fields contained less
than that shown here (figure 6.5). The cells staining appeared rather fragmented in their
morphology.
Neutrophil Elastase
Virtually no cells in the decidual stroma stained positively with this antigen (figure 6.6).
Positively staining cells were seen in small numbers in blood vessels within the decidua.
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6.4: DISCUSSION
These results confirm that decidua parietalis collected from the myometrial aspect of the
uterus produces IL-8. This production seems to be affected by the steroid environment in
which the explants are cultured. A suppression in production is seen during culture with
dexamethasone and progesterone as compared with control samples but this is not
significant in the above results, possibly due to the large variations between the samples.
Suppression of production by dexamethasone and progesterone would be expected from
work in similar tissues, such as choriodecidua, endometrium l47450 an(j cervix 43. In
this study the suppression observed appeared to continue after removal of the steroid
medium and careful washing of the explants (group B). This could be due to a continued
alteration in the intracellular release or production of IL-8 or may be because the
suppression is not a direct effect of the steroids but is mediated by other factors, such as
IL-1 or TNFa both of which have been shown to increase IL-8 production 153. A
destabilisation of the mRNA for these cytokines by the steroids used could have a
relatively long acting effect on decreasing IL-8 production.
The use of explants, rather than cell cultures in this study is supported by work
demonstrating that decidual tissue explants produce lower levels of IL-8 (and many other
inflammatory cytokines) than decidual cells cultured in the same conditions, suggesting
that the preparation of cell cultures may stimulate cytokine production 346.
Treatment with progesterone alone after initial suppression of production by
dexamethasone and progesterone (Group C) did not cause a significant recovery in IL8
production. The explants that received no further progesterone or dexamethasone showed
a similar continued suppression of production (as described above), so the effect of
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progesterone may be weak. However when interpreting the effect of progesterone on this
tissue it may be significant that it had been exposed to high levels of progesterone in utero
prior to culture.
Addition of mifepristone and progesterone after initial suppression (group D) did not
produce a significant rise in IL-8 production as compared with addition of no further
steroids or the addition of progesterone alone although a non-significant rise in production
was seen. This may again be due to the wide variation in these samples but it suggests
that the initial suppression by dexamethasone and progesterone is not overcome by the
addition of mifepristone. Further studies could be performed to assess if increasing
concentrations of mifepristone would produce a significant increase in IL-8 production.
Mifepristone has an antiglucocorticoid action and it may be that this is of more importance
in overcoming the continuing suppression of IL-8 production seen in group B than its
antiprogesterone effects.
These results do not show a significant effect of mifepristone on increasing IL-8
production in third trimester decidua. This is in contrast to recent work showing that
administration of mifepristone in vivo in the first trimester results in a time-dependent
increase in IL-8 production by cultured decidua35'. This difference could be due to the
differing progesterone concentrations between the first and third trimesters. It may also be
that there are other factors necessary for the effect of mifepristone on IL-8 production,
such as other cytokines which are modulated following administration of mifepristone to
women but which are not affected during in vitro culture with mifepristone. In
choriodecidual cells from the maternal surface of third trimester chorion IL-8 production
was decreased by progesterone and increased by mifepristone150. This may represent a
difference between choriodecidual cells and decidua parietalis or be due to the smaller
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inter-sample variability found in this study. As mentioned above decidual cell culture
production of IL-8 is greater than explant production and the effect of steroids may also
vary between the two preparations.
The perivascular location of IL-8 in the first and third trimester decidua mirrors the
position of PGE2 in early decidua as shown by Cheng et al in their studies 337 387 where
it was shown that treatment with RU486 caused a decrease in local PGDH and an increase
in PGE2 in the perivascular area. In view of the synergism that has been shown to exist
between IL-8 and PGE2 in other tissues 144 their similar localisation in decidua suggests a
similar synergism may occur there. This in turn could relate to recruitment of neutrophils
from the decidual vessels around the time of parturition. In the staining for neutrophil
elastase little positive staining was seen in the decidua obtained from elective caesarean
sections. There could be several reasons for this. The antibody used may not stain the
elastase once the neutrophils are activated which may occur rapidly in tissue with
potentially high levels of IL-8. Alternatively, as these decidual samples are pre-labour the
tissue levels of IL-8 may either not be sufficient or may be prevented by some other factor
from recruiting neutrophils. High local levels of endogenous progesterone may inhibit the
production of IL-8.
There are leucocytes present in the third trimester decidua, which are CD45 +ve. This is a
non-specific marker for leucocytes (the leucocyte common antigen or LCA). The cells
thus stained are generally CD68 -ve. The latter antibody is a macrophage marker raised
against Gaucher cells. In this study the proportion of CD 56+ cells in the decidua was not
assessed but as discussed in Chapter 1, this has previously been found to reduce in the
third trimester as compared with the first trimester.
177
The decidua in this study was obtained by curettage at the time of elective caesarean
section. Decidua collected in this way contains fewer chorionic cells than that taken off the
chorion and is a closer representation of the decidual tissue in direct contact with the
myometrium. Factors released by decidua may have an effect on the myometrium and
thus could have a role in stimulating contractions. The decidua parietalis is also in close
contact with the cervix and so there may exist a network of local factors between these two
tissues integral to the initiation of both cervical ripening and myometrial contractions. It
has previously been shown that the collagenase involved in cervical ripening is derived
from neutrophils from blood vessels ~ 35 IL-8 from decidua, in addition to that
produced by the cervix 43 may have a role in recruiting these neutrophils and in their
activation causing release of collagenase. IL-8 has also been shown to be present in
amniotic fluid ]-7 and at least some of this is thought by that group to be of decidual
origin. In this context IL8 has been postulated to have a role in 'clearing debris' post¬
partum.
There are, therefore, many potential roles for IL-8 being produced by decidua in the third
trimester, including effects on the cervix and myometrium. In order to clarify these
further, samples of decidua are required from other stages of labour. However, it is not
easily possible to collect decidua during normal labour and decidua collected from
intrapartum caesareans may differ intrinsically from that found in labour following a more
'natural course'.
6.5: CONCLUSION
IL-8 is produced by the decidua parietalis in the third trimester prior to labour. This
production may be related to an ability of the decidua to recruit neutrophils from blood
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vessels around which it has been immunolocalised. There are leucocytes present in the
decidua, of which some are CD45 and some CD68 positive. In this study few neutrophils
were identified in the decidual tissue.
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Graph 6.1: Effect of progesterone and dexamethasone on IL-8 production (mean±sem,
ng / mg) as compared with control treatment over 24 hours. (p= 0.08).
treatment
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Graph 6.2: Median percentage change (±sem) in IL-8 production in each treatment group
at 48 and 72 hours as compared with production at 24 hours.
Figure 6.1: IL-8 positive immunostaining in a
section of first trimester decidua (x40)
showing staining in the perivascular area.
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Figure 6.2: IL-8 negative immunostaining in a
section of first trimester decidua (x40)









Figure 6.3: IL-8 positive immunostaining in a
section of third trimester decidua obtained at
elective caesarean (x40) showing staining
in the perivascular area.
Figure 6.4: CD45 positive immunostaining in a
section of third trimester decidua
obtained at elective caesarean (x20).
Figure 6.5: CD68 positive immunostaining in a
section of third trimester decidua obtained at
elective caesarean (x20).
Figure 6.6: Neutrophil elastase positive immunostaining
in a section of third trimester decidua obtained at elective caesarean (x20).
Chapter VII:
THE EFFECT OF MIFEPRISTONE ON THE PRODUCTION OF
INFLAMMATORY MEDIATORS BY FIRST TRIMESTER CERVIX
7.1: Introduction.






The progesterone antagonist mifepristone has previously been shown to soften the cervix
in the first trimester as an adjunct to medical -62,321 or surgical termination3-7 of
pregnancy and to promote cervical ripening in the third trimester of pregnancy in monkeys
303 and in humans 334. The exact mechanism by which this occurs is unclear although it
is known that mifepristone acts on the progesterone receptor to antagonise the effects of
progesterone -64.
Cervical ripening prior to parturition at term is associated with an influx of neutrophils into
the cervical stroma with an associated release of the collagenase they contain which causes
dissociation of the collagen fibres -G35 This has been proposed to occur in the presence
of an inflammatory type reaction in which the cytokine interleukin-8 (IL-8) and
prostaglandin Eo (PGE2) interact to attract and activate neutrophils in the cervical
stroma89. Monocyte chemoattractant peptide-1 (MCP-1) has been proposed to be
involved in the recruitment of inflammatory cells which could produce IL-8 and other
cytokines such as IL-1 and IL-6 in the cervix during ripening. Mifepristone may act by
directly increasing the levels of such mediators in the cervix or by antagonising an
inhibition of their production by progesterone.
This study aimed to examine the production of inflammatory mediators by cervical
biopsies obtained at surgical termination of first trimester pregnancies in primigravid
women who had received mifepristone 6, 12, 24 or 36 hours prior to termination. These
levels were compared to those in a control group of women who were not given any
preoperative treatment. The mediators studied were PGEt, PGF2a, their metabolites and
the cytokines IL-8 and MCP-1.
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7.2: SUMMARY OF METHODS
The study group consisted of thirty women of less than 9 weeks amenorrhoea who were
to have a suction termination of pregnancy. None of the women included had had any
previous pregnancies. Informed consent was obtained from all those who participated.
The women were randomised into five treatment groups, each consisting of six women, to
receive 200 mg of mifepristone at 6, 12, 24 or 36 hours or no treatment prior to the
termination. The surgeons performing the terminations were blinded to the treatment
allocation of the women. Women were not included if they had serious medical
conditions, were less than 16 years old or were otherwise unable to give informed
consent. At the time of suction termination a biopsy of the cervix was taken using punch
biopsy forceps and was transported in complete culture medium for incubation. The
biopsies thus obtained measured about 3mm by 5mm. The study was approved by the
Lothian Ethics Committee.
Tissue culture and radioimmunoassay protocols.
The cervical biopsies were cultured for 24 hours in complete medium as described in
chapter 4. Their production of the mediators studied was then analysed by
radioimmunoassay.
Statistical analysis.
Statistical significance was tested using Fishers protected least significant difference




All the patients had surgical termination of pregnancy within 45 minutes of the allocated
time according to their treatment group. The patient characteristics are shown in figure 1.
There were no significant differences between the groups (p > 0.05) in terms of their age,
body mass index or gestation at the time of termination of pregnancy. Three patients (one
in the control group, one given mifepristone 6 hours and one 24 hours prior to
termination) were of gestations greater than 63 days but less than 68 days.
Radioimmunoassax results.
The results of the assays for levels of PGE2, PGEM, PGF2Uj PGFM, IL-8 and MCP-1
are shown in Graphs 1, 2 and 3. None of the differences demonstrated reached
significance at the stated level (< 0.05).
The production of PGE2 shows a slight increase across the treatment groups but this was
not significant. One biopsy produced a large amount of PGF2« after pretreatment with
mifepristone 6 hours prior to sampling. There was an increase in production of PGF2U in
samples obtained when mifepristone was given 36 hours prior to sampling as compared to
when it was given 12 hours before but again this did not reach a statistically significant




These first trimester cervical biopsies all demonstrated production of the inflammatory
mediators studied, regardless of whether mifepristone was given prior to sampling and of
the timing of mifepristone pretreatment. It has been postulated that cervical ripening
occurs by an inflammatory process 41 and there is accumulating evidence of a cascade of
inflammatory mediators that interact during cervical ripening both at term and at other
stages of pregnancy. During cervical ripening the collagen of the stroma is degraded by
collagenase which appears to be derived from neutrophils recruited into the cervical
stroma-6-35. IL-8 is a potent attractor and activator of neutrophils and it has been shown
by this study that the first trimester cervix is capable of producing this cytokine,
confirming the findings of Barclay et al 43. The effects of IL-8 in attracting and activating
neutrophils have been demonstrated in rabbit skin to be increased by PGEo 14-T43. If
such synergism occurs in the cervix it may that administration of mifepristone, while not
causing a statistically significant increase in either mediator could cause sufficient
alterations in their production to affect neutrophil activation in the cervix.
Monocyte chemotactic peptide-1 (MCP-1) is a 76 amino acid cytokine which attracts blood
monocytes and is also chemotactic for basophils, eosinophils and lymphocytes but not for
neutrophils 134 Tissue macrophages are unresponsive to the actions of MCP-1 whereas
blood monocytes respond to its chemotactic effect170. MCP-1.is produced in large
amounts by monocytes and also causes an increase in monocyte secretion of IL-1 and IL-
6171. IL-1 in particular is known to stimulate IL-8 production 131 and so release of MCP-
1 could act as an indirect stimulant of IL-8 production. MCP-1 also acts on basophils to
stimulate histamine and leukotriene release 134. As with IL-8 its production by cells has
been shown to be stimulated by IL-1, TNFa and LPS 134 All the biopsies which had
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been exposed to mifepristone produced more MCP-1 than the control group. MCP-1
production may lead to an increase in the recruitment of monocytes into the cervix and the
release of further immunoactive mediators such as IL-1 and IL-6 which could in turn
increase IL-8 production and stimulate degradation of the cervical stroma. PGE2 limits
MCP-1 expression in lung fibroblasts1-4 and if it has a similar action in the cervix could
act as a 'brake' on the inflammatory cascade.
Mifepristone is known to soften the cervix in the first trimester of pregnancy and has been
shown to be as effective as gemeprost (16, 16-dimethyl-trans A 2 PGEi methyl ester,
Cervagem) in a blinded study comparing them with placebo for preoperative cervical
ripening prior to vacuum aspiration in the first trimester of pregnancy3-7. The
intraoperative blood loss was significantly decreased by both treatments as compared with
placebo with no difference in their effectiveness. In our study it was found that the degree
of softening following mifepristone administration was so marked that it affected the type
of biopsy obtainable. It was for this reason that a punch biopsy was taken rather than a
Trucut needle biopsy. The latter method may have been advantageous as it would have
been expected to obtain a sample from above the ectocervix from which at least some of
the punch biopsy was obtained. It proved impossible however to obtain an adequate
specimen using the Trucut needle following mifepristone administration.
In women in the first trimester of pregnancy administration of mifepristone prior to
sampling and culture of decidual tissue has been shown to decrease the levels of
prostaglandin dehydrogenase (PGDH) and increase the tissue levels of PGE2 and PGEM
present -87. Culture of decidual tissue collected from such women showed increased
PGF2« production and decreased PGFM (the metabolite of PGF2«) levels compared with
control tissue -91. Although mifepristone has been shown to increase prostaglandin levels
193
in these studies its action in causing cervical ripening in the first trimester may not be
directly related to alterations in prostaglandin production. In this study we have found no
significant alterations in prostaglandin production by the cervix following mifepristone
administration. Other studies of the human cervix in the first trimester have shown that
administration of mifepristone does not alter the subsequent in vitro bioconversion of
radiolabeled arachodonic acid to thromboxane, PGE2, PGF2a 308 or the production of
12-hydroxyeicosatetraenoic acid (HETE) or leukotrienes -83. In women, the effect of
mifepristone in causing increased cervical softening and dilatation in the first trimester of
pregnancy is not reversed by the concomitant administration of naproxen (a
cyclooxygenase inhibitor). -94 These studies suggest that either the mechanism of action
of mifepristone in causing cervical softening is not solely mediated through prostaglandins
and also that other synthetic pathways producing prostaglandins unaffected by diclofenac
and naproxen may involved.
In the late pregnant monkey oral administration of mifepristone led to an increase in the
amniotic fluid levels of 6-keto-PGFla, PGFM. PGF2a and PGEM which increased in that
order over time -95. This increase was not observed, however, until at least 40 hours
after mifepristone administration by which time an increase in uterine contractile activity
was already evident. This observation is in contrast to the finding in the same study that
in spontaneous labour intra-amniotic prostaglandins and their metabolites increase before
the onset of regular uterine activity. It may be that if we had administered mifepristone at
time points longer before termination of pregnancy significant differences in cervical
production of prostaglandins and their metabolites may have been found.
Mifepristone is known to cause clinically significant softening and dilatation of the cervix
of women in the first trimester of pregnancy. Further work is needed to demonstrate
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whether alterations in the monocyte or neutrophil populations of the cervix occur
following mifepristone administration.
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Figure 1: Patient age (years, mean±SD), body mass index (BMI) (mean±SD) and
gestation (days, mean ±SD) for each of the treatment groups.
Age BMI Gestation
Control 21.33 (3.27) 23.52 (4.15) 58.67 (5.35)
6h 22.17 (5.00) 24.42 (3.15) 60.33 (4.41)
12h 20.50 (3.56) 23.57 (3.77) 53.50 (7.61)
24h 22.83 (2.64) 25.48 (3.78) 57.17 (5.85)
36h 20.67 (4.41) 22.25 (2.99) 50.67 (12.11)
Figure 2a: Production of PGE2, PGEM, PGF2a and PGFM (ng / mg, mean±sem) by
cervical biopsies from each of the treatment groups.
pge2 pgem pgf2a pgfm
Control 0.99 (0.39) 0.45 (0.17) 1.85 (0.71) 0.52 (0.17)
6 hours 1.05 (0.69) 0.59 (0.30) 5.20 (4.31) 0.55 (0.30)
12 hours 1.62 (0.56) 0.82 (0.50) 1.47 (0.60) 0.50 (0.18)
24 hours 1.83 (0.61) 0.24 (0.05) 2.03 (0.81) 0.65 (0.17)
36 hours 2.02 (0.68) 0.60 (0.20) 3.18 (1.27) 0.74 (0.29)
196
Figure 2b: Production of IL-8 and MCP-1 (ng / mg, mean±sem) by cervical biopsies
from each of the treatment groups.
IL-8 MCP-1
Control 1.99 (0.64) 0.15 (0.08)
6 hours 2.09 (0.78) 1.52 (0.93)
12 hours 3.07 (0.76) 1.05 (0.23)
24 hours 2.82 (1.21) 1.16 (0.61)
36 hours 2.77 (0.82) 0.29 (0.18)
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Graph 1:
Mean (± sem) production of IL-8 and MCP-1 (ng / mg) by cervical biopsies after
pretreatment with mifepristone 6, 12 , 24 or 36 hours prior to biopsy as compared with



















Mean (±sem) production of PGE2 and PGEM (ng / mg) by cervical biopsies after
pretreatment with mifepristone 6, 12 , 24 or 36 hours prior to biopsy as compared with
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CONCLUSIONS AND DISCUSSION OF RESULTS OF CLINICAL AND
LABORATORY STUDIES.
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The process of parturition is evidently a complex procedure involving the interaction of
many factors which appear to act in a cascade with the potential for amplification and
dampening of the ensuing events. The mechanism by which this occurs must eventually
lead to cervical effacement and dilatation and to the establishment of regular effective
uterine contractions.
As discussed in the initial two chapters, this process seems likely to be regulated, at least
in part, by the locally available concentration of progesterone. There is accumulating
evidence of an inflammatory type cascade, in which increased production of mediators,
such as the chemokines, IL-8 and MCP-1, and prostanoids, such as PGE2 and PGF2«
interact to produce an influx of lymphocytes and neutrophils. The former cells can
elaborate other chemokines, such as IL-1, IL-6 and TNF-a which are capable of
perpetuating this cascade. Neutrophils, when activated, release collagenases and
elastases. which as discussed above, are thought to be essential for the collagen
dissociation associated with cervical ripening. The presence of this inflammatory
environment may stimulate myometrial contractions which are favoured by an increase in
the number of intercellular gap junctions, the presence of which enhances coupling
between these cells.
In the studies described in the preceding chapters it has been attempted to further elucidate
the mechanism of such a hypothesis. The role of progesterone in maintaining uterine
quiescence has been examined by studying the effects of its antagonist mifepristone on the
cervix in the first and third trimesters of human pregnancy. The capability of placental,
decidual and cervical tissue explants to release IL-8 has also been studied and the effects
of steroids on this production examined. The role of MCP-1 in promoting cervical
ripening in the first trimester after mifepristone administration has also been assessed. In
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the placental and decidual tissue studied the localisation of IL-8 has been determined
immunohistochemically and the associated population of white cells has been broadly
assessed.
Mifepristone has been shown to increase cervical ripening in primigravid women prior to
labour induction. This effect was significant when a dose of 200mg was used and was
just below significance when 50mg was used. The use of mifepristone prior to labour
induction also decreased the subsequent requirement for oxytocin, as was reported in a
previous study 334 However, in our results a small increase in the number of Caesareans
performed for fetal distress after the use of 200mg mifepristone as compared to placebo
was found. While this may be a function of the relatively small numbers involved, it may
also be a true effect and further studies of the use of mifepristone for this purpose must
carefully evaluate this.
The positive effect of progesterone antagonism in promoting cervical ripening in the third
trimester adds support to the proposition that it is a decrease in functional local
progesterone that stimulates naturally occurring cervical ripening at term. It also seems
that antagonism of progesterone may prime the myometrium to the effects of oxytocin,
whether endogenous or exogenous. This may occur by an increase in the number of gap
junctions present, as is seen in the guinea pig after onapristone administration305. In the
first trimester administration of mifepristone prior to termination of pregnancy was found
to cause a time-dependent increase in the production of MCP-1 by cervical explants.
Withdrawal of progesterone may thus act to promote influx of monocytes which are
capable of maintaining an inflammatory environment. If this effect is also seen in the third
trimester the increase in chemokine concentration could provide an explanation for the
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clinically confirmed promotion of cervical ripening observed following mifepristone
administration.
These studies confirmed that the cervix in the first trimester is capable of synthesising
prostanoids and the chemokines IL-8 and MCP-1. The placenta and decidua at term have
also been shown to produce large amounts of IL-8 in culture. In the placental tissue
studied, the production of IL-8 was significantly increased after labour as compared with
the production by tissue obtained at elective Caesarean section. This increase is
supportive of the hypothesis that parturition is associated with an increase in IL-8 which
would be capable of attracting neutrophils into the stroma of the uterine tissues where
release of their lytic enzymes could alter the tissue structures and favour parturition. The
time course of this increase was not however determined and it remains possible that the
increase in IL-8 production seen after labour is an effect, rather than a cause of parturition.
The effects of dexamethasone, progesterone and antigestagens on IL-8 production were
not consistently demonstrated in the above studies. This was, at least in part, due to the
wide variations in IL-8 production by the explants. This was particularly seen in the
decidual explants, in which the production of IL-8 varied widely between the four samples
as did the change seen in this production on treatment with steroids. The decidual samples
studied were all obtained at the time of elective Caesarean, but although all were obtained
at similar gestations the actual proximity of the onset of parturition cannot be known and
may have had a profound effect on the response of the tissue. Although the samples were
washed it may be that variations in the amount of blood cells retained by the tissue altered
their IL-8 production. Despite this, a trend was observed whereby IL-8 production was
suppressed by dexamethasone and progesterone, the effect of the former being more
pronounced and was stimulated by treatment with mifepristone. If these suppositions
were to prove to be real effects this would be supportive of the role of progesterone
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withdrawal and IL-8 production at the time of labour. However, such an inference cannot
be drawn from these results.
In both the placenta and the decidua in the third trimester IL-8 was found to be localised
around blood vessels. This is as been previously reported in the endometrium 148 and is
in keeping with its putative role in neutrophil recruitment into these tissues. In neither
tissue were significant quantities of cells found that stained positively with the neutrophil
elastase protocol. This commercial antibody did stain the tonsil tissue used as a positive
control. This may reflect a true lack of neutrophils in these tissues or it may be that the
antibody did not detect neutrophils after activation and degranulation had occurred. It may
be that the leucocytes present in uterine tissues are atypical and are not as easily detected
with the standard techniques and markers used here. There are leucocytes, stained
positive with CD-45, present in small concentrations in the placenta and in larger amounts
in the decidual tissue. Cells staining with CD-68, a macrophage marker, were also found
in the tissue stroma. It may be that these tissues contain other, more atypical leucocytes
that would require more detailed study to localise.
It is therefore proposed that at the time of parturition the withdrawal of progesterone
promotes a local increase in inflammatory mediators and cell types. The changes seen as
the cervix ripens are associated with an influx of neutrophils which release lytic enzymes,
such as collagenase, that cause loosening of the collagen stroma. IL-8, an inflammatory
chemokine, is a potent attractor and activator of neutrophils and has been found to be
released by the cervix, placenta and decidua. Its production could be increased by a
cascade of effectors, in which monocytes, attracted into the cervical or uterine tissues by
MCP-1, could elaborate other mediators, such as IL-1, IL-6 and TNF-a .
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Further work is needed to test this hypothesis. The effects of mifepristone administration
on third trimester uterine tissues could be studied, possibly by its administration prior to
elective Caesarean sections. The effects of steroids on the production of IL-8 and other
inflammatory mediators such as MCP-1 by uterine tissues also requires further study with
large numbers of samples to decrease the effects of individual variation.
It will only be once the mechanisms by which labour occurs are more fully understood
that more effective methods can be developed to induce labour in pregnancies that are
post-term or in which continuation of the pregnancy poses a significant risk to the fetus or
the mother. Many and various methods have been proposed to induce labour, with
prostaglandins and oxytocin currently being the most effective options available.
However, these methods are not always successful and can involve risks to the mother
and fetus during their administration. It may be that administration of effectors proposed
to be part of the inflammatory cascade prior to labour, such as IL-8 or MCP-1 could result
in more efficient and successful induction of labour.
FUTURE WORK.
Based on the findings reported in this thesis there are several potential areas for further
study. Further clinical studies of the use of mifepristone in the third trimester could be
undertaken. It would be important that these assessed fetal well-being following treatment
administration. Mifepristone may be of benefit in inducing labour in multiparous women
and in higher doses than studied herein may be able to induce labour without the addition
of prostaglandin pessaries.
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The role of IL-8 in causing neutrophil influx into the cervix during parturition requires
further study. In many tissue types IL-8 has been found to be regulated by
dexamethasone. The potential regulation of IL-8 by steroid hormones, in particular
progesterone could be examined in more detail in human uterine tissues. The molecular
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ii: IL8 non-stick buffer
iii: Prostaglandin assay buffer
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2. Assay protocols









i. Complete medium: RPMI 1640 supplemented with:
10% fetal calf serum
0.3 mg/ml L-glutamine
lOOIU/lOOug penicillin and streptomycin
20^g/ml gentamicin
ii. IL8 non-stick buffer:
6.05g trizma base
2.5g bovine serum albumin (BSA)
10ml 10% tween 80
0.5g sodium azide
pH to 7.6
iii. Prostaglandin assay buffer:










i. "BioRad" protein assay.
After 48 hours of treatment the samples were washed twice with PBS and were then
treated with 1ml of IN NaOH overnight. The protein content of each was estimated using
the BioRad assay according to the manufacturers instructions. This utilises a colorimetric
assay to estimate the total protein concentration in tissue by comparison with a standard
curve prepared from serial dilutions of bovine serum albumin. Following removal of the
second application of culture medium, the placental explants were treated overnight with
IN NaOH. A standard curve was prepared from 1.4mg/ml bovine serum albumin by
serial dilution 1:1 with IN NaOH. 20]A of sample or standard had 100y,d Biorad reagent
added to it and colorimetry performed at 620nm. Results were again analysed using
AssayZap (Biosoft, Cambridge, UK).
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ii. Radioimmunoassay protocol.
Standards: Serially diluted in 0.5ml of buffer + tween
Prepare tubes as below:
std/sample buffer antiserum label non-stick
buffer
TOTAL 100/d 100/d
NSB 200//1 100//1 100/d
Bo 100//1 100//1 100/d 100//1
Standard 100/d 100/zl 100/d 100/d
Sample 50//1 50/zl 100/zl 100/d 100/d
Cover tubes and incubate overnight.
Add 0.5ml of second antibody (anti-rabbit), this does not get added to the 'total count'
tube
Leave for 15mins
Place on magnetic trays for 5mins
Tip excess of all tubes (except total count) and count using multigamma counter.
Radioimmunoassay for PGE and F
Samples were moxed immediately after collection using lx Mox B solution (see above).




(All steps at room temperature unless otherwise indicated)
1. Frozen sections of tissue and control tissue (tonsil) were fixed in 10% neutral buffered
formalin (NBF). lOminutes
2. Sections washed in phosphate-buffered saline 2x5 minutes
3. Endogenous peroxidase block with 3% hydrogen peroxide diluted in distilled water
10 minutes
4. Sections washed in phosphate-buffered saline 2x5 minutes
5. First non-immune block with normal swine serum (1:10 dilution) 20 minutes
6. Primary antibody application using rabbit anti-lL8 diluted 1: 500 in PBS or (as
negative) rabbit IgG 1 : 500. Incubated at 37C. 60 minutes:
7. Sections washed in phosphate-buffered saline (tween) with the negative controls being
washed separately. 2x5 minutes
8. Second non-immune block with normal swine serum (1:10 dilution) 20 minutes
9. Secondary antibody, biotinylated swine anti-rabbit 1: 300, applied. 30 minutes
10. Sections washed in phosphate-buffered saline (tween) 2x5 minutes
11. ABC complex applied 30 minutes
12. Sections washed in phosphate-buffered saline (tween) 2x5 minutes
13. DAB applied 8 minutes
14. Reaction stopped by immersing sections in tap water 5 minutes
15. Sections stained with haematoxylin 8 seconds:
16. Excess washed off in tap water 5 minutes
17. Dehydration by sequential immersion in 70%, 90%, absolute alcohol 2minutes each
18. Section immersed in xylene for at least 5 minutes and then mounted.
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ii. CD45 Protocol:
(All steps at room temperature unless otherwise indicated)
1. Sections dewaxed in Histoclear 5 minutes
2. Sections rehydrated with absolute, then 90%, then 70% alcohol 2minutes each
3. Wash with distilled water 2x5 minutes
4. Wash with PBS 2x5 minutes
5. Endogenous peroxidase block with 3% hydrogen peroxide diluted in distilled water
10 minutes
6. Sections washed in phosphate-buffered saline 2x5 minutes
7. First non-immune block with normal horse serum (1:10 dilution) 20 minutes
8. Primary antibody application using mouse anti CD45-RB diluted 1: 50 in PBS or (as
negative) mouse IgG 1 : 50. Incubated at 37C 60 minutes
9. Sections washed in phosphate-buffered saline (tween) with the negative controls being
washed separately. 2x5 minutes
10. Secondary antibody, biotinylated horse anti-mouse applied. 30 minutes
10. Sections washed in phosphate-buffered saline (tween) 2x5 minutes
11. ABC complex applied 30 minutes
12. Sections washed in phosphate-buffered saline (tween) 2x5 minutes
13. DAB applied 8 minutes
14. Reaction stopped by immersing sections in tap water 5 minutes
15. Sections stained with haematoxylin 8 seconds:
16. Excess washed off in tap water 5 minutes
17. Dehydration by sequential immersion in 70%, 90%, absolute alcohol 2minutes each
18. Section immersed in xylene for at least 5 minutes and then mounted.
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iii. CD68 Protocol:
(All steps at room temperature unless otherwise indicated)
1. Sections dewaxed in Histoclear 5 minutes
2. Sections rehydrated with absolute, then 90%, then 70% alcohol 2minutes each
3. Wash with distilled water 2x5 minutes
4. Wash with PBS 2x5 minutes
5. Endogenous peroxidase block with 3% hydrogen peroxide diluted in distilled water
10 minutes
6. Sections washed in phosphate-buffered saline 2x5 minutes
7. Trypsin digestion using 0.1% trypsin in 0.1% Ca Cl2 in distilled water at pH 7.8.
Incubated at 37C. 15 minutes
8. Wash with tap water 2x5 minutes
9. Wash with PBS 2x5 minutes
10. First non-immune block with normal horse serum (1:10 dilution) 20 minutes
11. Primary antibody application using mouse anti CD68 diluted 1: 50 in PBS or (as
negative) mouse IgG 1 : 50. 60 minutes
12. Sections washed in phosphate-buffered saline (tween) with the negative controls being
washed separately.
13. Secondary antibody, biotinylated horse anti-mouse applied.
14. Sections washed in phosphate-buffered saline (tween)
15. ABC complex applied
16. Sections washed in phosphate-buffered saline (tween)
17. DAB applied
18. Reaction stopped by immersing sections in tap water
19. Sections stained with haematoxylin











21. Dehydration by sequential immersion in 70%, 90%, absolute alcohol 2minutes each
22. Section immersed in xylene for at least 5 minutes and then mounted.
iv. Neutrophil elastase protocol:
(All steps at room temperature unless otherwise indicated)
1. Sections dewaxed in Histoclear 5 minutes
2. Sections rehydrated with absolute, then 90%, then 70% alcohol 2minutes each
3. Wash with distilled water 2x5 minutes
4. Wash with PBS 2x5 minutes
5. Endogenous peroxidase block with 3% hydrogen peroxide diluted in distilled water
10 minutes
6. Sections washed in phosphate-buffered saline 2x5 minutes
7. First non-immune block with normal horse serum (1:10 dilution) 20 minutes
8. Primary antibody application using mouse anti a - neutrophil elastase diluted 1: 50 in
PBS or (as negative) mouse IgG 1 : 50. Incubated at 37C 60 minutes
9. Wash in PBS (tween) negative controls being washed separately. 2x5 minutes
10. Secondary antibody, biotinylated horse anti-mouse, applied. 30 minutes
10. Sections washed in phosphate-buffered saline (tween) 2x5 minutes
11. ABC complex appl ied 30 minutes
12. Sections washed in phosphate-buffered saline (tween) 2x5 minutes
13. DAB applied 8 minutes
14. Reaction stopped by immersing sections in tap water 5 minutes
15. Sections stained with haematoxylin 8 seconds:
16. Excess washed off in tap water 5 minutes
17. Dehydration by sequential immersion in 70%, 90%, absolute alcohol 2minutes each
18. Section immersed in xylene for at least 5 minutes and then mounted.
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Regulation of interleukin 8 production in the term human
placenta during labor and by antigestagens
Catherine L. Elliott, MB, ChB,a Rodney W. Kelly, PhD,b Hilary O.D. Critchley, MD,a Simon C.
Riley, PhD,a and Andrew A. Calder, MDa
Edinburgh, United Kingdom
OBJECTIVE: Our purpose was to assess the effects of labor and antigestagens on production of interleukin
8 by the term human placenta and to localize interleukin 8 in first- and third- trimester placentas.
STUDY DESIGN: The study was conducted by the Department of Obstetrics and Gynaecology of the
University of Edinburgh. Five placentas were collected after spontaneous and cesarean deliveries. Explants
were cultured in the presence of mifepristone, lilopristone, or onapristone.The production of interleukin 8
was determined by specific radioimmunoassay, and the immunolocalization of interleukin 8 was determined
in sections of first- and third-trimester placentas.
RESULTS: All explants produced interleukin 8. Production was significantly increased (P< .05) after sponta¬
neous delivery. In placentas delivered spontaneously, onapristone significantly increased production of inter¬
leukin 8 (P< .05), whereas in those from cesarean deliveries lilopristone caused a significant increase in
production (P < .05). In the third-trimester placenta interleukin 8 was localized in the perivascular area of
fetal vessels. In first-trimester villi it was peripherally located in syncytiotrophoblast.
CONCLUSION: The human placenta at term is capable of producing interleukin 8, which is localized around
the perivascular area of the villi. Production is increased after spontaneous labor and to varying degrees by
the antigestagens studied. Interleukin 8 may have a role in the onset of parturition by recruiting and acti¬
vating neutrophils at the placental site. (Am J Obstet Gynecol 1998;179:215-20.)
Keywords: Interleukin 8, placenta, labor, cytokines
Interleukin 8 (IL-S) was first described1- as a peptide
released by stimulated monocyte cultures and was shown
both to attract and activate neutrophils.'1 It is a 72-amino-
acid chemokine that has subsequently been demon¬
strated to be released by many cell types, including
fibroblasts,4 macrophages, endothelial cells, and even
phagocytosing neutrophils."' IL-8 is also present in and
released bv many uterine tissues, including placenta,"
chorion-deciclua,' and cervix.1 The influx of neutrophils
has been postulated to be an integral part of the onset of
parturition, particularlv in the cervix, where the collage-
nase involved in ripening appears to be derived from
peripheral neutrophils that increase in number in the
cervix during this pr ocess.'-'"11 The presence of IL-8 iit
these diverse reproductive tissues and its known svner-
gism with prostaglandin K.> (PGE») in attracting
neutrophils to skin sites'-1-11 suggests a wider role for' IL-8
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in the initiation of labor than in cervical ripening alone.
Furthermore, IL-8 production in other uterine tissues,
such as cervix,8 chorion-decidua,' and endometrium14 is
strppressecl by progesterone. This effect may be
reversible bv antigestagens, such as mifepristone,' which
mav have an inducing effect on the initiation of labor.
The aim of this study was to examine the release of IL-
8 bv term human placenta before and after labor had
ensued. The regulation of IL-8 production by three
antigestagens was studied to determine a possible regula¬
tors role in the induction of the labor process.
Furthermore, the localization of IL-8 in the first- and
thircl-trimester placenta was determined by immunohis-
tochemical techniques.
Material and methods
Placental explants. Placentas were collected from
women at elective cesarean section or after spontaneous
delivers at term (37 to 41 sveeks' gestation, n = 5 in each
group). No svoman had been exposed to prostaglandins
or oxvtocic agents before delivers', although all patients
routinels received 10 IU oxvtocin (Syntocinon, Sandoz)
at cesarean delivers or 5 IL of oxytocin and 500 |ig ol
ergometrine (Syntometrine, Sandoz) at sagittal delivery
before the delisery of the placenta. Immediately after
delivers', a piece of villous tissue approximately 1 to 2 cm
in diameter svas dissected from each placenta from a
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Fig 1. IL-8 production (mean ± SEM) by explants of placental
villous tissue obtained after spontaneous (solid bars) and elective
cesarean (open bars) delivery and maintained in tissue culture for
24 and 48 hours. Statistical significance is denoted by symbols:
Two asterisks, P< .005; asterisk, P< .05.
central cotyledon, avoiding any obvious large-stem blood
vessels or areas of calcification; the tissue was transported
to the laboratory in sterile 0.9% saline solution.
Under sterile conditions the basal plate of the placenta
was dissected off and large vessels were removed. Pieces
of placenta measuring approximately 5 mm3 were cut
from the remaining tissue and washed 3 times in phos¬
phate-buffered saline solution (Dulbecco's medium) to
remove maternal and fetal blood cells. One piece was
placed in each well of a 24-well plate on sterile capillary
matting (CellGraft) containing 1 mL of culture medium
(RPMI 1640 with fetal calf serum, l.-glutamine, penicillin,
streptomycin, and gentamicin). Forty-eight explants were
prepared in this manner from each placenta: these were
divided into 4 treatment groups, each comprising 12
replicates. The 4 treatments used were control (ie, no
antigestagen added to the culture medium) and the
antigestagens mifepristone (RU486) (1 (H' mol/L),
onapristone (1(H> mol/L), and lilopristone (10~6
mol/L). The plates were incubated at 37:C in 5% carbon
dioxide in humidified air. After 24 hours, the medium
was collected, replaced with the same treatment, and
collected again after a further 24 hours. This medium
was stored at -20°C until the assav for IL-8 was
performed.
Immunoassay for IL-8. A rabbit antibodv. which was
raised against the intact 72-amino-acid 11.-8 peptide
synthesized bv use of tluorenvl ntethoxv carbonyl chem-
istrv, was used in a radioimmunoassav as previously
described.1"4 Recombinant IL-8 was used to produce data
for the standard curves. The assay was performed
overnight with the addition of a buffer containing serum
albumin and Tween to minimize nonspecific binding.
The counts were analyzed with the AssayZap program
(Biosoft, Cambridge, United Kingdom).
Estimation of protein content. After 48 hours of treat¬
ment the samples were washed twice with PBS and were
then treated with 1 mL of TVsodium hydroxide overnight.
The protein content of each was estimated with the
BioRad assay according to the manufacturer's instruc¬
tions. This method uses a colorimetric assay to estimate
the total protein concentration in tissue by comparison
with a standard curve prepared from serial dilutions of
bovine serum albumin. .After removal of the second
application of culture medium, the placental explants
were treated overnight with lA'NaOH. A standard curve
was prepared from 1.4 mg/mL bovine serum albumin bv
serial dilution 1:1 with l.Y sodium hydroxide. Next 100
pL Biorad reagent was added to 20 |iL of sample or stan¬
dard and colorimetry performed at 620 nnr. Results were
analyzed with AssayZap.
Data analysis. The IL-8 production was expressed as
nanograms of IL-8 per microgram of protein. The results
obtained were tested for significance using a parametric
test, Fisher's protected least significant difference
(StatView), and significance at the level of P < .05 was
determined.
Immunocytochemistry. Tissue samples of placentas
were collected after elective cesarean section at term (37
to 39 weeks' gestation) from singleton pregnancies
uncomplicated bv diabetes or hypertensive disorders.
Sections from each placenta, including the basal plate,
were dissected, immediately embedded in OCT (Miles
Inc. Elkhart, Incl) and placed in an isopentone tray that
was surrounded by liquid nitrogen. The frozen OCT
block was then stored at -70°C before it was cut into
approximately 5-pm sections with a microtome. First-
trimester villi were collected from 4 women during
surgical termination of pregnancv and processed in the
same manner.
The method used for immunocytochemistrv is as
previously described by Critchley et ah13 Frozen sections
of tissue were fixed in 10% neutral buffered formalin for
10 minutes and then washed in phosphate-buffeted
saline solution before staining. The primary antibodv was
a polyclonal rabbit antibody as described lor the
immunoassav. This primarv antibodv was preabsorbed
with synthetic IL-S peptide (100 pg/rnL) and this and
rabbit IgG were used as negative antibodv controls.
Sections of tonsil were used as positive tissue controls, as
in the above-mentioned study.I:>
Endogenous peroxidase activity was blocked with Y,
hvdrogen peroxide diluted in distilled water. 1 In¬
sertions were then washed in phosphate-buffered saline
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Fig 2. IL-8 production (mean ± SEM) by explants of placental villous tissue obtained after spontaneous (solid bars) and
elective cesarean (ojien bars) delivery, untreated (control medium, Q or treated with onapristone (O, 1 |imol/L),
mifepristone (A/, 1 pmol/L), or lilopristone (L, 1 pmol/L) for 24 and 48 hours in culture.
solution, after which the first nonimmune block (normal
swine serum diluted 1:10) was applied for 20 minutes at
room temperature. Without washing, the primary anti¬
body was then applied at a 1:500 dilution to the tested
sections and the negative antibody control was applied at
the same dilution to the negative controls. All sections
were incubated at 37°C for 60 minutes. After a further
wash in phosphate-buffered saline solution (the negative
controls were washed separately to avoid contamination
with the primary antibody), a second nonimmune block
was applied in the same manner as the first followed by
application of the secondary bridging antibody (biotinv-
lated swine a-rabbit 1:300, DAKO, Glostrup, Denmark).
The third stage in the staining used an avidin-biotin-
complex peroxidase (Vectastain ABC kit. Vector
Laboratories, Peterborough, United Kingdom) prepared
according to the manufacturer's instructions with 3,3'-
diaminobenzidine tetrahvdrochloride as the chromagen.
giving a brown coloration. The sections were then coun-
erstained with Harris' hematoxvlin, dehvdrated in
ascending alcohol concentrations, cleared with xvlene,
mounted, and examined bv light microscopy.
Results
Production of interleukin 8 by placenta. All explants of
placental tissue released 11.-14 into the culture medium.
irrespective of the presence or absence of labor or treat¬
ment with antigestagens (Fig 1).
The culture medium was replaced after 24 hours and
IL-8 release increased in all samples in the second 24
hours of culture. This increase was significant (P < .05)
for the control samples from both elective cesarean and
spontaneous deliveries and for the cesarean samples
treated with onapristone and the spontaneously deliv¬
ered placentas that were treated with mifepristone or
with lilopristone.
After spontaneous delivery, for each treatment group
and at each time point, all placental explants produced
more IL-8 than the explants collected from women not in
labor. As illustrated for the control groups in Fig 1, this
was a significant increase (P< .05) at both time points.
The effects of three antigestagens—onapristone,
mifepristone and lilopristone—on IL-8 production in
both tvpes of placenta were also examined and are
shown in Fig 2. In the spontaneously delivery group
those treated with onapristone produced significantlv
more IL.-8 than the control samples at 24 and 48 hours,
whereas in the elective delivery group lilopristone at 24
hours caused a significant increase in production over
control samples (P< .05 in each case).
Localization of interleukin 8 in placenta. In the third-
irimester v illi IL-8-positive immunostaining was found to
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Fig 3. 11,-8 inmtunolocali/.ilion. A, Third-trimester placenta after spontaneous delivery showing positive !i.-S imnutnnstaining around
larger stem vessels offeta! vascuhtture ft): B. third-lrimesler placenta alter spontaneous delivery—negative control showing no specific
immunostaining in stem vessels; C. lit 'si-trimester placenta showing positive 11.-8 staining in sv ncvtiotrophohlast (.si: D. tonsil, positivetissue' ce>mre>1. (Original magnifications xgu.t
he localized piedominantlv in lite pet avascular walls of
larger (stem) fetal vessels as shown in Fig .'I. .1. with little
positive ll.-iS immtmoreaeliviiv in capillaries or other
v illous core tissue or It ophohlast. A negative control
section ol third-trimester placenta demonstrating no
specific II.-,s imtminorcactivitv in larger letal vessels or
other villous tissues is shown in Fig 8. It. In first-trimester
placentas. II.-N was localized predotninanllv in the devel¬
oping svnev tiotrophohlast of placental villi (Fig a. (').
loitsil was used as a tissue control lot 11 .-8 inuiuinos-
laining. with 11.-8 localized to the areas around hlood
vessels (Fig 8. I)\. No staining was demonstrated in anv¬
il egative control sections of phieenta or tonsil t Fig 8. /<"t.
Comment
I Itese studies demonstrate that the hitman placenta
produces 11 .-8 and that 11 lis production is int teasel I during
lahor and also hv culture with antigestagens.
Alt increase in ll.-S before the onset ol spontaneous
labor could lacilitate recruitment of neutrophils into the
uterine environment. It has been shown that in skin sites
II-8 and f'CIF.j act sv nergisticallv to increase the influx of
neutrophils.1-1 "• and it mav he that such synergism extends
to the reproductive tissues where at the time of parturition
there is an increase in local levels of prostaglandins that
have an established role in the initiation and progression
of lahor. Once recruited into the uteroplacental tissue,
neutrophils could he activated hv 11.-8 causing release of
Ivtic en/vmes. such ;ts collagenase and elastase. which
niav cause loosening of the tissue matrix in the cervix.1
ehnrioti-dccidua,1'1 and fetal membranes.'' IL-8 mav
therefore he part of a cascade of inflammatory agents,
including other cytokines and prostaglandins involved in
the initiation ol parturition. However, it is also possible
that the increase in 11.-8 production seen after vaginal
deltvet v is an effect and not a cause ol labor. It mav be
that the mechanical stress of contractions leads to
enhancement of the capabilitv ol the placental tissue to
pioducc 11.-8. More detailed studv of the time course ol
11.-8 production during labor would he required to
.'Sv vv i
. v 'Iw aVa: 1- •
v -r-A '^v»yS v
* a tfti, . . iv
§0$m;
;■ r ;"v i.
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further clarify its role in parturition. However, the
placenta cannot be directly sampled during spontaneous
labor in women and although tissue can be obtained at
emergency cesarean delivery performed during labor,
these cases may differ inherently from those resulting in
vaginal delivery.
There were no other obviously significant differences
in the placentas to account for the difference in produc¬
tion after labor, as the elective deliveries were all at term
and were not performed for placental insufficiency,
growth retardation, or metabolic abnormalities. The
spontaneously delivered placentas resulted from labors
that were not induced or augmented with prostaglandins
or oxytocics. All women whose infants are delivered vagi¬
nally in our unit routinely receive oxytocin and
ergometrine after delivery of the fetus; at cesarean
oxytocin alone is given. It seems unlikely that
ergometrine would have a significant effect on IL-8
production.
It has previously been shown that IL-8 production is
down-regulated by both progesterone8'14 and dexam-
ethasone.18 The addition of antigestagen to the culture
medium increased IL-8 production to a significant
degree in the spontaneous delivery placentas treated
with onapristone and in the cesarean delivery placentas
treated with lilopristone for 24 hours. Currently
antigestagens are being studied in clinical trials for
cervical ripening and induction of labor in the third
trimester.19 The local antagonism of progesterone in
uterine tissues could increase IL-8 levels permitting
recruitment of neutrophils and also lead to increased
local levels of PGE<>.2" In first-trimester decidua, mifepri¬
stone treatment increases perivascular PGE.> levels and
decreases its metabolism.-' -'- A parallel increase in IL-8
and PGE._, levels in placenta at term would enhance the
synergistic effects of these two agents on neutrophil
recruitment. A significant increase in IL-8 production
after all the antigestagen treatments may not have been
demonstrated in this study as the amount of
antigestagen used may not have been sufficient to antag¬
onize the large endogenous progesterone production of
the placenta. It could also be that particularly after spon¬
taneous deliverv the response of the placental cells to
exogenous agents has altered.
In summary, these studies demonstrate that the term
placenta constitutive!)' produces IL-8, which is localized
principally around the perivascular area of the villi. This
production of IL-8 is increased after spontaneous labor,
increases with culture duration, and is stimulated to
varying degrees bv some antigestagens. IL-8 may have a
role in the onset of parturition bv recruiting and acti¬
vating neutrophils at the placental site facilitating release
of lytic enzymes; hence antigestagens mav aid the induc¬
tion of labor by increasing the influx of neutrophils into
the placenta. Further work is now under way to establish
the controlling mechanisms involved in the stimulation
of IL-8 during labor and the potential role of antigesta¬
gens in regulating IL-8 production and the timing of the
onset of birth.
We thank Gail Carr and Sengupta Chatterjee for their
technical assistance.
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